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CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES  
Cardiovascular implantable electronic devices, such as the implantable 
cardioverter defi brillator (ICD) and the biventricular pacemaker providing cardiac 
resynchronization therapy (CRT), used either alone or in combination (i.e., CRT-
defi brillator or CRT-D), have gained increasing acceptance and are now implemented 
on a large scale in subgroups of patients with heart disease.1 Currently, more than 
800.000 patients in Europe are living with an implantable electronic device and this 
number is expected to increase in the future.2 
ICD and CRT treatment: How does it work?   
Th e ICD (Figure 1) continuously monitors the 
rhythm of the heart for the occurrence of life-
threatening tachyarrhythmias originating in 
the right or left ventricle. During a ventricular 
tachycardia (VT) the rhythm is accelerated, often 
resulting in a reduced pumping function of the 
heart. Th is causes a drop in blood pressure leading 
to dizziness or loss of consciousness. An untreated 
VT can deteriorate into ventricular fi brillation 
(VF) – a cardiac arrest with an electrical chaos 
in the ventricles making them quiver rather 
than contract properly – which without prompt 
intervention will almost always lead to sudden cardiac death (SCD). VFs can also have 
a sudden onset, e.g. during myocardial ischemia. SCDs account for approximately 
50% of all deaths from cardiovascular disease,4 with about 80-90% of these deaths 
being attributable to ventricular tachyarrhythmias.5 In case of sustained VT, the ICD 
uses anti-tachycardia pacing (ATP), which involves short bursts of pacing impulses 
at faster rates than the tachycardia, or low energy shocks (cardioversion) to prevent 
progression into VF.6 When ATP and cardioversion are unsuccessful or in case of 
sudden-onset VF, the ICD can deliver immediate defi brillation by high-energy shocks 
(up to 800 volts) to restore normal heart rhythm.6 
CRT is indicated for a subgroup of patients with congestive heart failure (CHF), 
which is a chronic and debilitating disease characterized by symptoms of tiredness and 
shortness of breath, and signs of peripheral and/or lung edema, arising as a consequence 
of a structural or functional abnormality of the heart.7 Th e prevalence of CHF in 
the Western world is estimated at 2-3%.8,9 In the 51 countries that fall under the 
European Society of Cardiology, there are at least 15 million people with CHF,8 and 
this number is expected to increase in the future due to the ageing of the population and 
improved survival of cardiac patients.10,11 Mortality and morbidity rates are high,12,13 






  Figure 1. ICD3
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In approximately one third of patients with CHF, 
the electrocardiogram (ECG) shows a prolonged 
QRS interval (>120 ms), indicating that the 
depolarization of the ventricles is delayed.16 Th is 
can be a result of a left or right bundle branch block 
or a nonspecifi c intraventricular conduction delay, 
leading to disruption of the normal, coordinated 
and simultaneous distribution of the electrical 
signal to the two ventricles. Th is may further 
impair the already diminished ventricular ejection 
fraction (i.e., the fraction of blood pumped out of 
the ventricles with each heart beat).17 CRT – or biventricular pacing – is intended to 
modulate the inter-/intraventricular conduction delay by simultaneously pacing both 
ventricles. CRT devices (Figure 2) have at least two leads, one in the right ventricle 
and another inserted through the coronary sinus to pace the lateral free wall of the left 
ventricle. For patients in normal sinus rhythm, there is also a lead in the right atrium 
to facilitate synchrony with the atrial contraction. As ventricular tachyarrhythmias are 
common in CHF patients,18 CRT is often combined with ICD therapy (i.e., CRT-D). 
Expanding indications and implantation rates
ICD therapy was initially only indicated as secondary prevention in patients who 
had survived an initial sudden cardiac arrest. Th e landmark secondary prevention 
trials, such as the Antiarrhythmics Versus Implantable Defi brillator (AVID) trial, 
the Canadian Implantable Defi brillator Study (CIDS) and the Cardiac Arrest Study 
Hamburg (CASH), showed a signifi cant reduction in mortality (28%) with ICD 
therapy compared to antiarrhythmic drugs, which was almost entirely due to a 50% 
reduction in arrhythmic death.19 With the widespread acceptance of the ICD for the 
secondary prevention of SCD and the change from epicardial to transvenous ICD 
implantation, attention turned to the usefulness of the ICD for primary prevention of 
SCD in patients with left ventricular dysfunction who did not experience prior life-
threatening arrhythmias but are considered at high risk. A series of primary prevention 
trials, e.g., the Multicenter Automatic Defi brillator Implantation Trial (MADIT(-II)) 
and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), demonstrated 
a signifi cant reduction in mortality (26%) with the ICD.20 Hence, ICD indications 
have expanded from secondary prevention to also include primary prevention of SCD. 
From 2001 onwards, several large-scale randomized clinical trials, e.g., 
the Multicenter InSyncRandomized Clinical Evaluation (MIRACLE) trial, the 
Comparison of Medical Th erapy, Pacing, and Defi brillation in Chronic Heart Failure 
(COMPANION) trial and the Cardiac Resynchronization-Heart Failure (CARE-HF) 
trial, have shown that CRT leads to improvements in CHF symptoms, functional 
         General introduction 
 Figure 2. CRT
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capacity and left ventricular function, and reduced mortality and hospitalization in 
patients with moderate to severe heart failure symptoms (New York Heart Association 
(NYHA) functional class III or IV) despite optimal pharmacological therapy, with a 
depressed left ventricular ejection fraction of ≤35% and a prolonged QRS interval 
of ≥120ms.21,22 CRT(-D) is recommended as a class I indication, level A evidence, as 
a means to improve prognosis in these patients.8 In 2010, the indications for CRT 
were expanded to also include mildly symptomatic CHF patients (NYHA functional 
class II) on optimal pharmacological therapy, with a left ventricular ejection fraction 
≤35% and a QRS duration ≥150 ms, in order to reduce morbidity and slow down 
disease progression.23 Th is recommendation is based on the results of recent trials, 
i.e., the MADIT-CRT, the Resynchronization Reverses Remodeling in Systolic Left 
Ventricular Dysfunction (REVERSE) trial, and the Resynchronization/Defi brillation 
for Ambulatory Heart Failure Trial (RAFT), showing that CRT(-D) therapy is benefi cial 
in patients with mild CHF symptoms.24-26 Despite large-scale studies demonstrating 
that the majority of patients benefi t from CRT, a signifi cant proportion (10-40%) 
of patients do not respond to this treatment and are considered nonresponders. No 
clear consensus regarding the defi nition of a positive response to CRT exists,27 and 
the mechanisms responsible for benefi ts versus no benefi ts are not fully understood.28
Based on the criteria in the major trials, the number of patients in Europe 
indicated for ICD or CRT therapy has steadily increased over time, but only a fraction 






Figure 3. Percentage of patients fulfi lling the criteria for the major ICD/CRT(-D) trials, which 
actually get implanted in Western Europe 
Based on data from EUCOMED and European guidelines.29,30
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THE PATIENT PERSPECTIVE
Living with a cardiovascular implantable electronic device
Device therapy is a state-of-the-art medical technology which is continuously evolving 
and is associated with a range of challenges for patients. Besides dealing with their 
life-threatening condition, ICD/CRT(-D) patients have to live with the risk of 
procedural and device-related complications, such as infection and lead dislocation, 
potential hardware malfunctioning leading to advisory notices, and – appropriate and 
inappropriate – ICD shocks. Inappropriate shocks refer to the device giving a shock 
although in fact no life-threatening arrhythmia occurred. These issues may all have a 
negative impact on morbidity and mortality, but also on the psychological functioning 
and quality of life of patients.31,32 
Although device therapy is well tolerated by the majority of patients, a subset of 
patients with an ICD/CRT-D report heightened psychological distress and impaired 
health status following implantation.33-35 Health status refers to the patient’s perception 
of how a disease or treatment affects his/her function, symptoms, and quality of life, 
with quality of life being the discrepancy between actual and desired function.36,37 
The most common psychological problems reported by ICD patients are depression, 
anxiety and specific device- or disease-related concerns such as fear of ICD shocks, 
device malfunction, and fear of death.38,39 Depressive symptoms are experienced by 
24-33% of the ICD recipients.38 Anxiety is more prevalent, with studies indicating 
that approximately 24-87% of ICD recipients report increased levels of anxiety post 
implantation, with 13-38% meeting diagnostic criteria for an anxiety disorder such as 
posttraumatic stress disorder.38,40
 
The importance of examining the patient perspective and its determinants
Patient reported outcomes are receiving increased recognition as important 
cardiovascular endpoints in clinical trials and are recommended as performance 
measures of high quality care, as they offer physicians insight into their patient’s physical 
and psychological needs and may guide clinical decision making.36,41 They are essential 
for patient centered care, as patients want to know how a treatment will affect their 
symptoms, function, and quality of life, particularly because some patients may prefer 
a better health status over prolonged survival.42,43 Besides being important outcome 
measures and key components of patient centered care, patient reported outcomes 
are important for secondary prevention. Poor patient health status and psychological 
distress have been associated with increased risk of mortality and hospital admissions 
in CHF and ICD patients,44-47 and also with the onset of ventricular tachyarrhythmias 
in ICD patients,48,49 independent of indicators of disease severity. 
There is a significant gap in our understanding of the determinants of patient 
reported outcomes.50 Research has shown that the physician’s evaluation of the patient’s 
health,51 and objective indicators of disease severity,52,53 are only marginally associated 
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with the health status as reported by patients. Also, the evidence on the infl uence of 
age,33 sex,54 ICD shocks,55 indication (primary versus secondary prevention),56 and 
advisory notices57 on patient reported outcomes is mixed. Th is raises the question 
whether psychological factors, such as personality factors, e.g., the distressed (Type 
D) personality (i.e., the combination of negative aff ectivity and social inhibition), 
pre-implantation ICD concerns, or lack of social support,58-63 might infl uence the 
relationship between obvious device- and disease-related factors and patient reported 
outcomes in ICD/CRT(-D) patients. Figure 4 provides an overview of the clinical, 
demographic, and psychological factors that might be or have been associated with 
patient reported outcomes in ICD and/or CRT(-D) patients. It is essential to know the 
determinants of patient reported outcomes, in order to identify high-risk patients who 
may not benefi t optimally from device therapy and might need additional treatment.
AIMS AND OUTLINE OF THIS DISSERTATION
Th e current dissertation focuses on the patient perspective on cardiovascular 
implantable electronic device therapy. Some of the potential clinical (disease- and 
device-related) versus psychological associates of patient reported outcomes following 
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Part one: The impact of disease- and device-related factors
The first part of this dissertation addresses the impact of disease- and device-related 
factors on patient reported outcomes in ICD/CRT patients. The first three chapters 
discuss the association between patient health status and established physician-rated 
indicators of disease severity in CRT patients. Chapter 2 provides an overview of these 
traditional indices currently used to determine response to CRT and discusses their 
agreement with changes in patient perceived health following implantation based on 
analysis of the existing literature and case reports. The next two chapters elaborate 
on this topic and focus on the NYHA functional class, which is used as a measure of 
the physician’s impression of the presence and severity of symptoms and functional 
limitations in patients with CHF. Results of a multicenter prospective study examining 
the influence of baseline NYHA functional class (II versus III) on change in patient 
reported health status in the first 12 months after CRT-D are presented in Chapter 3. 
Next, the study described in Chapter 4 examines the association between improvement 
in NYHA functional class and patient reported health status in the first 2 months 
after CRT implantation in a sample of patients recruited from the University Medical 
Center Utrecht, the Netherlands. 
Besides indices of disease severity, device-related factors such as advisory notices 
and ICD shocks might influence patient reported outcomes in ICD/CRT-D patients. 
There is a paucity of research on the psychological impact of device advisory notices, 
and evidence is mixed. Little is also known about the best way of communicating the 
risk associated with an advisory to patients. Hence, Chapter 5 evaluates whether the 
Sprint Fidelis advisory and the mode used to inform patients about the associated 
risks influences psychological distress, device related concerns, health status, and 
device acceptance as reported by a sample of Danish ICD patients. Yet even without 
complications, ICD treatment may qualify as a potential traumatic stressor as it is a 
constant reminder of the underlying life-threatening condition and is able to deliver 
an uncontrollable shock. The prevalence and determinants of posttraumatic stress 
symptoms in a sample of 300 ICD patients implanted at the Erasmus Medical Center, 
Rotterdam, the Netherlands, are outlined in Chapter 6. 
Part two: The importance of psychological factors 
In addition to disease- and device-related factors, psychological factors could play a role 
in determining patients reported outcomes in ICD/CRT patients and might explain 
why some patients do not benefit from cardiovascular implantable electronic device 
therapy. Chapter 7 reports on a study in German ICD patients investigating whether 
somatosensory amplification – the tendency to be more aware of and attentive to weak 
or diffuse bodily sensations and to appraise them as abnormal and symptomatic of 
disease – could explain why female patients might report more psychological distress 
following implantation than males. Also, personality factors might influence differences 
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in patient reported health outcomes. For example, accumulating evidence has shown 
that Type D personality is associated with adverse health outcomes. A meta-analysis of 
studies evaluating the influence of Type D personality on patient reported physical and 
mental health status in cardiovascular patients is presented in Chapter 8. Distress levels 
in patients could even be related to partner factors leading to poor communication 
and lack of social support. In Chapter 9, the impact of the personality of the partner 
(i.e., Type D personality) in combination with that of the patient on anxiety and 
depression levels in ICD patients is addressed. Another psychological factor that 
might be essential in identifying patients at risk for adverse outcomes, is poor device 
acceptance – which refers to the psychological accommodation and understanding 
of the device and the derivation of benefit in terms of biopsychosocial functioning. 
The Florida Patient Acceptance Scale (FPAS) is one of the few instruments available 
to measure ICD acceptance. In Chapter 10, the psychometric properties of the FPAS 
and correlates of device acceptance are examined in a cohort of Dutch ICD patients. 
In Chapter 11 the main findings of this dissertation will be discussed and implications 
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ABSTRACT
Background Cardiac resynchronization therapy (CRT) is a promising treatment for 
a subgroup of patients with advanced congestive heart failure (CHF) and a prolonged 
QRS interval. Despite the majority of patients benefiting from CRT, 10% to 40% 
of patients do not respond to this treatment, labeled as nonresponders. Given that 
there is a lack of consensus on how to define response to CRT, the purpose of this 
viewpoint is to discuss currently used definitions and their shortcomings, and to 
provide recommendations as to how an expansion of the criteria for CRT response 
may be useful to clinicians. 
Methods and Results Analysis of the literature and case reports indicates that 
the majority of established measures of CRT response, including New York Heart 
Association (NYHA) functional class and echocardiographic, hemodynamic, and 
neurohormonal parameters, are poor associates of patient reported symptoms and 
quality of life. Moreover, the potential moderating role of psychological factors in 
determining health outcomes after CRT has largely been neglected.
Conclusions It is recommended to routinely assess health status after CRT with 
a disease-specific questionnaire in standard clinical practice and to examine its 
determinants, including psychological factors such as personality traits and depression. 
This may lead to improved (secondary) treatment and prognosis in CHF patients 
treated with CRT. 
Versteeg H, Schiffer AA, Widdershoven JW, Meine M, Doevendans PA, Pedersen SS. Response to cardiac 
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INTRODUCTION
Congestive heart failure (CHF) is a debilitating and persistent clinical syndrome, 
typified by symptoms of tiredness and breathlessness, and signs of tachypnoea 
and hepatomegaly, in addition to objective evidence of a structural or functional 
abnormality of the heart at rest.1,2 In the United States, approximately 5 million 
people have CHF,3 and of the more than 900 million people living in the countries 
that fall under the European Society of Cardiology, at least 15 million people have 
the disease.1 Despite important advances in medical therapy, mortality and morbidity 
rates are still high.4,5 
Cardiac resynchronization therapy (CRT) is a promising treatment for a 
subgroup of patients with advanced CHF and a prolonged QRS interval.6,7 This inter-/ 
intraventricular conduction delay is recognizable on the electrocardiogram as a bundle 
branch block which may further impair the ventricular ejection fraction.8 The precise 
mechanisms underlying the benefits of CRT are not clear, but appear to be related 
to modulation of the conduction delay which can optimize contractile synchrony, 
improve systolic function and reduce mitral regurgitation.9 Especially patients with a 
QRS duration ≥155 ms and depressed left ventricular pressure rise  (dP/dtmax ≤700 
mmHg/s) should show the greatest improvement with CRT.10 Although studies have 
shown that only patients with left bundle branch block (LBBB) benefit from CRT,11 
no distinction is made between the sides of electrical block in the current guidelines.1 
CRT has been shown to improve quality of life and functional status, and to 
reduce mortality and morbidity.12,13 Therefore, CRT has been used extensively over 
the last years in patients with end-stage CHF who remain symptomatic (New York 
Heart Association (NYHA) functional class III-IV) despite optimal pharmacological 
therapy, have a depressed left ventricular function (left ventricular ejection fraction 
(LVEF) <35%), and a prolonged QRS interval (>120 ms). In the most recent guidelines 
for CHF, CRT is recommended as a class I indication, level A evidence, as a means to 
improve prognosis in these patients.1 Despite large-scale studies demonstrating that 
the majority of patients benefit from CRT, a significant proportion of patients do 
not respond to this treatment, labeled as nonresponders.12,14 A complicating factor 
in this context is that there is a lack of consensus on how to define response to CRT. 
In studies using a composite score of subjective and/or objective measures of clinical 
status (e.g. NYHA class, quality of life, hospitalization, and mortality), 11-33% of 
the patients were classified as nonresponders after 6 months of CRT.6,15,16 In recent 
echocardiographic studies, the percentage of nonresponders was even larger; no positive 
response, defined as a reduction of ≥15% in left ventricular end-systolic volume 
(LVESV), was observed in up to 44% of patients.16,17 The purpose of this viewpoint 
is to discuss currently used definitions of CRT response and their shortcomings, and 
to provide recommendations as to how an expansion of the criteria for CRT response 
may be useful to clinicians.
   Criteria for CRT response
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PROBLEMS WITH THE DEFINITION OF RESPONSE TO CRT
Currently, fi ve types of indices are used to determine CRT response (Table 1):
(1) clinical, such as NYHA class and quality of life; (2) functional, for example, oxygen 
uptake at peak exercise (VO2max) and the distance walked in 6 minutes (6MWD); (3) 
echocardiographic, including LVEF and left ventricular end-diastolic and end-systolic 
volumes (LVEDV, LVESV); (4) hemodynamic, like dP/dtmax and the cardiac index; 
and (5) neurohormonal, for example, B-type natriuretic peptide (BNP) level.14,18 
Appendix I gives an overview of the clinical trials that investigated the eff ects 
of CRT on one or more of these indices, compared to optimal medical treatment 
or implantable cardioverter defi brillator (ICD) therapy, in patients with a class I 
indication for CRT without atrial fi brillation. Th e presented results stem from the 
primary publications of these trials.6,11,19-25 From this overview, it becomes clear that 
the trials use diff erent endpoints to assess CRT response and that the results vary 
widely. But all trials included measures of clinical response, which represents relief 
of symptoms and improved quality of life. It is the most subjective index of CRT 
response and one of the most important targets of treatment in patients with CHF.26 
In standard clinical practice, the clinical CRT response is most often defi ned as an 
improvement in ≥1 NYHA class, with NYHA class traditionally being used as a 






a VO2max and 6MWD are not entirely objective, as they are also dependent on subjective factors such as the 
motivation of the patient
6MWD=6-minute walking distance; BNP=brain natriuretic peptide; dP/dtmax=maximum rate of (left 
ventricular) pressure rise; LVEDV=left ventricular end-diastolic volume; LVEF=left ventricular ejection 
fraction; LVESV=left ventricular end-systolic volume; NYHA=New York Heart Association; VO2max=oxygen 
uptake at peak exercise. 
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CHF patients.27 
Although NYHA class is associated with prognosis in CHF,28,29 it has been 
criticized as a single marker for clinical response, as the method of assignment is not 
standardized,30,31 the interrater reliability is poor,31,32 and there is only a moderate 
association between clinician assigned NYHA class and patient reported severity of 
symptoms, quality of life, psychological distress, and life satisfaction.33-37 In addition, 
most of the variation in quality of life scores cannot be explained by NYHA class, 
with the possibility that clinically relevant changes in health status can occur in the 
absence of changes in NYHA class.38,39 Therefore, NYHA class cannot be used as a sole 
outcome measure reflecting clinical CRT response. In addition, NYHA classification 
is predominantly a measure of functional status,40 while CHF patients experience not 
only functional losses but also a variety of psychosocial, socio-economic, and emotional 
concerns that affect their overall quality of life.41,42 A more holistic assessment of the 
symptoms and quality of life of CHF patients is needed in routine clinical care, as it 
may help improve monitoring and treatment of patients receiving CRT. 
Moreover, research indicates that patients’ self-reported symptoms and quality 
of life have unique prognostic value. Studies conducted in CHF patients showed that 
poor patient reported health status predicts mortality and hospitalization, independent 
of demographic factors and indicators of disease severity, with the likelihood that this 
finding may be extrapolated to CRT patients.43,44 To the best of our knowledge, only 
one study analyzed quality of life as a predictor of mortality after CRT in a clinical trial. 
Results showed that the baseline quality of life score predicted pump failure death at 
3 months in unadjusted analysis.45 In adjusted analysis however, quality of life was no 
longer significant, likely due to the relatively short follow-up period, the small number 
of events and the use of a generic instead of a disease-specific questionnaire. It is 
recommended to assess health status with a disease-specific questionnaire, for example 
the Minnesota Living with Heart Failure questionnaire (MLHFQ) or the Kansas City 
Cardiomyopathy Questionnaire (KCCQ), as a disease-specific measure seems to have 
greater prognostic value compared to health status assessed with a generic measure.44 
The MLHFQ and the KCCQ are self-report scales, with good metric and 
applicability properties, that adequately reflect change over time in health status.46 
It was found that the KCCQ summary score was more discriminative of change in 
heart failure status than NYHA classification, 6MWD, the generic Short Form-12 
and EuroQol-5D scores, weight, and BNP levels.47 In sum, the incorporation of 
health status measures in longitudinal care offers a complete and consistent distillation 
of patients’ health status over time and may optimize secondary prevention.48 For a 
more in-depth discussion of the clinical utility of health status assessment in cardiac 
patients, see a recent seminal paper by Spertus.48  
   Criteria for CRT response
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Besides shortcomings in the assessment of the clinical CRT response, there is a 
gap in our understanding of its determinants.49 Research has shown that the severity 
of cardiac dysfunction as measured by echocardiographic and hemodynamic measures 
is only marginally associated with clinical health outcomes such as heart failure 
symptoms,50 quality of life,35 and NYHA class.7 Recent results of large prospective, 
multicenter trials showed that various echocardiographic measures of ventricular 
dyssynchrony and LV volume were unable to distinguish between patients who showed 
improvement of ≥1 NYHA class and those who did not after 6 months of CRT.16,51 
Two studies reported a disagreement between the echocardiographic response, defined 
as >15% reduction in LVESV or ≥15% relative increase in LVEF, and the clinical 
response (an improvement by ≥1 NYHA class) in 24-27% of the patients treated with 
CRT.52,53 To illustrate this discrepancy between clinical and echocardiographic and 
hemodynamic CRT responses, we report two cases seen in our clinical practice:  
Case 1: The patient is a 62-year old man with a history of anteroseptal myocardial 
infarction who had NYHA class III-IV CHF due to ischemic cardiomyopathy and 
a LBBB with a QRS duration of 140 ms. At the time of implantation of the CRT-
device with an ICD, that is a CRT-D, his LVEF was 24%, BNP level 249 pmol/L, 
and VO2max 14.8 ml/kg/min. Six months after the implantation, there was no 
echocardiographic or functional response, as there was no reverse remodeling with the 
left ventricle still dilated with 7.2 cm, an LVEF of 22%, and a paced QRS duration of 
160 ms. The BNP level had increased to 265 pmol/L and the VO2max was even lower 
than prior to implantation at 12.4 ml/kg/min. However, the patient reported that 
he felt much better since the implantation and had improved to NYHA class II-III. 
The patient could perform more physical exertion and was no longer short of breath 
during daily activities. 
Case 2: The patient is a 76-year old woman with a history of dilated cardiomyopathy 
and an out of hospital cardiac arrest due to ventricular fibrillation for which an ICD 
was implanted. Because of worsening of CHF symptoms to NYHA class III despite 
optimal medical treatment, an LVEF of 25%, an LBBB with a QRS duration of 
190 ms, and a BNP level of 155 pmol/L, the ICD was upgraded to an CRT-D. Six 
months after the upgrade, there was a significant improvement in echocardiographic 
parameters, with a significant decrease in left ventricular end-diastolic diameter from 
6.7 to 5.1 cm, an increase in LVEF to 31%, a decrease in QRS duration to 150 ms, 
and in BNP levels to 71 pmol/L. Despite these echocardiographic and neurohormonal 
responses, the patient reported no improvement in CHF symptoms. The patient was 
still classified as NYHA class III, as she still suffered from fatigue and shortness of 
breath during ordinary daily activities. 
These case reports and previous study results indicate that the clinical CRT 
response cannot be fully explained by changes in established echocardiographic, 
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without objective improvement might be attributed to a placebo effect, although we 
cannot rule out the influence of other factors, in particular because some patients 
do not feel better despite echocardiographic or hemodynamic responses. Numerous 
studies have been conducted to determine the value of other parameters in predicting 
clinical CRT (non)response, for instance, intraventricular dyssynchrony measured 
by tissue Doppler imaging,17,54 total scar burden,55 and left ventricular lead electrical 
delay.56 
THE ROLE OF PSYCHOLOGICAL FACTORS
Up till now, the possible influence of psychological factors on CRT response has largely 
been neglected, with a paucity of studies having examined the role of psychological 
factors in health outcomes after CRT. A recent study showed that the personality 
trait negative affectivity (i.e., the tendency to experience increased negative emotions) 
exerted a stable adverse effect on perceived health status and disability, with patients 
scoring high on negative affectivity reporting poorer health status and more cardiac 
symptoms and disability over a 2-month period after CRT implantation.57 However, 
the study did not control for the effect of echocardiographic and hemodynamic 
changes after CRT on health status. The interaction of traits, such as Type D 
personality (increased negative affectivity paired with social inhibition) may also 
influence the clinical CRT response, as this personality subtype has been associated 
with poorer quality of life and more symptoms and emotional distress in patients with 
CHF,58 ischemic heart disease,59 tachyarrhythmia’s,60,61 and peripheral artery disease.62 
In addition to personality traits, other psychological factors may be of importance 
in determining the clinical CRT response. For instance, several studies found that 
depression is common among patients with CHF and CAD, and is associated with an 
increase in cardiac morbidity and mortality and worse health status outcomes in these 
patients, independent of the underlying cardiac disease severity.63-66 The American 
Heart Association advocates screening heart patients for depression to identify those 
who may require further assessment and treatment,67 but more research is needed 
to investigate if this would improve depressive symptoms and cardiac outcomes in 
these patients.68 Also, positive affect, coping style, loneliness, and marital quality may 
have notable effects on health outcomes in CHF patients receiving CRT,69-71 and may 
explain why some patients do not report better health status despite echocardiographic 
and hemodynamic improvements.  
CONCLUSIONS AND RECOMMENDATIONS
The majority of established indicators of CRT response, including NYHA class 
and echocardiographic and hemodynamic parameters, are poor associates of 
patient reported symptoms and quality of life. As these indicators largely determine 
clinicians’ care, and quality of life is very important from the patient’s perspective, 
   Criteria for CRT response
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current treatment of CHF might fail to satisfy patients’ needs.35 Moreover, it might 
be debatable whether a patient who does not report a better health status, despite 
improvements in established parameters of CRT response, is a true responder. Hence, 
we would recommend that patient-reported outcomes, such as health status, be assessed 
in standard clinical practice, in addition to objective measures of CRT response, in 
order to enhance risk stratifi cation in CRT patients and to identify patients who 
may not benefi t optimally from this treatment. With routine assessment of health 
status with a disease-specifi c questionnaire, patients whose health status does not 
improve after CRT can be identifi ed and additional treatment options (e.g., changes 
in medication or psychological support) be considered. Th e incorporation of health 
status as a performance measure of high quality care has also been recommended 
by the American College of Cardiology, the American Heart Association, and the 
American Medical Association.72 
As emphasized in a report from the National Heart, Lung and Blood Institute 
in the US,73 studies are warranted that examine the determinants of patients’ 
perception of symptoms and quality of life, including the potential moderating role 
of psychological factors, in particular personality traits. Knowing which factors are 
associated with negative patient reported health outcomes may provide targets for 
secondary intervention, thereby improving the clinical CRT response. In turn, this 
may even result in reduced morbidity and mortality after CRT, as patient reported 
health status provides additional information to indicators of CHF severity in 
predicting prognosis.44 An overview of our recommendations is provided in Table 2.
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Chapter 3
Eff ect of cardiac resynchronization therapy-defi brillator 
implantation on health status in patients with mild 
versus moderate symptoms of heart failure
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ABSTRACT
Background Indications for cardiac resynchronization therapy (CRT) have expanded 
to include patients with mild congestive heart failure (CHF) symptoms (New York 
Heart Association (NYHA) functional class II) because of a demonstrated morbidity 
reduction in this subset of patients. However, little is known about post implantation 
changes in their self-reported health status compared to patients with more severe 
CHF. The aim of this study was to examine the influence of baseline NYHA functional 
class on health status changes in the first 12 months after implantation of an CRT-
defibrillator (CRT-D). 
Methods Patients with a first-time CRT-D (N=169, 75% men, mean age=62.1±10.7 
years) were recruited from 3 Dutch hospitals. All patients completed the Short 
Form Health Survey 36 (SF-36) at the time of implantation and at 12 months after 
implantation. 
Results Both mildly (NYHA functional class II, n=54) and moderately (NYHA 
functional class III, n=115) symptomatic CHF patients showed improved health status 
in several SF-36 domains at 12 months after CRT-D implantation. When adjusting 
for baseline health status, the groups did not differ with respect to their health status 
improvement over time, but after adjustment for demographic and clinical factors, the 
mildly symptomatic patients reported relatively more improvement in General Health 
(B=10.15, SE=3.31, p=.003) and Social Functioning (B=10.64, SE=3.74, p=.005). 
Conclusions NYHA functional class II patients reported equal, and in some domains 
even more improvement in health status compared to NYHA functional class III 
patients at 12 months post CRT-D implantation. Hence, CRT not only prevents 
clinical adverse events in patients with mild CHF symptoms but also improves health 
status.
Versteeg H, van den Broek KC, Theuns DAMJ, Mommersteeg PMC, Alings M, van der Voort PH, 
Jordaens L, Pedersen SS.  Effect of cardiac resynchronization therapy-defibrillator implantation on health 
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INTRODUCTION
Besides reducing mortality and morbidity, another important target of treatment in 
congestive heart failure (CHF) patients is relief of symptoms as well as improvement in 
health status and quality of life.1 Several trials have shown that cardiac resynchronization 
therapy (CRT), often in combination with an implantable cardioverter defibrillator 
(ICD) leads to improved patient reported outcomes in patients with moderate to severe 
(New York Heart Assocation (NYHA) functional class III or IV) CHF symptoms,2-5 
but the few available studies on patients with mild (NYHA functional class I or II) 
CHF symptoms did not demonstrate any health status benefits of CRT with ICD 
(CRT-D) implantation.5,6 An explanation could be that mildly symptomatic patients 
have less room for improvement or that the follow-up time should be longer than the 
6 months used in the latter studies in order to be able to demonstrate a benefit.7 No 
study so far has directly compared the health status improvements reported by mildly 
and moderately symptomatic CHF patients after CRT-D implantation. 
Hence, the objective of this multicenter prospective study was to examine changes 
in several health status domains in the first 12 months after CRT-D implantation in 
patients with mild (NYHA functional class II) versus moderate (NYHA functional 
class III) CHF symptoms.
METHODS
Patients receiving a first-time CRT-D implantation between May 2003 and September 
2009 at the Erasmus Medical Center, Rotterdam, the Catharina Hospital, Eindhoven, 
and the Amphia Hospital, Breda, the Netherlands, and with NYHA functional class 
II or III CHF symptoms constituted the patient sample for the present study. Patients 
included in the Erasmus Medical Center participated in the ongoing Mood and 
personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS). Exclusion criteria for all hospitals were 
significant cognitive impairments, a history of psychiatric illness other than affective/
anxiety disorders, a life expectancy less than 1 year, NYHA functional class I or IV 
CHF symptoms, and insufficient knowledge of the Dutch language. 
At baseline and at 12 month follow-up, patients were asked to complete a set of 
standardized and validated questionnaires. The study protocol was approved by the 
Medical Ethics Committees of the participating hospitals. The study was conducted in 
accordance with the Helsinki Declaration, and all patients provided written informed 
consent. 
Demographic variables included sex, age, marital status (single versus having a 
partner), employment status (currently employed versus unemployed) and educational 
level (primary schooling or lower versus secondary schooling or higher), and were 
obtained via purpose-designed questions at baseline. Information on smoking and 
the use of psychotropic medications was also obtained through purpose-designed 
 Health status improvement after CRT-D
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questions at baseline. Information on other clinical variables, including cause of heart 
failure (ischemic versus non-ischemic), ICD indication (primary versus secondary 
prevention), NYHA functional class (II versus III), left ventricular ejection fraction 
(LVEF; ≤35% versus >35%), QRS duration (<150ms versus ≥150 ms), diabetes, and 
cardiac medications, were extracted from patients’ medical records. Information 
on the occurrence of shocks (appropriate and inappropriate) during follow-up was 
obtained by means of device interrogation. 
The Short Form Health Survey 36 (SF-36) was used to assess health status.8 
The SF-36 comprises 36 items, divided into 8 subscales: Physical Functioning, 
Role Physical Functioning, Bodily Pain, General Health, Social Functioning, 
Role Emotional Functioning, Mental Health, and Vitality. Scores on the subscales 
are linearly converted into a score between 0 and 100. A higher score on the SF-
36 domains represents better functioning; a high score on the Bodily Pain domain 
indicates absence of pain. The Dutch version of the SF-36 has been validated in several 
Dutch populations and has a good internal consistency with a mean Cronbach’s alpha 
of .84 across all scales.9 Patients were asked to complete the SF-36 at baseline and at 
12 months after implantation. 
Discrete variables were compared using Chi-square tests and continuous variables 
(e.g. the baseline health status scores) using Student’s t tests for independent samples. 
Paired-samples t tests were used to evaluate intragroup changes in health status scores 
from baseline to 12 months. To compare the NYHA functional class II and III 
patients with respect to change in health status in the first 12 months after CRT-D 
implantation, analyses of covariance (ANCOVAs) were performed, with the absolute 
change in health status (12-month score minus baseline score) as the outcome variable 
and baseline health status scores as covariate. Because we expected the health status 
scores of NYHA functional class II and III patients to differ at time of implantation, 
we included baseline health status score as a covariate to correct for the phenomenon 
of regression to the mean.10 Finally, a set of demographic and clinical variables were 
included as covariates to adjust for potential confounding. A priori, on the basis of 
published research, we decided to include age, sex, ICD indication, cause of heart 
failure, LVEF, QRS duration, diabetes, psychotropic medications, and ICD shocks. 
All tests were two-tailed, and p-values of ≤.05 were considered to indicate statistical 
significance. A Bonferroni correction was applied to adjust for multiple comparisons 
(p≤.006 (p=.05/8)). All analyses were performed with SPSS 17.0 for Windows (SPPS 
Inc., Chicago, Illinois). 
RESULTS
Information on NYHA functional class was not reported in the medical records for 25 
of the 261 patients willing to participate. Of the remaining 236 patients, 14 did not 
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up. Th e 169 patients eligible for analysis (72%) were on average less likely to have 
diabetes mellitus (14% versus 27%, p=.01) and to have ischemic causes of heart failure 
(50% versus 69%, p=.003), but more likely to use angiotensin-coverting enzyme 
(ACE)-inhibitors (82% versus 71%, p=.03) compared to excluded patients (n=92). 
No other systematic diff erences were found between participants and nonparticipants 
on baseline characteristics. 
 Health status improvement after CRT-D
Table 1.Baseline characteristics for the total sample and stratifi ed by mildly (NYHA II) versus 
moderately (NYHA III) symptomatic CHF
Results are presented as n (%), unless otherwise stated.
*p≤.05 
a Less than secondary school
ACE=angiotensin converting enzyme; NYHA=New York Heart Association functional class; 
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Baseline characteristics of the total patient sample and stratified by mild CHF 
symptoms (NYHA functional class II) versus moderate CHF symptoms (NYHA 
functional class III) are listed in Table 1. Of the 169 patients, 54 (32%) had mild CHF 
symptoms at the time of implantation. These patients were more likely to have  ICDs 
for secondary prevention and less likely to use diuretics compared to patients with 
moderate CHF symptoms. No other statistically significant differences were found 
between mildly and moderately symptomatic patients on baseline characteristics. 
At baseline, NYHA functional class II patients reported significantly better health 
status across 3 of 8 domains compared to NYHA functional class III patients: Physical 
Functioning (M=59.02, SE=3.03 versus M=43.73, SE=2.21, t167=3.98, p<.001), Role 
Physical Functioning (M=38.43, SE=5.64 versus M=16.30, SE=2.76, t79.4=3.52, 
p=.001), and Vitality (M=55.25, SE=2.47 versus M=43.42, SE=1.86, t167=3.69, 
p<.001). Changes in health status scores across the domains of the SF-36 from 
baseline to 12- month follow-up are shown in Figure 1. Paired samples t tests showed 
that the NYHA functional class II patients significantly improved across 3 of 8 health 
status domains: Role Physical Functioning (Mdiff=19.91, SE=5.81, t53=3.42, p=.001), 
Social Functioning (Mdiff=16.90, SE=3.19, t53=5.30, p<.001), and Vitality (Mdiff=8.89, 
SE=2.45, t53=3.63, p=.001). The NYHA functional class III patients improved in 6 of 
8 health status domains, except for Role Emotional Functioning (Mdiff=9.57, SE=4.54, 
t114=2.11, p=.04) and General Health (Mdiff=0.72, SE=1.97, t114=0.37, p=.71). 
To correct for the phenomenon of regression to the mean we performed 
ANCOVAs including baseline health status as a covariate. Given an equal (or averaged) 
score at baseline, the NYHA functional class II and III patients did not significantly 
differ with respect to their change in health status from baseline to 12 months after 
implantation (Table 2). However, when adjusted for demographic and clinical factors, 
NYHA functional class II patients scored on average 10.15 points higher on General 
Health (SE=3.31, p=.003) and 10.64 points higher on Social Functioning (SE=3.74, 
p=.005) at 12 months after implantation compared to the NYHA functional class III 
patients.  
With respect to the demographic and clinical factors, the use of psychotropic 
medication was associated with significantly less improvement (range B’s=-10.59 to 
-16.45, all ps≤.006), while prolonged QRS duration (≥150 ms) was associated with 
more improvement (range B’s=10.99 to 19.67, all ps≤.006) in 3 of 8 health status 
domains. Of note, ICD shocks during follow-up were not associated with change in 
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Figure 1. Changes in health status scores of mildly (NYHA II) versus moderately (NYHA III) 
symptomatic CHF patients
 Health status improvement after CRT-D
Reported p-values represent the signifi cance levels of the intragroup changes in health status
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DISCUSSION
In the present multicenter prospective study, we compared changes in patient reported 
health status in the fi rst 12 months after CRT-D implantation in patients with mild 
(NYHA functional class II) versus moderate (NYHA functional class III) CHF 
symptoms. Both patient groups showed improved health status in several domains. 
When adjusting for baseline health status, the changes in health status over time were 
similar for both groups. However, after adjustment for demographic and clinical 
factors, the mildly symptomatic patients reported relatively more improvement in 
general health and social functioning. 
To our knowledge, this is the fi rst study directly comparing mildly and 
moderately symptomatic CHF patients regarding changes in health status after 
CRT-D implantation. Our results corroborate those of earlier studies in patients with 
moderate CHF symptoms showing signifi cant improvement in patient reported health 
status after CRT-D implantation.2-5 However, we were also able to show health status 
benefi ts of CRT-D in mildly symptomatic patients, which has not been shown by 
previous studies.5,6 Th ese studies used a relatively short follow-up period of 6 months 
and reported an overall health status score only. Th e present results indicate that 
mildly symptomatic patients report improvements in several health status domains at 
12 months after CRT-D implantation; in some domains even more than moderately 
symptomatic patients. 
Th e present results are important in light of the recent expansion of the indications 






Table 2. Infl uence of baseline NYHA functional class (II versus III) on change in health status 
over time
Results of the ANCOVAs, adjusted for baseline health status
a A positive B-value indicates more improvement in health status of the NYHA II group compared to the 
NYHA III group; a negative B-value indicates less improvement in health status of the NYHA II group 
compared to the NYHA III group, given equal baseline values.
NYHA=New York Heart Association functional class.
    
   
   
   
   
   
   
   
   
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Automatic Defibrillator Implantation Trial (MADIT)–CRT, Resynchronization 
Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial, and 
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) have 
shown that CRT-D is beneficial in these patients.12–14 The present study suggests 
that mildly symptomatic CHF patients might also benefit from CRT-D in terms 
of improved health status. Improved patient reported health status is not only an 
essential treatment goal in itself,1 but is also important for secondary prevention, 
because impaired health status is associated with poor prognosis in CHF patients, 
independent of indicators of disease severity.15 Further studies are needed to determine 
whether CRT-D leads to better long-term clinical outcomes and survival in patients 
with mild CHF symptoms and whether the health status benefits seen at 12 months 
are also present in the long-term.11 
Besides NYHA functional class III symptoms, another clinical factor associated 
with less health status improvements in the first year after CRT-D was the use of 
psychotropic medication at time of implantation. Early identification and adjunctive 
treatment of patients with these risk factors might be useful in clinical practice. A 
factor that was associated with more health status improvement was a prolonged QRS 
duration (≥150 ms), which emphasizes that CRT-D is particularly effective in patients 
with significant inter-/intraventricular conduction delays. Previous studies, including 
REVERSE and MADIT-CRT, also showed that especially patients with a QRS 
duration ≥150 ms derived the greatest clinical benefit from CRT-D.7,16 This should 
be investigated further, as QRS duration might be an essential factor in predicting 
response to CRT. 
The limitations of the present study must be acknowledged. First, we did not 
control for CRT response or nonresponse, because we had no information on changes 
that may have occurred in NYHA classification, LVEF, and QRS duration during the 
follow-up period. Yet research has shown that changes in these parameters are only 
marginally associated with patient reported changes in CHF symptoms and quality 
of life.17,18 Second, health status was assessed with a generic rather than a disease-
specific measure, using a disease-specific measure generally being more sensitive to tap 
symptoms important to patients.15 Third, the sample size of NYHA functional class II 
patients (n=54) was relatively small. 
Despite these limitations, this study also had several strengths, including its 
prospective study design with a 12-month follow-up period and the inclusion of several 
domains of health status. Most previous studies on health status in CRT- D patients 
have reported overall scores of health status.5,6,19 The results of the present study show 
that it is important to look at the dimensions of health status separately, because using 
an overall score of health status may mask differences between subgroups on different 
dimensions of health status. 
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Improvement in NYHA functional class and patient 
reported health status following CRT in the PSYHEART 
study - Who knows best: Th e physician or the patient?
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ABSTRACT
Background A positive clinical response to cardiac resynchronization therapy (CRT) 
implies improvement in health status, including relief of symptoms, a decline in 
functional limitation, and improved quality of life. In cardiology practice, this is often 
defined as an improvement in NYHA functional class. We examined the association 
between improvement in physician rated NYHA functional class and patient reported 
health status in the first 2 months after CRT implantation. 
Methods Consecutively implanted CRT patients (N=101, mean age=65.2±10.1, 
28 women, NYHA: II (21), III (77), IV (3)) were recruited from the University 
Medical Center Utrecht, the Netherlands. All patients completed the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) at the time of implantation and 2 months 
post implantation. Information on NYHA functional class was obtained from patients’ 
medical records. 
Results Of all patients, 42 (41.6%) improved by ≥1 NYHA class in the first 2 months 
after CRT implantation. Of the 59 patients whose NYHA functional class remained 
stable, 61% reported clinically relevant improvements in the KCCQ overall summary 
score, while only 45% of the patients reporting better health status also improved 
in NYHA functional class. Logistic regression results (ps≥.05) and c-statistics (range 
0.53-0.61) confirmed that improvement in NYHA functional class was not associated 
with improvement in KCCQ scores. 
Conclusions Our results show a large discrepancy between improvement in physician 
rated NYHA functional class and patient reported health status in the first 2 months 
after CRT implantation. This emphasizes that health status measures may have 
additional value over NYHA functional class in assessing short-term clinical response 
to CRT. 
Versteeg H, Meine M, Tuinenburg AE, Doevendans PA, Denollet J, Pedersen SS.  Improvement in 
NYHA functional class and patient reported health status following CRT in the PSYHEART study - 
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INTRODUCTION
Cardiac resynchronization therapy (CRT), often in combination with an implantable 
cardioverter defibrillator (ICD; CRT-D), is a promising treatment for a subset of 
patients with congestive heart failure (CHF).1 CRT is recommended in patients who 
remain symptomatic (New York Heart Association (NYHA) functional class II-IV) 
despite optimal pharmacological therapy, with a depressed left ventricular ejection 
fraction (LVEF ≤35%), and an inter-/intraventricular conduction delay (QRS 
duration ≥120 ms, or ≥150 ms in NYHA functional class II patients).2 Large-scale 
studies have demonstrated that the majority of these patients benefit from CRT,3,4 but 
a significant proportion (10-40%) of patients does not respond to this treatment and 
are labeled nonresponders,5,6 although no consensus exists regarding the definition of 
a positive response to CRT.7
As CHF is a debilitating chronic disease, a main goal of treatment is not only 
to prolong life, but also to relieve symptoms and to improve function and quality 
of life.7,8 In clinical practice, this improvement in patient health status is most often 
defined as an improvement in ≥1 NYHA functional class. However, previous studies 
indicate that there is only a moderate association between physician rated NYHA 
functional class and patient reported health status, and most of the variation in health 
status scores cannot be explained by NYHA functional class alone.9-11 These results 
suggest that clinically relevant changes in health status can occur in the absence of 
changes in NYHA functional class. Detecting changes in patient reported health status 
is not only essential to determine response to treatment as experienced by patients,12 
but also for secondary prevention as poor health status is an independent predictor of 
mortality and hospital readmission in CHF patients.13,14 
The objective of the current study was to examine the association between 
improvement in physician rated NYHA functional class and patient reported health 
status in the first 2 months after CRT-implantation.   
METHODS
Study design and participants 
Patients receiving a first-time CRT(-D) implantation according to the current guidelines 
(NYHA functional class ≥II, LVEF ≤35 %, QRS ≥120 ms) in 2009 and 2010 at the 
University Medical Center Utrecht (UMCU), the Netherlands, comprised the patient 
sample for the current study. Patients participated in the ongoing ‘The influence of 
PSYchological factors on health outcomes in HEART failure patients treated with 
Cardiac Resynchronization Therapy: A prospective, single-center, observational study 
(PSYHEART-CRT). The PSYHEART-CRT study was primarily designed to examine 
whether psychological factors moderate the effect of objectively assessed CRT 
response on patient reported outcomes in CHF patients. Exclusion criteria were age 
 NYHA functional class versus health status
Proefschrift.indd   53 13-9-2011   7:28:55
54
<18 or >85 years, a history of psychiatric illness other than aff ective/anxiety disorders, 
cognitive impairments (e.g. dementia), on the waiting list for heart transplantation, 
and insuffi  cient knowledge of the Dutch language. One day prior to implantation 
(baseline) and 2 months after implantation, patients were asked to complete a set of 
standardized and validated questionnaires. Th e study protocol was approved by the 
Medical Ethics Committee of the UMCU. Th e study was conducted in accordance 
with the Helsinki Declaration, and all patients provided written informed consent. 
Measures
Demographic and clinical variables
Demographic variables included sex, age, marital status (single versus having a partner), 
employment status (currently employed versus unemployed), and educational level 
(primary school or lower versus secondary school or higher), and were obtained via 
purpose-designed questions at baseline. Information on clinical variables, including 
etiology (ischemic versus non-ischemic), ICD indication (primary versus secondary 
prevention), NYHA functional class (see text box below for classifi cation criteria), 
LVEF, QRS duration, atrial fi brillation, diabetes, renal insuffi  ciency (creatinine >120 
umol/L), smoking, and cardiac and psychotropic medication, were extracted from 
the patients’ medical records. For patients with a CRT-D device, information on the 
occurrence of shocks (appropriate and inappropriate) during follow-up was obtained 
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Disease-specific health status
The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to assess 
disease-specific health status.15 The KCCQ is a 23-item, self-report questionnaire 
that quantifies physical limitation, symptoms, social function, and quality of life of 
patients with CHF. These 4 health status subscales can be combined into a single 
overall summary score. Scores are transformed into a score from 0 to 100, with higher 
scores representing better functioning, fewer symptoms, and better quality of life. The 
validity and reliability of the KCCQ have previously been established and the measure 
was shown to be highly sensitive to clinical change in CHF patients over a 6-12 week 
period.15-17 A mean difference over time of ≥5 points on the KCCQ overall summary 
score is considered a small, but clinically relevant change and has been associated 
with an 11% change in the adjusted hazard ratio of hospitalization and cardiovascular 
death.13,17 
Statistical analyses
Discrete variables were compared with the Chi-square test and continuous variables 
with Student’s t test for independent samples. The absolute changes in KCCQ health 
status scores were calculated (2 months minus baseline scores) and dichotomized 
into ‘improved’ versus ‘not improved’. Regarding the KCCQ overall summary score, 
absolute changes of ≥5, ≥10, and ≥20 points were used to represent small, moderate, 
and large improvements, respectively.17  Patients with stable and deteriorated KCCQ 
scores were combined because of limited sample size in the deterioration category; 
only 15 patients (14.9%) reported clinically relevant deteriorations in the KCCQ 
overall summary score (≥5 points) from baseline to 2 months. 
Univariable and multivariable logistic regression analyses were performed 
to examine whether improvement in NYHA functional class was associated with 
improvements in KCCQ scores. A priori, we decided to include age, sex, etiology, 
baseline NYHA functional class, LVEF, QRS duration, AF, diabetes, renal insufficiency, 
and psychotropic medication in multivariable analyses. Odds ratios (OR) and their 
corresponding 95% confidence intervals (CI) and c-statistics are reported. The 
c-statistic is equivalent to the area under the Receiver Operating Characteristic (ROC) 
curve and represents the ability of improvement in NYHA functional class to correctly 
discriminate patients who report clinically relevant improvement in KCCQ scores 
from those who do not. A c-statistic value of 0.50 indicates no discriminative ability, 
whereas a value of 1.00 indicates perfect discrimination.18 All tests were two-tailed, 
and a Bonferroni correction was applied to adjust for multiple comparisons, with 
p≤.007 (p=.05/7) indicating statistical significance. All analyses were performed with 
SPSS 17.0 for Windows (SPPS Inc., Chicago, Illinois). 
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Table 1. Baseline characteristics for the total sample, and stratifi ed by (1) stable vs. improved 
NYHA class, and by (2) not improved vs. improved (≥5 points) KCCQ overall summary score
Results are presented as n (%), unless otherwise stated.
*p≤.05; **p≤.01; ***p≤.001
a Less than secondary school
ACE=angiotensin converting enzyme; NYHA=New York Heart Association functional class; LVEF=left 
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RESULTS
Participants versus nonparticipants on baseline characteristics
138 consecutive CRT patients were asked to participate, of which 107 patients 
consented (response rate 77.5%). Six of these patients were not included in the 
analyses, as they did not complete the KCCQ (n=2) or their NYHA functional class 
was not reported (n=4) at follow-up. There were no systematic differences between 
participants (N=101) and nonparticipants (n=37) on baseline characteristics (results 
not shown). 
Baseline characteristics of stable versus improved patients
Baseline characteristics of the total sample and stratified by (1) stable versus improved 
NYHA functional class and by (2) not improved versus improved KCCQ overall 
summary score (≥5 points), are shown in Table 1. Of all patients, 42 (41.6%) patients 
improved by ≥1 NYHA functional class in the first 2 months after CRT implantation 
(i.e., 2 patients improved by 2 classes, 40 patients improved by 1 class). These patients 
were more likely to be in NYHA functional class III or IV (95.2% versus 65.8%, 
p<.001; of note, only 3 patients were in NYHA functional class IV, they all improved 
to class III) and had a lower mean LVEF prior to implantation compared to the 59 
patients whose NYHA functional class did not improve (21.7±7.3 versus 24.9±7.3, 
p=.03). There were no other systematic differences between these two patient groups 
on baseline characteristics. In total, 67 (66.3%) patients reported clinically relevant 
improvement in KCCQ overall summary score. These patients did not differ regarding 
baseline characteristics from patients reporting no KCCQ improvement. 
Of note, one patient received an CRT-P and only 2 of the remaining 100 patients 
experienced appropriate ICD shock(s) during the follow-up period, one of them 
improved from NYHA functional class III to II, the other remained stable in NYHA 
functional class III. However, both reported no improvement in KCCQ overall 
summary score. None of the patients experienced inappropriate shocks. 
 
Association between improvement in NYHA functional class and KCCQ scores 
The patients with stable versus improved NYHA functional class did not differ in their 
baseline KCCQ subscale and overall summary scores (all ps>.05). Figure 1a shows 
the percentage of patients reporting improvement in KCCQ subscale scores stratified 
by stable versus improved NYHA functional class. Two thirds (59.3%-69.5%) of 
the 59 patients with stable NYHA functional class reported better functioning, less 
symptoms, or improved quality of life from baseline to 2 months post implantation. 
These proportions were lower than in the group of patients with improved NYHA 
functional class (70.7%-78.6%), but Chi-square tests showed that they were not 
significantly different (all ps>.007). Regarding the KCCQ overall summary score 
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(Figure 1b), 36 (61.0%), 33 (55.9%), and 23 (39.0%) of the patients with stable NYHA 
functional class reported small, moderate, and large improvements, respectively, versus 
31 (73.8%), 27 (64.3%), and 20 (47.6%) of the 42 patients with improved NYHA 






Figure 1a. Percentage of patients reporting improvements in KCCQ health status subscale 
scores, stratifi ed by stable versus improved NYHA functional class
Figure 1b. Percentage of patients reporting small, moderate, and large improvements in 
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Table 2 represents the results of the logistic regression analyses showing that 
improvement in NYHA functional class was not associated with improvements in 
KCCQ (subscale) scores (all ps>.007). Accordingly, the c-statistics ranged from 0.53-
0.61, indicating that improvement in NYHA functional class performs no better 
than chance in discriminating patients that experience improvements in KCCQ 
scores from those who do not. Improvement in NYHA functional class was most 
accurate, but still poor, in discriminating patients with improvements in the KCCQ 
quality of life score (c-statistic=0.61). When adjusting for age, sex, etiology, baseline 
NYHA functional class, LVEF, QRS duration, AF, diabetes, renal insuffi  ciency, and 
psychotropic medication, the associations between improvement in NYHA functional 
class and KCCQ scores remained non-signifi cant (range ORs=0.88-3.27, all ps>.007). 
Of note, none of the included covariates was signifi cantly associated with improvement 
in KCCQ scores (all ps>.007). 
DISCUSSION
In the current prospective study, we examined the association between improvement 
in physician rated NYHA functional class and patient reported health status in the 
fi rst 2 months after CRT implantation. Results showed that in patients whose NYHA 
functional class remained stable, 60-70% did report improvements in health status 
(domain) scores. By contrast, only 45-47% of patients experiencing small to large 
improvements in overall health status also improved in NYHA functional class. 
Logistic regression results and c-statistics confi rmed that improvement in NYHA 
functional class was not associated with improvement in KCCQ scores. 
 NYHA functional class versus health status
Table 2. Consistency between improvement in NYHA functional class and KCCQ scores
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The current results emphasize previous findings that NYHA functional class 
should likely not be used as the sole measure reflecting changes in the severity of 
symptoms and functional limitations in CHF patients.9-11 which is now often the case 
in clinical practice and research trials. The NYHA functional classification system 
has been criticized due to the method not being standardized19,20 and due to poor 
interrater reliability.20,21 The class that the physician decides to assign to a patient 
depends on the questions the physician asks and his/her interpretation of what 
comprises ‘ordinary physical activity’ and ‘slight’ versus ‘marked’ limitations.20 In 
addition, criteria often used to determine NYHA functional class include ‘self-reported 
walking distance’ and ‘difficulty in climbing stairs’.20 These criteria, however, primarily 
assess general functional status and many factors may influence the patient’s answer, 
including comorbidities, environmental and psychosocial factors, and perception 
of distance.20,22,23 Serial assessment of patient reported health status using a disease-
specific questionnaire offers physicians important additional information on how the 
patient is doing over time.12,22 Also, it may optimize secondary prevention as health 
status measures have been shown to predict mortality and hospital readmissions in 
patients with CHF independent of traditional biomedical risk factors.13,14 
Improvement in health status is particularly important from the patient perspective, 
as their primary concerns revolve around how a disease or treatment affects their 
daily lives,8,24 Patient reported health status has been recommended as a performance 
measure of high quality care by the American College of Cardiology, the American 
Heart Association, and the American Medical Association,25 and is increasingly seen 
as an important endpoint in clinical research.26 Yet, the incorporation of health status 
measures in routine clinical practice is less common and more challenging due to a 
number of practical, methodological, and attitudinal barriers.27,28 When these barriers 
are adequately addressed, the implementation of patient reported outcomes in clinical 
practice could have a number of potential benefits for both the physician and the 
patient.27,29 It could enable physicians to detect and treat physical or psychological 
problems that otherwise might go unrecognized, promote the role of patients in 
clinical decision making, and enhance physician-patient communication, which in 
turn might improve patient satisfaction with care and adherence to treatment.12,27,30 
Preliminary evidence from oncology shows that incorporation of a health status 
measure in the clinical management of patients does not increase the time burden to 
physicians when they see patients for clinical consultations.30
The present study showed that neither improvement in NYHA class nor any of the 
baseline demographic and clinical factors included in adjusted analyses were associated 
with improvement in health status. These results are on a par with earlier studies 
showing a discrepancy between objective measures of disease severity and patient 
perceived symptoms and quality of life.11,31,32 A growing body of evidence suggests 
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have a notable impact on patient reported health status in CHF patients, irrespective 
of cardiac disease severity.33-37 Studies are warranted that examine the demographic, 
clinical, and psychosocial determinants of patient health status after CHF treatment, 
which may help identify targets for secondary prevention.38 
The limitations of the current study should be acknowledged. First, the follow-
up period of 2 months might be too short to adequately assess response to CRT. In 
the first months after implantation, patient’ health might be positively influenced by 
a placebo-effect, but also negatively by pain at the implantation site, limited arm and 
shoulder motion, and a driving restriction. However, our results show that clinically 
relevant changes in health status can occur within this short period of time. Second, 
our patient sample was relatively small and we had to combine patients with stable 
and deteriorated KCCQ scores into one group. Future studies with larger patient 
samples and longer follow-up periods are needed to confirm our results and to identify 
the determinants of health status changes after CRT implantation. Finally, for logistic 
reasons baseline assessment was done one day prior to implantation, which may have 
resulted in more impaired health status due to pre-implantation distress. However, the 
instruction of the KCCQ calls for the rating of symptoms, function, and quality of 
life in the past two weeks. 
The present study also has several strengths. First, we used a disease-specific 
measure to assess health status, which was previously shown to be highly responsive 
to clinical change over a 6-week period.16,17 We also examined proportions of patients 
who showed benefit instead of mean group changes. As previously mentioned, health 
status scores are influenced by demographic, clinical, and psychosocial factors, so 
there is a large variability in individual responses. Therefore, earlier studies on CRT 
response presenting mean changes in health status (i.e., the CRT group improved by 
5 points more than the control group) could be misleading. For clinical practice, it 
is more relevant to focus on the proportion of patients achieving a particular benefit 
from treatment, be it a small, moderate, or large benefit, as this reflects changes in 
individual patients.39 
To conclude, our results show a large discrepancy between improvement in 
physician rated NYHA functional class and patient reported health status in the first 
2 months after CRT implantation. This emphasizes that health status scores may have 
additional value over NYHA functional class in assessing short-term clinical response 
to CRT. Hence, we would recommend the incorporation of health status measures in 
clinical practice to gain a better understanding of individual CHF patients’ experiences 
and responses to treatment.  
 NYHA functional class versus health status
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ABSTRACT
Background Few studies have investigated the association between implantable 
cardioverter defibrillator (ICD) and lead advisory notifications and patient reported 
outcomes (PROs). We examined (i) whether the mode used to inform patients about 
a device advisory is associated with PROs, and (ii) whether patients with a device 
advisory report poorer PROs compared to non advisory controls.
Methods Patients (n=207) implanted with an ICD at Aarhus University Hospital, 
Denmark, with a Sprint Fidelis lead subject to advisory and a non advisory control 
group (n=510) completed a set of standardized PRO measures. A Bonferroni correction 
was applied to all statistical PRO comparisons to adjust for multiple comparisons, 
with a p-value of .0038 (.05/13 PROs) indicating statistical significance.
Results Device advisory patients did not differ significantly on PROs according 
to mode of notification (all ps>.0038). They also did not differ significantly from 
controls on mean scores of depression, anxiety, device acceptance, and health status 
(all ps>.0038). Differences were only found on ICD concerns (p<.0001) and on the 
mental health status domain (p=.003), with advisory patients reporting fewer ICD 
concerns and a better mental health status than non advisory controls. 
Conclusions The mode used to inform ICD patients about the advisory was not 
associated with PROs, nor was the overall well being of device advisory patients 
impaired compared to non-advisory controls. These results indicate that ICD patients 
are generally able to cope with a device advisory.
Pedersen SS, Versteeg H, Nielsen JC, Mortensen PT, Johansen JB.  Patient reported outcomes in Danish 
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INTRODUCTION
Implantable cardioverter defibrillator (ICD) therapy is the first line treatment for 
the primary and secondary prevention of sudden cardiac death.1 Despite its medical 
benefits, ICD therapy is associated with a potential for procedure-related (e.g., 
infection and bleeding) and device-related complications (e.g., inappropriate shocks 
and lead dysfunction).2,3 Device-related complications, such as device dysfunction and 
lead fracture, have increased in the last decade, although it is not a new phenomenon.4 
However, guidelines are now in place from the Food and Drug Administration and 
the Heart Rhythm Society on device performance and also on how device advisory 
notifications should be communicated to patients.5
Device advisories may have an adverse influence on patient reported outcomes 
(PROs), such as well being and quality of life. As voiced in an editorial published 
in 2008 related to the Sprint Fidelis advisory, there is an urgent need to examine 
the influence of advisory notifications on patient well being both with respect to the 
impact of the advisory itself but also with respect to how to communicate the risk 
to patients.6 A true estimation of the impact of advisories on patients may serve to 
counterbalance the associated negative publicity in the press, which has led to patients 
turning down this potentially life-saving treatment as reported in the United States.7 
Few studies have examined the impact of device advisory notifications on 
patients, as assessed with PROs. In a recent viewpoint,8 we identified 6 studies, with 
sample sizes ranging from 31-86 patients with hardware subject to a Class I or a Class 
II advisory.9-14 The evidence for a psychological impact of device advisory notifications 
is mixed, as shown in an update of the literature, as presented in Table 1. Little is also 
known about the most appropriate way of communicating the risk associated with an 
advisory to patients and whether different modes may have a differential influence on 
PROs.6
In the current study, we examined (i) whether the mode used to inform patients 
about the Sprint Fidelis device advisory (i.e., informing patients by letter calling them 
in for an urgent clinical follow-up visit versus informing them ad-hoc during a routine 
clinical visit) is associated with mean scores on PROs, and (ii) whether patients with a 
device advisory notification report poorer PROs compared to non-advisory patients, 
assessed with both disease-specific and generic measures. 
METHODS
Study design and participants
Patients (n=207, response rate 87%) implanted with an ICD between 1993 to 
2009 at Aarhus University Hospital (Skejby), Denmark, and with a lead (6931 or 
6949) subject to the Medtronic Sprint Fidelis ICD lead advisory, completed a set of 
standardized and validated PROs between September and October 2009. The Sprint 
           Device advisory and patient reported outcomes
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Fidelis ICD lead advisory was issued due to potential lead fracture that could lead to 
unnecessary (inappropriate) shocks but also failure to deliver life-saving defibrillating 
shocks. Lead Integrity AlertTM (LIA; Medtronic, Mineapolos, MN, USA) software was 
made available for download to the device which would alert patients of potential lead 
failure. In Denmark, the Sprint Fidelis lead advisory was issued on October 15, 2007. 
All of our patients were informed about the LIA software and the rationale at the time 
of downloading it to their device.
Patients were informed about the advisory in one of the following two ways: (i) 
by letter in December of 2008, calling patients in for an urgent clinical follow-up visit, 
and (ii) ad-hoc during a routine clinical visit. Hence, for patients in group (i) the time 
interval between the device advisory notification and completing the questionnaires 
was 9 months, whereas for group (ii) the interval was variable. Both groups had the 
LIA software downloaded to their device during the clinical follow-up visit. 
A control group of patients (n=510), implanted with an ICD between 1991 and 
2006 at our institution but whose hardware was not under advisory, had completed 
the same questionnaires for a previous study (response rate 84%).15,16 For the majority 
of the control patients (i.e., 95%), the main indication for ICD was secondary 
prevention, as primary prevention was not generally implemented in Denmark before 
2007. Both advisory and control patients had to be ≥18 years of age to be eligible to 
participate. For both groups, if the questionnaire was not returned within 2 weeks, 
a reminder was sent by post including a duplicate questionnaire. The study was 
conducted according to the Declaration of Helsinki. 
Measures
Demographic and clinical variables
Information on demographic and clinical variables was obtained from the Danish 
ICD Register17 or from purpose-designed questions in the questionnaire. 
Symptoms of anxiety and depression
We used the 14-item Hospital Anxiety and Depression Scale (HADS) to assess 
symptoms of anxiety and depression.18 Items are answered on a 4-point Likert scale 
from 0-3 (score range 0-21), with 7 items contributing to the anxiety and depression 
subscales, respectively. A high score on the HADS indicates more symptoms of anxiety 
and depression. A cut-off score ≥8 for both subscales represents probable clinical levels 
of anxiety and depression.19 The HADS is a valid and reliable instrument that has been 
used across the world in cardiac and non-cardiac populations,19 and that is not prone 
to confounding by symptoms of somatic disease.20
Device-related concerns
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is an 8-item self-report measure tapping into concerns about the ICD giving a shock 
(e.g., ‘I am worried about my ICD firing’).21,22 Items are rated on a 5-point Likert scale 
from 0 (not at all) to 4 (very much so), with a higher score indicating a higher level 
of device-related concerns (score range 0-32). The internal consistency of the 8-item 
ICDC is good, with Cronbach’s alpha=.91.22 Previously, we have shown that high 
levels of pre implantation ICD concerns predict mortality in ICD patients.23 
Device acceptance
Device acceptance was assessed with the 18-item Florida Patient Acceptance Survey 
(FPAS).24 Items (e.g., ‘When I think about the device, I avoid doing things that I enjoy’ 
and ‘I feel less attractive because of my device’) are rated on a 5-point Likert scale from 
1 (strongly disagree) to 5 (strongly agree) Of all items, 15 contribute to a total score, 
while the remaining 3 items are filler items. A high score indicates better acceptance. 
The convergent, divergent, and discriminant validity of the FPAS are good, and the 
scale has been shown to be internally consistent, as indicated by Cronbach’s alpha of 
.83 for the total scale. Previously, we have validated the FPAS in Danish ICD patients, 
with this specific language version indicating good validity and reliability.25 
Health status
We used both a disease-specific and generic measure of health status. The Minnesota 
Living with Heart Failure Questionnaire (MLHFQ) is a disease-specific measure, 
comprising 21 items.26 Items are answered on a 6-point Likert scale from 0 (no) to 5 
(very much). The total score ranges from 0 to 105, with a higher score indicating poor 
health status. The measure is psychometrically sound, with good internal consistency 
as measured by Cronbach’s alpha=.91-.96 for the total scale. 
The Short Form Health Survey (SF-36) is a generic measure of health status, 
comprising 36 items that contribute to 8 domains: Role Physical Functioning, 
Role Emotional Functioning, Physical Functioning, Mental Health, Vitality, Social 
Functioning, Bodily Pain, and General Health.27,28 Scale scores range from 0 to 100, 
with a higher score indicating better functioning. The scale has good reliability with 
Cronbach’s alpha ranging from .65 to .96 for all subscales.27 
Statistical analyses
The three patient groups, that is (i) device advisory patients informed by letter urging 
them to come in for a clinical follow-up visit, (ii) device advisory patients informed 
ad-hoc during a clinical follow-up visit, and control patients without a device or leads 
subject to an advisory notification, were compared on baseline characteristics using 
analysis of variance (ANOVA) with a post-hoc Bonferroni correction (if applicable) 
for continuous variables and the Chi-square test for nominal variables. Student’s t 
test for independent samples was used to compare the two device advisory groups 
           Device advisory and patient reported outcomes
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on PROs, and the device advisory group (irrespective of how information was given 
about the advisory) with the control group on PROs. Due to multiple comparisons 
that increase the chance of finding a statistically significant result and to prevent 
making a Type I error (also known as a false positive), we used a Bonferroni correction 
for these analyses. Accordingly, given that we had 13 PROs, we divided the standard 
p-value of .05 by 13, using a p-value of .0038 to indicate statistical significance for 
the interpretation of these results. However, for all results both in the text and in 
the figures the exact p-value for each comparison is also reported. All analyses were 
performed using SPSS 17.1 for Windows (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Baseline characteristics
Baseline characteristics stratified by advisory groups (i) and (ii) versus no advisory 
(control group) are displayed in Table 2. The groups did not differ systematically on 
baseline characteristics, except that advisory group (i) patients were more likely to have 
a defibrillator with cardiac synchronization therapy (CRT-D) device than advisory 
group (ii) patients and controls, and advisory group (ii) patients were more likely to be 
prescribed beta-blockers compared to advisory group (i) patients and controls. Time 
since first ICD implant was longer for controls compared to advisory group (i) and 
(ii) patients.
Patient reported outcomes in advisory patients stratified by mode of notification
No statistically significant differences were found on psychological distress (Figure 
1a) and health status (Figure 1b) between group (i) patients who were notified about 
the device advisory by letter calling them in for an urgent clinical follow-up visit and 
group (ii) patients who were informed ad-hoc during a routine clinical follow-up visit, 
with all ps>.0038 which was chosen to indicate statistical significance. 
Patient reported outcomes stratified by device advisory versus control patients
Given that we found no statistically significant differences on PROs between the 
two advisory groups stratified by mode of notification, we merged the groups (i) 
and (ii) and compared device advisory patients with a non-advisory control group 
to examine potential differences in PROs. There were no statistically significant 
differences between advisory and non-advisory patients on symptoms of depression 
and anxiety, while advisory patients reported less ICD concerns than non-advisory 
controls (5.12±6.04 vs. 7.67±8.28, p<.0001) (Figure 2a). As for device acceptance 
and disease-specific and generic health status, there was only one difference between 
groups, with advisory patients reporting better mental health status than non-advisory 
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Table 2. Baseline characteristics stratifi ed by device advisory versus no advisory
Results are presented as n (%) unless otherwise indicated.
(i) Notifi cation of the device advisory by letter in December of 2008 calling patients in for an urgent clinical 
follow-up, and (ii) ad-hoc during a routine clinical visit.
a Group diff erences were signifi cant between controls and device advisory (i) patients and between controls and 
device advisory (ii) patients (post-hoc Bonferroni ps<.0001) but not between device advisory (i) and device 
advisory (ii) patients (post-hoc Bonferroni p=1.00)  
ACE=angiotensin converting enzyme; ARB=Angiotensin II receptor antagonists; CRT-D=cardiac 
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

   

    
    
    
    
    
    
    
    


























































































































































































































Figure 1. (a) Psychological distress and (b) health status stratifi ed by device advisory notifi cation 
mode

















































All comparisons were non significant with a Bonferroni correction (all ps > .0038),

































































































































































Figure 2. (a) Psychological distress and (b) health status stratifi ed by device advisory status
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DISCUSSION
Device advisories may be unnerving to patients and may reduce patient confidence in 
their device. For this reason, it is important to examine the impact of device advisories 
on patient well being and device acceptance both with respect to the impact of the 
advisory itself but also with respect to how best to communicate the risk to patients.6 
In the current study, we examined the association between mode of informing patients 
about the Sprint Fidelis lead advisory and PROs and the association between having 
an ICD lead subject to an advisory versus no advisory and PROs, as assessed with a 
broad range of PROs, including both disease-specific and generic measures tapping 
into patient distress, health status, device concerns, and acceptance. 
The mode used to inform ICD patients about the device advisory – that is calling 
patients in for an urgent clinical follow-up visit versus informing patients ad-hoc 
during a routine clinical visit – was not associated with psychological well being and 
health status in our patient cohort, nor was the well being and health status of device 
advisory patients impaired compared to patients without an advisory notice. In fact, 
non-advisory controls reported more ICD concerns and poorer mental health status 
than advisory patients, which is consistent with the findings of a previous study.13 
Concurrent with other studies, these results indicate that ICD patients are generally 
able to cope with a device advisory.8,12-14,29 Patients may implicitly accept that with 
increased complexity of technology to manage heart disease there is a trade off with 
respect to the risk of complications and hardware malfunctioning. The downloading 
of the LIA software, which was applicable to all patients with an advice notification 
in the current study, might also have helped to reinstate patient confidence in the 
device.30
It was somewhat surprising that the mode of notification about the device 
advisory had no influence on patient well being and health status in our study. A 
priori, we would have expected that patients receiving a letter calling them in for 
an urgent clinical follow-up would more likely be in a state of panic and therefore 
experience more distress than patients being informed about the advisory in a more 
gentle way during a subsequent clinical follow-up visit. It is possible, however, that 
the mode of debriefing patients about the device advisory may be of less importance 
compared to the source of the information (e.g., physician, manufacturer, news 
media, etc), which information is provided, and whether patients have the possibility 
to attend psychological counseling, as reported in some studies.11,12 In the current 
study, the notification about the device advisory was communicated by physicians. 
Previously, it has been suggested that patients prefer to learn about a device advisory 
from their physician rather than from the media.31 However, the latter study used 
vignettes and asked patients to rate their concerns with respect to a hypothetical rather 
than a real device advisory. A more recent study examining the influence of the source 






Proefschrift.indd   78 13-9-2011   7:29:10
79           Device advisory and patient reported outcomes
who heard about the advisory from news media and those who heard about the 
advisory from a physician, industry, or others.30 Given the absence of large-scale, well 
designed studies, it is too premature to draw any firm conclusions about the influence 
of mode and source of information about the device advisory on patient well being. 
Currently, the Heart Rhythm Society has provided recommendations to the 
industry and physicians with respect to monitoring device performance and how 
to handle device malfunctioning.5 Patient recommendations how to deal with a 
device advisory notification both at an emotional and at an behavioral level are also 
available.32 In addition, information on device performance is required to be included 
in the National Cardiovascular Data Registry (NCDR) ICD Registry in the United 
States.5 All these initiatives are of major importance in monitoring device performance 
and obtaining a true picture of the incidence of hardware malfunctioning and the 
concomitant risk to patient health. However, given that neither the recommendations 
from the Heart Rhythm Society nor those from NCDR ICD Registry include PROs 
– that is asking patients to rate the impact of hardware malfunctioning and device 
advisories on their well being and quality of life – the risk that the patient is still 
‘left behind’ is prominent, as posited in an editorial to the Sprint Fidelis advisory:6 
“However, in 2008 the important core issues regarding device reliability remain 
unsolved and longstanding issues regarding patient information and patient well 
being are even more acute.” The inclusion of routine and serial assessments of PROs 
in national registries such as the NCDR ICD Registry would enable us to track 
information on how device advisories affect patient well being, rather than relying on 
information from single-center and smaller scale ad-hoc studies.8 
The results of the current study should be interpreted with some caution. First, 
we used a convenience sample as a non-advisory control group. Second, as in previous 
studies examining the impact of a device advisory notification on patients,11,12,14 there 
was a time interval from the notification to patient completion of the PRO measures. 
It is possible that the advisory notification may have an impact on patient well being 
and quality of life of patients just after the notification, but that the impact of the 
advisory dissipates over time, reflecting that patients are able to adapt even short-term. 
Based on the design of our study, we are not able to deduce whether a short-term 
effect was present. Third, we did not evaluate patient perception of the risk of having 
a recalled Sprint Fidelis lead, which could potentially serve as a confounder on PROs. 
This dimension would be interesting to add to future studies on device advisory 
notifications, although it may not be patient perception of risk per se but rather whether 
this knowledge instills fear in and bothers patients that influences PROs. Fourth, the 
device advisory notification patients differed from the non-advisory patients on time 
since first ICD implant, with controls having had their ICD for a longer period of 
time. Time since first ICD implant may serve as a potential confounder on the results, 
although several studies do not support an influence of duration since implantation 
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on PROs.15,33 Fifth, the control cohort was predominantly secondary prevention 
patients,15 with the potential that indication might have confounded the results. 
However, based on the current literature on the impact of indication on PROs, there 
is no evidence to support this notion, with available studies showing no differences in 
PROs between primary and secondary prevention patients.34 
This study also has several advantages. To our knowledge, it is the largest study 
to date to examine the impact of a device advisory notification on patient well being 
except for the recently published study by Keren et al.29 Second, we included a broad 
spectrum of PROs tapping into patient distress and health status with the use of both 
disease-specific and generic measures. Disease-specific measures are generally more 
sensitive to tap symptoms that are relevant to patients and therefore less prone to floor 
and ceiling effects that may obscure results.35
In conclusion, the mode used to inform ICD patients about the Sprint Fidelis 
lead advisory was not associated with psychological well being and health status, as 
patients informed about the advisory by letter calling them in for an urgent clinical 
follow-up visit did not differ on psychological distress and health status from patients 
informed ad-hoc during a routine clinical visit. We also found no evidence that the 
well being and health status of device advisory patients is impaired as compared to 
patients without an advisory notice. Taken together, these results indicate that ICD 
patients are generally able to cope with a device advisory. Nevertheless, the arrhythmia 
community should consider the advantages of including routine and serial assessments 
of PROs in national registries in order to enhance our knowledge of the impact of 
device advisories on patient well being. If this is implemented as standard practice, 
with assessments available from the time of implantation, we would not only have 
a pre advisory assessment but also be able to track patient well being following the 
advisory over time, and hence to draw more firm conclusions about the impact on 
patients. For the future management and care of ICD patients, such information 
would be paramount given that ICD lead failures are likely to be here to stay. 
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Chapter 6
Posttraumatic stress in implantable cardioverter 
defi brillator patients: Th e role of pre-
implantation distress and shocks
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ABSTRACT
In this prospective study, we examined the prevalence and determinants of posttraumatic 
stress disorder (PTSD) in 300 patients (80.3% men, mean age=57.9±12.0) with 
an implantable cardioverter defibrillator (ICD). At 3 months post implantation, 
35 (11.7%) patients qualified for a diagnosis of PTSD. At 6 months, 21 of these 
patients still had PTSD, while 13 patients had developed new onset PTSD, resulting 
in a total of 34 (11.3%) patients with PTSD. Multivariable logistic regression 
analysis showed that Type D personality (OR=2.53, 95% CI:1.05-6.10), high pre-
implantation anxiety (OR=2.88; 95% CI:1.10-7.56), and shocks during follow-up 
(OR=5.78, 95% CI:1.51-22.12) were independently associated with PTSD at 3 
months. High pre-implantation anxiety (OR=4.24, 95% CI:1.64-11.00) and ICD 
concerns (OR=2.73, 95% CI:1.20-6.24) were associated with PTSD at 6 months. 
To conclude, a small subgroup of ICD patients is at risk of developing PTSD. These 
patients could be identified by their psychological vulnerability to experience distress 
prior to implantation. Psychosocial intervention may be warranted in these patients, 
as PTSD in ICD patients has been associated with an increased risk of mortality.
Versteeg H, Theuns DAMJ, Erdman RAM, Jordaens L, Pedersen SS. Posttraumatic stress in implantable 
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Subgroups of patients are at risk of posttraumatic stress disorder (PTSD) after a cardiac 
event, such as a myocardial infarction.1 Treatment with an implantable cardioverter 
defibrillator (ICD) may also qualify as a potential traumatic stressor, as it may serve 
as a constant reminder of the underlying cardiac condition, and is able to deliver 
an uncontrollable shock to terminate life-threatening ventricular tachyarrhythmias.2 
Two previous studies have reported severe PTSD symptoms in 13-25% of the ICD 
patients.3,4 It is essential to identify factors associated with an increased risk of PTSD 
after ICD implantation, given that severe PTSD symptoms may confer a 3-fold 
increased risk of mortality in ICD patients, independent of disease severity.4 To our 
knowledge, no study to date has examined the determinants of PTSD in ICD patients. 
We investigated the prevalence and determinants of PTSD symptoms at 3 and 
6 months post implantation, in a sample of 300 ICD patients (80.3% men, mean 
age=57.9±12.0) participating in the ongoing Mood and personality as precipitants of 
arrhythmia in patients with an Implantable cardioverter Defibrillator: A prospective 
Study (MIDAS) at the Erasmus Medical Center, Rotterdam, the Netherlands. The 
Posttraumatic Stress Diagnostic Scale (PDS) was used to assess symptoms of PTSD 
(i.e., intrusion, avoidance, and hyperarousal) at 3 and 6 months post implantation.5 
As potential determinants, the distressed (Type D) personality, pre-implantation 
ICD concerns, anxiety, depression, age, sex, partner, ischemic etiology, shocks during 
follow-up, previous myocardial infarction, diabetes, smoking, and use of psychotropic 
medication, were included in logistic regression analyses.  
At 3 months post implantation, 35 (11.7%) patients met the symptom criteria 
for a diagnosis of PTSD. Three months later, 21 (60%) of these patients still qualified 
for PTSD, while 13 patients had developed new onset PTSD, resulting in a total 
of 34 (11.3%) patients with PTSD 6 months post implantation. Table 1 shows 
that Type D personality, high pre-implantation anxiety, and shocks during follow-
up were independent determinants of PTSD at 3 months. At 6 months, only high 
pre-implantation ICD concerns and anxiety were significant determinants of PTSD, 
adjusting for demographic, clinical, and the other psychological factors. 
Despite ICD treatment being well accepted by the majority of patients, a 
subgroup of patients is at risk of developing symptoms of PTSD after implantation. 
At 3 months post implantation, ICD shock was the strongest determinant of PTSD, 
while pre-implantation anxiety and ICD concerns, but not shocks, were associated 
with PTSD at 6 months. These findings conform with previous studies acknowledging 
the importance of the patient’s psychological profile6,7 and shocks in determining 
post implantation distress.8,9 Early identification and treatment of patients’ fears 
and concerns might be beneficial,10 as PTSD symptoms have been associated with 
impaired health status and poor prognosis in cardiac patients.4,11 
Some limitations must be acknowledged. First, the PDS is a self-report measure 
that may overestimate the prevalence of PTSD.12 However, it has been validated 
  PTSD after ICD implantation
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against a structural interview and mirrors the DSM-IV criteria for a PTSD diagnosis.5 
Second, we had no information on PTSD symptoms prior to ICD implantation, yet 
patients were asked to rate the items on the PDS with respect to their ICD ensuring 
that PTSD could not be due to other traumatic events. Th ird, the follow-up period 
only extended to 6 months, with studies needed to examine the trajectory and 
determinants of PTSD symptoms after ICD implantation in the long term. Strengths 
include the prospective design and relatively large sample size. 
In conclusion, the fi ndings of this study indicate that a small subgroup of ICD 
patients is at risk of developing PTSD, and that these patients might be identifi ed 
by their psychological vulnerability to experience distress prior to implantation. 






Table 1. Variables associated with PTSD at 3 and 6 months
Multivariable logistic regression analysis
a Psychological variables were entered as dichotomous variables
*p≤.05; **p≤.01
ICD=implantable cardioverter defi brillator; MI=myocardial infarction
 
     


      
      
       
      

      
      
      

      
       
      
      
      
      
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ABSTRACT
Objective The present study examined whether female patients with an implantable 
cardioverter defibrillator (ICD) report more psychological distress than male patients, 
and whether somatosensory amplification mediates this relationship. 
Methods Consecutive ICD patients (N=241, 33% women) participating in the 
Living with an Implanted Cardioverter-Defibrillator (LICAD) Study, completed the 
Symptom Checklist-90 (SCL-90) and Somatosensory Amplification Scale (SSAS). 
Results Univariable linear regression analyses showed that female ICD patients reported 
more symptoms of anxiety (ß=.13, p=.04), phobic anxiety (ß=.13, p=.05), and somatic 
health complaints (ß=.15, p=.02), and scored higher on somatosensory amplification 
(ß=.24, p<.001) than men. Multivariable regression analyses, adjusted for demographic 
and clinical risk factors, revealed that somatosensory amplification was associated with 
more anxiety (ß=.48, p<.001), phobic anxiety (ß=.34, p<.001), and somatic health 
complaints (ß=.49, p<.001). Sobel tests indicated that somatosensory amplification 
mediated the association between sex and these 3 domains of psychological distress 
(p=.0005, .002 and .0006, respectively). 
Conclusions Somatosensory amplification mediated the relationship between female 
sex and heightened anxiety, phobic anxiety, and somatic health complaints in ICD 
patients. Women may be more likely to misinterpret bodily sensations as indicative 
of deterioration in their condition. Interventions focusing on modifying these 
dysfunctional beliefs may reduce their psychological distress.
Versteeg H, Baumert J, Kolb C, Pedersen SS, Denollet J, Ronel J, Ladwig KH.  Somatosensory 
amplification mediates sex differences in psychological distress among cardioverter-defibrillator patients
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INTRODUCTION
In the general cardiovascular literature and in epidemiological studies, women are 
known to report more psychological distress compared to men.1,2 Female sex has also 
been thought to be an independent risk factor for anxiety, depression, and impaired 
quality of life in patients treated with implantable cardioverter defibrillator (ICD) 
therapy.3-5 However, the few available studies on the influence of sex on psychological 
distress in ICD recipients are based on a relatively small number of women and show 
contradicting results.6  
Besides symptoms of psychological distress, health surveys and studies on 
physical symptom reporting have consistently found that women report more somatic 
symptoms compared to men.7,8 One explanation for this phenomenon may be that 
women are more aware of, and more attentive to, weak or diffuse bodily sensations.7 
This heightened selective attention to bodily sensations may lead to reactions of affect 
and cognitions that intensify them.7 Barsky and colleagues described these individuals 
as somatosensory amplifiers: persons with a tendency to perceive normal somatic and 
visceral sensations as unusually intense, noxious, and disturbing.9 Somatosensory 
amplification involves three elements: 1) bodily hypervigilance; 2) a tendency to focus 
on certain relatively weak and infrequent bodily sensations; and 3) the disposition 
to appraise them as abnormal and symptomatic of disease rather than normalizing 
them.9
Two studies have shown that Japanese women scored significantly higher on 
somatosensory amplification than Japanese men, even after adjusting for age, somatic 
symptoms, and mood states.10,11 Among functional dyspepsia patients, female subjects 
had significantly higher somatosensory amplification scores than male subjects.12 
Several studies suggest that somatosensory amplification may not only be associated 
with the reporting of somatic symptoms, but also with negative affectivity and general 
distress, including symptoms of depression, anxiety, hostility, and decreased quality 
of life.9,12,13  
Taken together, evidence suggests that both female sex and somatosensory 
amplification are related to symptoms of psychological distress. Females may score 
higher on somatosensory amplification, which in turn may increase the risk of 
psychological difficulties, suggesting that somatosensory amplification may mediate 
the relationship between female sex and heightened psychological distress. Hence, 
the objective of the present study was to investigate whether women implanted with 
an ICD report more psychological distress than men, and whether somatosensory 
amplification mediates this relationship. This knowledge might help physicians to 
better understand and manage patients whose reported psychological symptoms do 
not match their clinical condition, with a view to providing adjunctive intervention 
and treatment.14     
     ICD distress, sex, and somatosensory amplification
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METHODS
Study design and participants
Consecutive patients (N=251) implanted with an ICD, participating in the Living 
with an Implanted Cardioverter-Defibrillator (LICAD) Study, comprised the patient 
sample for the current study. Patients attending the cardiology outpatient clinic of the 
German Heart Center Munich for routine ICD check-up participated in the baseline 
examination between January and May 1998 (first survey, n=148) and between April 
and June 2002 (second survey, n=54 ). Because the sample of the first and second 
surveys included only 17.3% female ICD patients, the LICAD survey was extended 
in 2002 and 2003 including only female patients (n=49). Patients were not included if 
their first ICD implantation was <3 months ago (to avoid benign transitory adaptation 
reactions), if they were <16 years of age, or had severe cognitive impairments. Overall, 
of 265 patients meeting the criteria, 14 (5.3%) refused to participate, leading to an 
initial patient sample of 251 patients.  During their visit for routine ICD check-up at 
the outpatient clinic, patients underwent a variety of additional clinical, psychometric, 
and psychophysiological tests as part of the LICAD study. Among these, patients were 
asked to complete a set of standardized and validated psychological questionnaires. 
For the current study, 10 patients were excluded due to missing data on self-report 
measures. Hence, analyses were based on 241 (96%) patients (67% men, mean 
age=58.5±13.9 years). The dropout analysis revealed no systematic differences in 
baseline characteristics between the non-responders and responders. 
The study was conducted according to the Helsinki Declaration, and written 
informed consent was obtained from all patients. The study was approved by the ethics 
committee of the Medical Faculty of the Technical University of Munich, Germany.
 
Measures
Demographic and clinical variables 
Information on clinical variables, including specific data regarding ICD treatment, 
was obtained from the patient records at the pacemaker outpatient clinic of the 
German Heart Center Munich. Left ventricular ejection fraction (LVEF) was assessed 
echocardiographically or angiograpically, and was classified into 3 categories (≥55%, 
35% to 54%, or <35%). Demographic characteristics were assessed in a standardized 
interview. Patients were also asked if they had experienced cardiac symptoms 
(palpitations, tachycardia, racing heart) or chest pain (at rest, at night, during exertion) 
in the last 4 weeks before the examination. 
Psychological distress
The German version of the Symptom Checklist-90 (SCL-90),15 a multidimensional 
self-report questionnaire, was used to measure psychological symptom status with a 
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Likert scale, ranging from ‘not at all’ (0) to ‘extremely’ (4). We included items from 
the following domains: Anxiety (10 items), Depression (14 items), Phobic Anxiety 
(7 items), and Anger-Hostility (6 items). In addition, 12 items on Somatic Health 
Complaints (e.g. heart/chest pain, headache, soreness of muscles, tingling of a part 
of the body) were included. For all domains, a missing value of an item was replaced 
with the mean of the other items, if at least 70% of the items of the subscale were 
completed. 
Somatosensory amplification 
Somatosensory amplification was assessed with the Somatosensory Amplification 
Scale (SSAS),13 which was translated into German according to standard practice. It is 
a 10-item self-report questionnaire asking the respondents to rate the degree to which 
each statement is ‘characteristic of you in general’, on an ordinal scale from 1 to 5. 
The items cover a range of uncomfortable bodily sensations (e.g., hunger contractions, 
being too hot or too cold), most of which generally do not connote serious disease. 
The total score ranges from 10 to 50, with a higher score indicating greater symptom 
amplification. The original SSAS has adequate internal consistency (Chronbach’s 
alpha=.82), and a considerable test-retest reliability (r=.79 over a median interval of 
74 days).13 Cronbach’s alpha was .65 in the current sample. 
Statistical analyses
Prior to investigating whether somatosensory amplification mediates the relationship 
between sex and psychological distress (as assessed with the SCL-90), we examined 
whether the assumptions underlying the mediation model according to Baron 
and Kenny (1986) were fulfilled: (a) Sex had to be associated with the domains 
of psychological distress; (b) sex had to be related to the hypothesized mediator 
somatosensory amplification; and (c) somatosensory amplification had to be associated 
with psychological distress, controlling for sex. Somatosensory amplification was 
considered a mediator if it accounted for the relation between sex and psychological 
distress. The assumptions for mediation were tested using a series of linear regression 
models. To allow for a more direct test of the mediation effect, Sobel tests were also 
conducted.16 Sobel tests, which are products of coefficient tests for the mediating 
variable effect, are used to test the significance of the mediating variable effect by 
dividing the estimate of the mediating variable effect by its standard error and comparing 
this value to a standard normal distribution. In contrast with causal step methods (e.g. 
the Baron and Kenny approach), Sobel tests are less prone to Type I errors and have 
more statistical power to detect mediation.17 Multivariable linear regression analyses 
were performed to adjust for the potential confounding effects of demographic and 
clinical risk factors on psychological distress. A priori based on the literature, age, 
marital status (single versus married/partner), educational level (secondary school 
     ICD distress, sex, and somatosensory amplification
Proefschrift.indd   95 13-9-2011   7:29:37
96
or less versus high school/university degree), time since implantation, ICD shocks 
(≥1), New York Heart Association (NYHA) functional class (class I-II versus class 
III-IV), LVEF (<35% versus ≥35%), resuscitation, coronary heart disease (CHD) or 
myocardial infarction (MI), smoking, and psychotropic medication, were selected as 
covariates besides sex. Sobel tests were performed with an SPSS macro by Preacher 
and Hayes (http://www.comm.ohio-state.edu/ahayes/ sobel.htm),18 as SPSS does not 
provide the possibility to directly test the mediation eff ect. SPSS for Windows, version 
17.0, was used for all other analyses. A p-value equal to or less than .05 was considered 
to be statistically signifi cant. 
RESULTS
Baseline characteristics stratifi ed by sex
Baseline characteristics stratifi ed by sex are presented in Table 1. Compared to men, 
female ICD patients were on average younger (55.04 versus 60.29 years, p=.01), less 
likely to be living with a partner (57.1% versus 79.2%, p<.001), to have marked 
limitations in physical activity (NYHA class III or IV: 15.2% versus 29.2%, p=.02), to 
be diagnosed with CHD or MI (36.3% versus 70.8%, p<.001) or hypercholesterolemia 
(26.6% versus 39.85, p=.05), but more likely to have been resuscitated (71.3% versus 
55.9%, p=.02), to have a LVEF of ≥55% (36.8% versus 18.1%, p=.002), to have 
experienced cardiac symptoms in the past 4 weeks (41.3% versus 23.0%, p=.003), 
and to be prescribed psychotropic medication (11.4% versus 3.7%, p=.04). No other 
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Results are presented as n (%), unless otherwise stated.
a t test; Chi-square test for all others
b Palpitations, tachycardia, and racing heart 
c Patients taking lipid-lowering medication
*p≤.05; **p≤.01; ***p≤.001
CHD=coronary heart disease; ICD=implantable cardioverter defi brillator; LVEF=left ventricular ejection 
fraction; NYHA=New York Heart Association functional class; MI=myocardial infarction
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   
     
  
   
   
   
     
     
  
   
   
   
   


    


    
     
     

     
     
     
     
     
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Test of the Mediation Model
We tested the hypothesis that somatosensory amplifi cation mediated the relationship 
between sex and psychological distress for each domain of the SCL-90, using a series 
of linear regression analyses. Results indicated that female sex was signifi cantly related 
to more Anxiety (ß=.13, p=.04, R2=.02), Phobic Anxiety (ß=.13, p=.05, R2=.02), 
and Somatic Health Complaints (ß=.15, p=.02, R2=.02), but not to Depression and 
Hostility (Table 2). Th e second assumption underlying the mediation model was also 
fulfi lled: sex was signifi cantly associated with somatosensory amplifi cation (ß=.24, 
p<.001, R2=.06), with women scoring higher on the SSAS than men (25.84±7.03 versus 
22.52±5.95). As the fi rst assumption for mediation was not fulfi lled for Depression 
and Hostility, the third assumption was solely examined for Anxiety, Phobic Anxiety, 
and Somatic Health Complaints. Multivariable linear regression analysis showed that 
a higher score on somatosensory amplifi cation was associated with signifi cantly more 
Anxiety (ß=.48, p<.001, ∆R2=.22), Phobic Anxiety (ß=.34, p<.001, ∆R2=.11), and 
Somatic Health Complaints (ß=.47, p<.001, ∆R2=.21), controlling for sex. Once 
somatosensory amplifi cation was included in the model, the eff ect of sex on Anxiety, 
Phobic Anxiety, and Somatic Health Complaints was no longer signifi cant (p=.80, 
.50, and .49, respectively), indicating perfect mediation (Figure 1). Sobel tests were 
performed to examine whether the indirect eff ect of sex on psychological distress via 
somatosensory amplifi cation was signifi cantly diff erent from zero. Th e results showed 
that somatosensory amplifi cation signifi cantly mediated the relation between sex and 
Anxiety (z’=3.46, p=.0005), Phobic Anxiety (z’=3.11, p=.002), and Somatic Health 











   
      
      
      
      
      
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Figure 1. Mediation models for sex, somatosensory amplifi cation, and anxiety/ phobic axiety 
/somatic health complaints
ß coeffi  cients for sex are direct eff ects above the path and mediated eff ects below the path. 
*p≤.05; ***p≤.001
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In extended multivariable linear regression analyses, somatosensory amplification 
remained significantly associated with more Anxiety (ß=.48, p<.001, ∆R2=.19), 
Phobic Anxiety (ß=.37, p<.001, ∆R2=.12), and Somatic Health Complaints (ß=.49, 
p<.001, ∆R2=.21), controlling for demographic and clinical variables (Table 3). None 
of the demographic and clinical variables were related to Anxiety, Phobic Anxiety, 
and Somatic Health Complaints, including shocks (ß=.01, p=.84; ß=.09, p=.19, and 
ß=-.08, p=.19, respectively), except for usage of psychotropic medication, which was 
associated with more Anxiety (ß=.13, p=.04, ∆R2=.02), and older age, which was 
associated with more Phobic Anxiety (ß=.17, p=.03, ∆R2=.02), and Somatic Health 
Complaints (ß=.16, p=.02, ∆R2=.02). Of note, when shocks were examined in a 
continuous manner or with a cut-off of ≥5 shocks, the results did not change. 
DISCUSSION
To the best of our knowledge, this is the first study to investigate the role of 
somatosensory amplification as a mediator between female sex and heightened 
psychological distress in ICD patients. Results from the univariable linear regression 
analyses showed that female ICD patients reported more symptoms of anxiety, phobic 
anxiety, and somatic health complaints (R2=.02), and scored significantly higher on 
somatosensory amplification (R2=.06) than male ICD patients. In multivariable 
analyses, somatosensory amplification accounted for about 20% of the variance in 
anxiety and somatic health complaints, and over 10% of the variance in phobic anxiety 
scores, while sex was no longer significantly associated with any of these domains. This 
indicates that somatosensory amplification mediated the relationship between female 
sex and heightened anxiety, phobic anxiety, and somatic health complaints in ICD 
patients, which was also confirmed by Sobel tests. 
The current results show that women with an ICD report more somatic health 
complaints than men, which is consistent with previous research.19 Female ICD 
patients also experienced more anxiety but not depression, which is in accordance 
with some,3,20 but not all studies.21-23 The majority of these studies might have been 
insufficiently powered to adequately detect sex differences on distress outcomes. 
Men tend to have different health attitudes than women; women seem to be 
more involved with health and illness issues and often have more responsibility in 
taking care of ill relatives.24 This might result in a higher selective attention to their 
body and a greater tendency to intensify bodily sensations and attribute them to 
physical illness.7 These are characteristic elements of somatosensory amplification.9 
Accordingly, the current study confirms earlier results that women are more likely 
to be somatosensory amplifiers than men,10-12 but it also extends previous research 
by showing that somatosensory amplification may explain sex differences in levels of 
anxiety, phobic anxiety, and somatic health complaints in ICD patients. 
Somatosensory amplification was associated with more somatic health complaints 
     ICD distress, sex, and somatosensory amplification
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and (phobic) anxiety while taking into account demographic and clinical variables, 
including LVEF and ICD shocks. This suggests that the self-reported tendency to 
amplify may be related to the variability in psychological distress among ICD patients, 
independent of the objective severity of the underlying cardiac disease and ICD 
therapy. In fact, female ICD patients reported more cardiac symptoms, somatic health 
complaints, and anxiety than men, while their condition was generally less severe as 
indicated by NYHA functional class and LVEF. Although shocks have previously been 
shown to increase the risk of psychological distress and impaired quality of life,3,25 
this was not confirmed by the present results and several other studies.26,27 These 
findings suggest that it may be timely to expand our focus beyond shocks as the sole 
determinant of psychological distress in ICD patients.
Several studies have failed to find a relationship between somatosensory 
amplification and heartbeat detection ability or pain sensitivity, suggesting that 
somatosensory amplification may not be caused by heightened physiological 
sensitivity.28-30 Rather, somatosensory amplification may be the result a disturbance 
in the awareness and interpretation of bodily sensations, which is confirmed by 
preliminary results from an electroencephalographic (EEG) study showing a 
significant relationship between somatosensory amplification and parameters of 
auditory event-related potentials reflecting cognitive processing of sensory input.31 
The amplifying perceptual and cognitive style has been emphasized as a risk factor for 
somatoform disorders, e.g. hypochondria - an obsessive and enduring preoccupation 
with the fear or belief that one has a serious illness.13 ICD patients with a tendency 
toward somatosensory amplification could experience their bodily sensations as 
so intense and disturbing, that they may hold the dysfunctional belief that these 
sensations are signs of disease or deterioration in their condition.32 Educational and 
psychological interventions are needed that focus on correcting the attributional 
errors of somatosensory amplifiers. A limited number of trials have demonstrated that 
cognitive-behavioral therapy (CBT) can effectively reduce amplification of somatic 
symptoms in individuals with atypical chest pain, palpitations, and hypochondria.33-36 
CBT as mainstay of treatment, or in combination with cardiac rehabilitation, has also 
been shown to be beneficial in reducing anxiety in ICD patients.37 More research is 
needed to see if CBT is (cost-)effective in reducing psychological distress and adverse 
secondary outcomes in ICD patients. 
The results of the current study should be interpreted with some caution due 
to the following limitations. First, the cross-sectional study design does not permit 
conclusions about the direction of causality between somatosensory amplification and 
psychological distress. It is possible that psychological distress causes ICD patients to 
amplify their bodily sensations. This interpretation might, however, be somewhat less 
likely than the converse, as the SSAS has considerable test-retest reliability, indicating 
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instruction of the SCL-90 calls for the rating of psychological distress in the past 7 
days, while the instruction on the SSAS asks the patient to consider how characteristic 
each item is of him/her generally.9 Another limitation of the cross-sectional design 
is the absence of information on the level of psychological distress before the ICD 
implantation. In addition, because of the lack of a healthy control group, it remains 
unclear whether the differences in psychological distress are preexisting in men and 
women in general, or if they reflect differences in adjustment to the cardiac disease 
condition or ICD implantation. Prospective, longitudinal studies are essential 
to address these questions adequately. Second, some authors have suggested that 
the SSAS is more likely an index of psychological distress than a valid measure of 
somatic sensitivity.28 However, the SSAS has been shown to predict somatic symptom 
reporting independent of, and in addition to, the presence of a physical illness and 
the level of anxiety and depression.38,39 Third, we used a generic, multidimensional 
scale (SCL-90) to assess psychological distress. In order to replicate the current 
findings with potentially more sensitive measures, it would be important to include 
disease-specific measures in future research. Finally, based on a theoretical rationale 
the current study examined somatosensory amplification as a potential mediator, but 
other psychological variables, for example, anxiety sensitivity and coping behavior, 
may also explain the sex differences in psychological distress.40,41 Future studies are 
needed to investigate the potential role of other mediators. This study also has several 
strengths, including the relatively large sample size and the use of Sobel tests, which 
allowed for a direct test of the mediational role of somatosensory amplification with 
greater statistical power and less susceptibility to Type I error rates than other formal 
methods of assessing mediation.18 
In conclusion, somatosensory amplification mediated the relationship between 
female sex and heightened self-reported anxiety, phobic anxiety, and somatic 
health complaints after ICD implantation, independent of demographic and 
clinical risk factors, including ICD shocks. This suggests the need to take possible 
effects of somatosensory amplification into account when studying sex differences 
in psychological distress among ICD patients. Female ICD patients may be more 
likely to perceive normal bodily sensations as unusually intense and indicative of 
deterioration in their condition. Education and psychological interventions, such as 
CBT, focusing on modifying these dysfunctional beliefs may reduce their levels of 
psychological distress. Future research is needed to confirm the findings of the current 
study using a prospective study design.  
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disease populations: A meta-analysis of prospective studies
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ABSTRACT
Background Knowledge of the factors associated with individual differences in patient 
reported outcomes is essential to identify high-risk patients and improve secondary 
prevention.  The objective of this meta-analysis was to examine the association between 
Type D personality and the individual differences in patient reported physical and 
mental health status among cardiovascular patients.
Methods A computerized search of the literature through PUBMED and PsychINFO 
(1995-May 2011) was performed and prospective studies were selected that analyzed 
the association between Type D personality and health status in cardiovascular 
patients. Two separate meta-analyses were performed for the association of Type D 
personality with physical and mental health status, respectively. 
Results Of all identified studies, 10 studies met the selection criteria. The meta-analyses 
showed that Type D was associated with a 2-fold increased odds for impaired physical 
health status (3035 patients, OR=1.94, 95% CI:1.49-2.52) and a 2.5-fold increased 
odds for impaired mental health status (2213 patients, OR=2.55, 95% CI:1.57-4.16). 
There was no significant heterogeneity between the studies on physical health status 
(Q=12.78, p=.17, I2=29.59), but there was between those on mental health status 
(Q=21.91, p=.003, I2=68.04). Subgroup analyses showed that the association between 
Type D and mental health status decreased yet remained significant when adjusting 
for baseline mental health status. 
Conclusions Type D personality was shown to be an independent correlate of impaired 
patient reported physical and mental health status in various cardiovascular patient 
groups. Clinicians should be aware of the association between chronic psychological 
distress and poor patient reported outcomes.  
Versteeg H, Spek V, Pedersen SS, Denollet J. Type D personality and health status in cardiovascular 
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INTRODUCTION
Patients with cardiovascular disease often experience a substantial degree of physical 
and psychosocial difficulties that lead to impairments in perceived health status.1,2 
Health status refers to patient’s perceptions of how their disease affects their function, 
symptoms and quality of life.3 Physical health status concerns the effect of disease on 
physical functioning including walking, climbing stairs, and household work; mental 
health status refers to effects on psychological well-being, social functioning, and 
vitality. 
Patient reported outcomes have gained increased recognition in cardiovascular 
disease.4 Poor patient reported health status has been associated with an increased risk 
of mortality and rehospitalization independent of disease severity.5,6 However, large 
individual differences exist in patient reported health status, which do not necessarily 
concur with the physician’s evaluation of the patient’s health,7 or with the patient’s 
objective clinical status.8,9 Rather, patients with similar conditions and disease severity 
may have distinct perceptions of their health,10 which should be taken into account 
in clinical practice. 
Understanding individual differences in patient reported outcomes is crucial in 
order to identify high-risk patients and improve patient-centered care.11 In addition 
to clinical and demographic factors, psychological factors may be associated with the 
perceived health status of cardiovascular patients,12,13 with the distressed (Type D) 
personality (i.e., the combination of negative affectivity and social inhibition traits) 
being one such factor.14 Type D individuals experience a broad range of negative 
emotions and tend to inhibit self-expression in social interaction.15 Type D has 
been associated with increased mortality and morbidity in various cardiovascular 
populations independent of standard biomedical risk factors.16,17
The objective of this meta-analysis was to examine the association between Type 
D personality and the individual differences in patient reported physical and mental 
health status among cardiovascular patients.
METHODS
Literature search and article selection
In a computerized search of the literature (Pubmed and PsychINFO for the period 
January 1995-May 2011), the following search terms were used: Type D personality in 
combination with health status or quality of life. Also, reference lists of included articles 
were checked by the first author (HV). The search was limited to original publications 
in peer-reviewed journals. Two independent raters (HV, JD) identified studies that: 
1) were conducted in cardiovascular populations; 2) analyzed the association between 
Type D (determined by the standardized method)18 and health status or health-related 
quality of life; 3) had a prospective design and 4) had a sample size of ≥100 patients. 
   Type D personality and health status
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Regarding multiple reports on the same dataset, only the article with the largest 
sample size was included in the meta-analyses. If necessary, corresponding authors 
were contacted with the request to provide additional information. A fl ow diagram of 
the literature search is shown in Figure 1.
End points
Th e end point was health status or health-related quality of life, assessed with a 
validated and standardized instrument. We conducted separate meta-analyses for the 
association of Type D personality with  physical and mental health status, respectively. 
Quantitative Data Synthesis
Adjusted odds ratios (ORs) from the studies were pooled, using the program 
Comprehensive Meta-Analysis version 2 (Biostat, Englewood, New Jersey). However, 
for one study adjusted ORs were not available,19 so we converted the time-related data 
into simple 2 X 2 tables for which unadjusted ORs and 95% confi dence intervals 
(CIs) were calculated. As we suspected a relatively large heterogeneity in results, we 
used the random eff ects method to generate a summary estimate of ORs and tested 
the amount of heterogeneity with the Q test of homogeneity and the I2 test, which 
indicates the proportion of total variance explained by heterogeneity. Th e potential 
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group, and study sample were examined in secondary analyses. Differences in effect 
estimates between the subgroups were assessed by comparing the pooled effect 
estimates with Chi-square analyses by means of the logarithms of these estimates. To 
evaluate the presence of publication bias, funnel plots were constructed by plotting 
the effect measure against the inverse of its standard error. We used Egger’s test of the 
intercept and the classic Fail-Safe N to test to estimate the severity of publication bias.
 
RESULTS
Of all identified studies, 10 met the selection criteria (Table 1). Authors of 7 of the 
included articles were contacted for additional information.20-26
Physical health status
All 10 studies were included in the meta-analysis on physical health status, comprising 
3035 patients.15,19-27 The mean follow-up period was 14.7 months, with follow-up 
periods ranging from 3 to 60 months. The pooled OR for the association of Type D 
personality with impaired physical health status was 1.94 (95% CI:1.49-2.52, p<.001) 
(Figure 2). There was no significant heterogeneity (Q=12.78, p=.17, I2=29.59), so no 
further secondary analyses were conducted. 
A funnel plot of the 10 studies did not suggest publication bias. Egger’s test 
showed no significant asymmetry (p(one-tailed)=.13). The fail-safe N indicated that 
another 84 null-studies would be needed for the p-value to exceed .05. 
Mental health status
Eight studies were included in the meta-analysis on mental health status, comprising 
2213 patients.19,21-27 The mean follow-up period was 6.9 months, with follow-up 
periods ranging from 3 to 24 months. The pooled OR for the association between 
Type D personality and impaired mental health status was 2.55 (95% CI:1.57-4.16, 
p<.001) (Figure 3). There was heterogeneity between studies (Q=21.91, p=.003, 
I2=68.04) and subgroup analyses showed that the 4 studies controlling for baseline 
health status had a significantly smaller (p=.001) pooled OR (1.57, 95% CI:1.01-
2.42; p=.04) compared to studies not controlling for baseline health status (OR=4.35, 
95% CI:2.83-6.69; p<.001). There were no significant differences for follow-up 
period, health status assessment, research group, and study sample.
A funnel plot of the 8 studies did not suggest publication bias. Egger’s test showed 
no significant asymmetry (p=.43). The fail-safe N indicated that another 88 null-
studies would be needed for the p-value to exceed .05. 
   Type D personality and health status



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Study name                    Statistics for each study                     Odds ratio and 95% CI
                              Odds    Lower   Upper
                               ratio      limit     limit    z-value    p-value
Dannemann (2010) 2.423      1.032     5.690      2.032       0.042    
Denollet (2000)        2.200      1.246     3.886      2.716       0.007
Pedersen (2007)           1.100      0.662     1.827      0.368       0.713
Pelle (2008)         1.153      0.655     2.029      0.494       0.621
Skodova (2011)  1.730      0.509     5.884      0.878       0.380
Pedersen (2010)           1.970      0.831     4.668      1.540       0.123
Pelle (2009) 2.760      1.551     4.912      3.451       0.001   
Aquarius (2007) 3.650      1.670     7.979      3.245       0.001
Mols (2010)   2.344      1.198     4.586      2.488       0.013
Pedersen (2007a) 2.110      0.923     4.825      1.770       0.077
  1.941      1.494     2.522      4.966       0.000
   0.1   0.2      0.5     1      2         5     10
Study name                    Statistics for each study                     Odds ratio and 95% CI
                              Odds    Lower   Upper
                               ratio      limit     limit    z-value    p-value
Dannemann (2010) 2.906      1.285     6.571      2.563       0.010    
Pedersen (2007)           1.870      1.192     2.934      2.723       0.006
Pelle (2008)         0.674      0.258     1.759     -0.806       0.420
Skodova (2011)  1.920      0.480     7.680      0.922       0.356
Pedersen (2010)           1.850      0.812     4.213      1.456       0.143
Pelle (2009) 6.180      3.394    11.253     5.956       0.000   
Aquarius (2007) 5.970      2.426    14.689     3.890       0.000
Pedersen (2007a) 2.830      1.242     6.449      2.475       0.013
  2.553      1.567     4.158      3.765       0.000
   0.1   0.2       0.5     1      2          5     10
Figure 2.  Meta-analysis of the association between Type D and physical health statusa
Figure 3. Meta-analysis of the association between Type D and mental health statusa
a the bottom line shows the pooled results
a the bottom line shows the pooled results
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DISCUSSION
This is the first meta-analysis evaluating the role of personality in explaining individual
differences in health status reported by cardiovascular patients. Results showed that 
Type D personality is independently associated with 2-fold increased odds for impaired 
physical health status and 2.5-fold increased odds for impaired mental health status in 
various cardiovascular patient groups.  After adjustment for baseline health status, the 
association of Type D with mental health status decreased but remained significant. 
Assessment of patient reported health status is a key component of patient-
centered clinical care,4 as patients want to know how a treatment will affect their 
symptoms, function, and quality of life, particularly because some patients prefer 
a better health status over prolonged survival.28 The incorporation of health status 
measures in clinical practice offers clinicians insight into their patient’s physical and 
emotional needs and may be useful in clinical decision making.4 To enhance patient-
centered care, identification of factors that are associated with individual differences in 
patient reported health status is essential.11 Knowing which factors are associated with 
negative patient reported outcomes may provide targets for improving health status and 
even prognosis, as patient reported health status has been shown to have incremental 
value over indicators of disease severity in predicting mortality and rehospitalisation.5 
Research has shown that the physician’s evaluation of the patient’s health and objective 
indicators of disease severity are only marginally associated with the health status as 
reported by patients.7-9 The findings of the current meta-analyses are in line with 
previous studies emphasizing the importance of also taking into account important 
psychological factors, such as Type D personality.12-14
Personality is a relatively stable construct that refers to a person’s ‘normal baseline’ 
or his/her general propensity to respond to stressful and life events,16 while health 
status is a state-dependent outcome that will vary over time and according to the 
individual’s personality disposition. As the current meta-analysis suggests, patients 
with a ‘baseline’ Type D personality are more prone to experience impaired health 
status. Yet their Type D personality traits persist following treatment that improves 
their health status,24 in the same way that a compromised immune system makes 
a person more prone to get an infection but persists after the infection has been 
treated.29 The stable adverse effect of Type D on health status is further emphasized 
by the finding that of the 6 studies in this meta-analysis that examined the Type D by 
time interaction effect,19,21-24,27 only one found it to be significant.21
Type D personality has previously been associated with a poor cardiovascular 
prognosis16 and a higher prevalence of cardiovascular risk factors.30 The current results 
indicate that cardiovascular patients with a Type D personality are also more prone 
to report impaired physical and mental health status compared to their non-Type D 
counterparts. There are several potential pathways that could explain this relationship.
First, it has been argued that the cardiovascular effects of psychological factors, 
   Type D personality and health status
Proefschrift.indd   115 13-9-2011   7:29:51
116
such as Type D personality, could be confounded by disease severity.31 However, studies 
in myocardial infarction and congestive heart failure patients have shown that Type 
D is not associated with markers of cardiac disease such as left ventricular ejection 
dysfunction,32 multivessel disease,32,33 or brain natriuretic peptide,34 contradicting the 
argument that Type D patients are by definition more severely diseased. Second, the 
finding that Type D patients report poorer health status might be a result of their 
dysfunctional symptom and illness perceptions. Individuals with a Type D personality, 
characterized by high negative affectivity, may be more likely to perceive and attend 
to normal bodily sensations and to interpret them as painful or pathological.35 Also, 
Type D patients tend to believe that their illness will have more serious consequences 
and that treatment will be less effective.36 Third, the impaired health status of Type D 
patients may be the result of less adequate self-management behaviour. Type D has 
been associated with an unhealthy lifestyle (e.g. smoking, alcohol consumption, not 
exercising),37 medication non-adherence,38 and inadequate consultation behaviour.25,39 
Psychosocial and behavioural interventions aimed towards modifying the dysfunctional 
illness beliefs and health behaviours of Type D patients might reduce their levels of 
distress and improve their mental and physical health.40
Some limitations should be acknowledged. First, 8 of the 10 studies included 
in this meta-analysis stem from our own group and there is a need for more research 
by independent groups. Lately, the number of Type D studies from other research 
groups has increased rapidly. Except for one null finding,26 these studies support the 
association between Type D personality and impaired health status.19,41-46 However, 
most of these studies had a cross-sectional design41,44,46 or a sample size <100 
patients,43,45 so only 2 studies from other research groups were included in the current 
meta-analyses.19,26 Second, a limitation of meta-analytic research is the inevitability of 
combining data from studies with heterogeneous designs. There was no heterogeneity 
in study results for physical health status but studies that adjusted for baseline health 
status found a smaller association between Type D and impaired mental health status. 
This may be due to the fact that Type D exerts a stable, adverse effect on mental health 
across time and situations;24 hence, adjusting for baseline mental health could lead to 
overcorrection. 
In conclusion, the current findings emphasize that Type D personality may partly 
explain some of the individual differences in health status reported by cardiovascular 
patients, independent of indicators of disease severity and depression. Researchers and 
clinicians should take into account the patient’s general propensity to psychological 
distress when seeking to identify patients at risk for poor health outcomes. This 
propensity to psychological distress can be reliably assessed with the 14-item Type 
D scale (DS14), which comprises little patient burden.18 The findings of this meta-
analysis indicate that the timely identification and treatment of high-risk patients with 
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Th e distressed (Type D) personality in both patients 
and partners enhances the risk of emotional distress in 
patients with an implantable cardioverter defi brillator
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ABSTRACT
Background A subgroup of patients with an implantable cardioverter-defibrillator 
(ICD) experiences emotional distress. This may be related to partner factors. We 
examined the impact of the personality of the partner (i.e., the distressed (Type D) 
personality) in combination with that of the patient on anxiety and depression levels 
in ICD patients.
Methods Consecutively implanted ICD patients (N=281, 80.1% men, mean 
age=58.3±11.0) and their partners (N=281, 20.6% men, mean age=56.5±11.7) 
completed the Type D Scale at baseline; patients also completed the Hospital Anxiety 
and Depression Scale at baseline and 6 months post implantation.
Results ANOVA for repeated measures, using the Type D main effects and the 
interaction effect, showed that the interaction Type D patient by Type D partner 
was significant (F1,277=7.0, p=.009) for depression as outcome, but not for anxiety 
(F1,277=3.1, p=.08). Post-hoc comparisons revealed that Type D patients with a Type 
D partner (n=23/281; 8.2%) experienced the highest depression levels compared to 
other personality combinations (all ps<.05). 
Conclusions ICD patients with a Type D personality report more depressive 
symptoms, but not anxiety, if the partner also has a Type D personality. This may be 
due to poor communication and lack of emotional support in the relationship. These 
results emphasize the importance of taking into account the psychological profile of 
the partner in the management and care of the ICD patient, and to direct behavioral 
support not only at the ICD patient but also at the partner. 
van den Broek KC, Versteeg H, Erdman RAM, Pedersen SS. The distressed (Type D) personality in both 
patients and partners enhances the risk of emotional distress in patients with an implantable cardioverter 
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INTRODUCTION
The implantable cardioverter defibrillator (ICD) is implanted in patients who have 
experienced a sudden cardiac arrest (secondary prevention) and in patients who 
are at risk for a sudden cardiac arrest, due to a decreased ejection fraction (primary 
prevention).1 The medical benefits of the ICD over pharmacological therapy are 
unequivocal in preventing sudden cardiac death in most patients,2 but adaptation 
problems exist in 25% to 33% of ICD patients who experience increased emotional 
distress,3,4 which in turn may trigger new life-threatening arrhythmias,5,6 and influence 
survival.7-9 These emotional problems may be more related to the psychological profile 
of the patient than to clinical factors, such as indication for the ICD, ICD shocks, or 
an ICD advisory.3,4,10-12 
Distress levels in patients may also be related to partner factors. In a mixed 
sample of post myocardial infarction patients and ICD patients, patients with a Type 
D (distressed) personality without a partner showed higher distress levels than Type 
D patients with a partner.13 Higher distress levels in cardiac patients have also been 
related to higher distress levels in their partners,14 and research has shown that partner 
distress levels can be as high as distress levels in patients with an ICD.15 In addition, 
lower survival rates were found in cardiac patients who reported low marital quality.16 
However, research has not focused on the influence of other partner characteristics, 
such as the personality of the partner, on patient distress. 
The distressed (Type D) personality refers to the joint presence of two broad and 
normal personality traits, namely negative affectivity and social inhibition.17 Persons 
with high levels of negative affectivity experience a broad range of negative emotions 
across time and situations. These persons generally have a gloomy view of themselves 
and the world. A high level of social inhibition refers to avoidance of social interactions, 
mainly because of fear of disapproval by others. Hence, Type D individuals are inclined 
to keep their negative feelings to themselves and not express them. Research, which 
has been performed primarily in cardiac populations, has shown that Type D patients 
are at increased risk for morbidity and mortality.18 Specifically in ICD patients, Type 
D personality is associated with increased emotional distress,4,13 impaired quality of 
life,10 and also with new life-threatening arrhythmias5 and mortality.9 Little is known 
about the impact of both the patient and his/her partner having a Type D personality. 
This combination may incur the highest risk for distress because both individuals 
experience high levels of negative emotions, but at the same time they do not disclose 
their emotions, resulting in poor communication and lack of social support in the 
patient-partner dyad.
Hence, the objective of this prospective study was to examine the impact of 
concordant versus discordant personality types (i.e., Type D personality) of the patient 
and the partner on symptoms of depression and anxiety in patients with an ICD. We 
hypothesized that the personality of the partner would influence distress levels in the 
    Type D partners and emotional distress in ICD patients 
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patient, and that the highest distress levels would be found in patients whose partner 
also has a Type D personality.
METHOD
Study design and participants 
The sample for this study comprised consecutive patients receiving an ICD 
implantation between August 2003 and December 2008 at the Erasmus Medical 
Center, Rotterdam, the Netherlands, and their partners. All patients and partners 
participated in the ongoing Mood and personality as precipitants of arrhythmia in 
patients with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS). 
Exclusion criteria were a life expectancy of less than 1 year, on the waiting list for heart 
transplantation, a history of psychiatric illness other than affective/anxiety disorders 
(i.e., a mental disorder involving abnormal moods and emotions), or with insufficient 
knowledge of the Dutch language. 
During clinical visits to the hospital, patients and their partners were asked to 
complete a set of standardized and validated psychological questionnaires at baseline 
(i.e., one day prior to ICD implantation) and at 6 month follow-up. Only patient and 
partner dyads with complete data were included in the statistical analyses. 
The MIDAS study protocol was approved by the medical ethics committee 
of the Erasmus Medical Center. The study was conducted conform to the ethical 
tenets developed by the World Medical Association, as espoused in the Declaration of 
Helsinki. All patients provided written informed consent.
Measures
Demographic and clinical variables
Demographic and clinical variables were obtained at baseline from the patients’ medical 
records and through purpose-designed questions. Demographic variables included 
gender, age, education (secondary school or less vs. high school/university), and 
working status. Clinical variables included indication for ICD implantation (primary 
vs. secondary prevention), cardiac resynchronization therapy (CRT), coronary 
artery disease (CAD) etiology, heart failure, diabetes mellitus, smoking, cardiac and 
psychotropic medication, and shocks (both appropriate and inappropriate) during the 
6-month follow-up period.
Type D personality
At baseline, both patients and partners completed the 14-item Type D Scale (DS14) 
to assess Type D personality.17 The DS14 consists of 2 subscales, negative affectivity 
(e.g., ‘I often feel unhappy’) and social inhibition (e.g., ‘I am a closed kind of person’), 






Proefschrift.indd   124 13-9-2011   7:30:03
125
0 (false) to 4 (true), with total scores ranging from 0 to 28 for both subscales. The 
patient had to complete at least 6 out of 7 items per subscale to be included in 
statistical analyses, with the 7th item being replaced by the mean of the other 6 scores. 
Patients scoring high on both subscales according to a standardized cut-off score ≥10 
are classified as Type D.18,19 The DS14 is a valid and reliable scale with Cronbach’s 
alphas of .88 and .86 and a high test-retest reliability over a 3-month period of r=.72 
and .82 for the negative affectivity and social inhibition subscales, respectively.18 A 
study in post-myocardial infarction patients demonstrated that the DS14 is a stable 
personality measure over an 18-month period and that scores are not confounded by 
indicators of disease severity.20  
Depression and Anxiety
Symptoms of depression and anxiety were measured with the Hospital Anxiety and 
Depression Scale (HADS), a self-report questionnaire with a 7-item anxiety and 
7-item depression subscale.21 Items are scored on a 4-point Likert scale ranging from 
0 to 3, with a score range of 0-21 for both subscales. Patients had to fill in at least 6/7 
items to be included in statistical analyses, with mean imputation begin used for the 
missing 7th item. The Dutch version of the HADS has been shown to be valid and 
reliable, with Cronbach’s alphas ranging from .71 to .86 for the depression subscale 
and from .80 to .84 for the anxiety subscale, and the test-retest reliability being .86 and 
.89, respectively.22 Patients completed the HADS at baseline and 6 months follow-up. 
Statistical analyses
To examine differences in baseline characteristics stratified by concordant and 
discordant Type D status of patients and their partners, we used the Chi-square test 
for discrete variables and analysis of variance (ANOVA), with post-hoc Bonferroni 
testing if applicable, for continuous variables. 
The independent impact of Type D personality of the patient and partner on 
patients’ depression and anxiety levels was examined by ANOVA for repeated measures 
with Type D personality of the patient, Type D personality of the partner, and their 
interaction as between-subject factors. When we found a significant three- or two-way 
interaction effect, we did not report on the main effects. Instead, we performed post 
hoc analyses with a Games-Howell (for unequal groups with unequal variances) or 
Hochberg T2 correction (for unequal groups with equal variances) to examine the 
differences between groups based on the combined Type D status of the patients and 
their partners. Also, paired-samples t tests were used to examine changes in depression 
and anxiety levels during follow-up. When we did not find a significant interaction 
effect, we reran the ANOVA without the interaction term. 
Analysis of covariance (ANCOVA) for repeated measures was performed to adjust 
for the potential confounding effects of age, gender, education (secondary school or 
    Type D partners and emotional distress in ICD patients 
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less vs. high school/university), ICD indication (primary vs. secondary), CRT, CAD, 
heart failure, shocks (≥1), diabetes, psychotropic medication, and smoking. 
All tests were two-tailed and p<.05 was used to indicate statistical signifi cance. 
All data were analyzed using SPSS.17.0 for Windows (SPSS Inc., Chicago, Illinois).
RESULTS
Baseline characteristics for the total group and stratifi ed by the personality of the 
patient and the partner
In total, 391 patients were approached, of which 281 could be included in the current 
analyses (see Figure 1 for a fl ow-chart of the sample selection). Th e mean age of the 
partners was 56.5±11.7 and 20.6% of partners were male. In total, 20 patients had 
received at least one ICD shock, with 5 patients receiving inappropriate shock(s) only, 
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Demographic and clinical characteristics for the total sample and stratifi ed by 4 
groups based on Type D status of patients and their partners are presented in Table 1. 
Th e fi rst group comprised non-Type D patients with non-Type D partners (n=172, 
61.2%), the second group non-Type D patients with Type D partners (n=51, 18.1%), 
the third group Type D patients with non-Type D partners (n=35, 12.5%) and the 
fourth group Type D patients with Type D partners (n=23, 8.2%). Th e 4 groups did 
not diff er systematically on any of the demographic or clinical variables.
Depression
ANOVA for repeated measures showed that the three-way interaction time by Type 
D patient by Type D partner was signifi cant (F1,277=7.0, p=.009).  Post hoc analyses 
were performed to examine the diff erences in depression levels between the 4 groups 
(Figure 2). Type D patients with Type D partners had signifi cantly higher baseline 
levels of depression compared to the other 3 groups (all ps<.001). Type D patients 
with a non-Type D partner had signifi cantly higher baseline depression levels 
compared to the non-Type D patients with (group 2: mean diff erence=2.7, p=.003) 
and without (group 1: mean diff erence=2.6, p=.001) a Type D partner. Baseline 
depression levels for non-Type D patients with and without a Type D partner were not 
signifi cantly diff erent (mean diff erence=-0.1, p=1.00). Paired samples t test showed 
that Type D patients with Type D partners and non-Type D patients with non-Type 
D partners experienced a signifi cant decrease in depression levels during follow-up 
(mean diff erence=2.2, p=.007, and mean diff erence=0.8, p=.001, respectively), while 
the depression levels in the other 2 groups remained stable over time. At 6 months, 
there was only a borderline signifi cant diff erence between depression levels of Type D 






Figure 2. Mean depression levels in ICD patients stratifi ed by Type D personality status of the 
patient and partner. 
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Anxiety
For anxiety, the time by Type D patient by Type D partner (F1,277=3.1, p=.08) and the 
Type D patient by Type D partner interaction eff ects were not signifi cant (F1,277=2.6, 
p=.11). In the ANOVA without the interaction term, between-subjects eff ects for 
Type D patients (F1,278=47.1, p<.001) and Type D partners (F1,278=6.03, p=.02) were 
signifi cant, indicating that the personality of the patient as well as the personality of 
the partner exerted a main infl uence on anxiety levels in the patient, with Type D 
patients and ICD patients with a Type D partner experiencing more anxiety than their 
counterparts (Figure 3). Anxiety levels declined signifi cantly over the 6 month follow-
up period (F1,278=30.2, p<.001). Th is decline was not related to the specifi c personality 
type of patients nor partners (F1,278=2.4, p=.12, and F1,278=0.1, p=.75, respectively)
Multivariable analyses
Our main results did not change in adjusted analyses. Between-subjects eff ects of 
covariates showed that depression and anxiety levels were signifi cantly diff erent 
according to educational level (F1,266=10.8, p=.001, and F1,267=9.7, p=.002, respectively) 
and use of psychotropic medication (F1,266=7.2, p=.007, and F1,267=21.8, p<.001, 
respectively), with plots showing increased depression and anxiety levels in patients 
with lower education and in patients who use psychotropic medication. Shocks were 
neither signifi cantly associated with depression nor anxiety levels (F1,266=0.5, p=.48, 
and F1,266=2.9, p=.09, respectively).
    Type D partners and emotional distress in ICD patients 
Figure 3. Mean anxiety levels in ICD patients stratifi ed by Type D personality status of the 
patient and partner. 
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DISCUSSION
The findings of the current prospective study showed that not only the personality of the 
patient but also the combination with the partner’s personality influenced depression 
levels in ICD patients, with Type D patients with a Type D partner experiencing 
the highest depression levels compared to other personality combinations. These 
patients also showed the largest decline in depression levels within 6 months post 
ICD implantation. There was no effect of patient/partner personality combination 
on anxiety, but both patient and partner personality types did exert a main effect on 
anxiety. This indicates that anxiety levels in Type D patients were higher than in non-
Type D patients, but that it did not matter whether the partner was Type D or not, 
and also that anxiety levels were higher in ICD patients who have a Type D partner 
compared to ICD patients who did not have a Type D partner, but that the Type D 
status of the patient did not have additional value in these two groups.
Our finding that personality of the partner may influence distress levels in patients 
is in line with previous studies that also focused on the impact of partner factors on 
patient well being, although none of the previous studies specifically focused on the 
personality of the partner. For instance, Moser and Dracup reported that anxiety in 
spouses was positively related to emotional distress in cardiac patients.23 Distress in 
partners has also been shown to influence survival in patients.16 Finally, studies have 
shown that distress in partners of patients with a chronic disease is associated with poor 
health status in partners, through prolonged sympathetic activation and pronounced 
platelet activation and impaired endothelial function in partners.24,25
We do not know why Type D patients with a Type D partner are particularly 
vulnerable for developing depression, but can only speculate that it has to do with a 
number of factors that hamper communication in the patient-partner dyad. Generally, 
individuals with a Type D personality have a gloomy view of life and therefore, may 
view the ICD implantation as a negative event. Hence, both the Type D patient and 
the Type D partner may feel frustrated but at the same time are not willing to discuss 
the impact of living with an ICD on their lives. For this reason, it is unlikely that 
a Type D partner will ask the patient how he/she feels in order to avoid instilling 
conversations about fear. In addition, the patient is unlikely to be forthcoming with 
his/her uncertainties and worries. Due to misconstrued consideration and lack of 
communication, the Type D patient and the Type D partner may not be able to 
disclose their negative feelings within the boundaries of their relationship. Lack of 
support in combination with frustration may lead to depression, as lack of support is 
a known risk factor for increased emotional distress and adverse clinical events, such 
as mortality.26  
We can only speculate why the combination of personalities seems to play no role 
in relation to anxiety. Perhaps it has to do with the type of emotion, with symptoms 
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physiological level. Anxiety symptoms are more difficult to hide and therefore are 
more visible than depressive symptoms, making it more evident that the patient is 
distressed. 
Our longitudinal findings reflected a general decline in depression and anxiety 
levels within 6 months following ICD implantation, which has also been shown 
by others.27 Type D patients with a non-Type D partner showed the largest decline 
in depression levels. This may reflect a real decline and not just regression to the 
mean, as the group non-Type D patients with non-Type D partners, who had the 
lowest depression levels, also showed a significant decline. The largest decline in the 
Type D patient-partner dyad may be attributed to Type D patients receiving extra 
attention from family and friends following the implantation, thereby encouraging 
them to express insecurities and concerns. Although Type Ds generally will refrain 
from talking about their negative feelings, this encouragement from significant others 
together with the fact that they have just undergone a major life event – the ICD 
implantation – may help them bridge their usual fear of talking about their emotions. 
In addition, given that these patients had the highest level of depression, there was 
more room for improvement in this group compared to the other groups.
In the current study, shocks were unrelated to depression and anxiety. Although 
ICD shocks tend to be viewed as the primary culprit if patients become anxious 
or experience a deterioration in quality of life,28 a recent viewpoint indicates that 
evidence for a role of shocks on anxiety, depression, and quality of life in the general 
arrhythmia literature is mixed and perhaps more complex than previously assumed.12 
Due to the limited number of patients having received a shock during the follow-up 
period, it was not possible to differentiate appropriate from inappropriate shocks, 
although these may have a differential effect on emotional distress. Similarly, a focus 
on the number of shocks may be warranted, as the Canadian Implantable Defibrillator 
Study (CIDS) showed a dose-response relationship between shocks and quality of 
life,29 although none of the other primary and secondary prevention trials confirmed 
this dose-response relationship.12
The limitations of the current study should be acknowledged. First, baseline 
assessment was one day before the implantation, which may have resulted in more 
increased anxiety and depression scores, due to anticipatory anxiety. For logistic 
reasons, it was not feasible to administer questionnaires prior to one day before 
implantation. Some patients know several weeks in advance that they will have an 
ICD implanted, while others receive an ICD acutely following a large infarction or a 
sudden cardiac rest. Given that all patients are admitted one day prior to implantation, 
this time point was chosen in order standardize the baseline assessment. Second, 
the follow-up period was limited to 6 months. Third, anxiety was measured using 
a general measure instead of a disease-specific measure. However, the HADS is less 
prone to confounding by disease severity, as the HADS does not include somatic 
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items.21 Fourth, the prevalence of shocks was rather low, making it difficult to draw 
firm conclusions about the impact of shocks on distress levels. Finally, the group of 
Type D patients and Type D partners was rather small. Despite these limitations, to 
our knowledge, this is the largest study to date of patient and partner dyads with an 
ICD and the only study to have examined the influence of both the personality of the 
patient and the partner on patient distress levels.
Future studies are warranted to replicate the findings of our study, and also to 
examine the impact of the partner’s personality in combination with the personality 
of the patient on patient morbidity and mortality, as several studies indicate that poor 
marital quality is related to mortality in patients.16 In addition, research is warranted 
that examines the pathways through which combinations of personality in patients 
and partners may lead to increased emotional distress in patients, in order to be able 
to develop effective interventions.
These results emphasize the importance of taking into account the psychological 
profile of the partner in the management and care of the ICD patient. Currently, 
partners of patients with somatic disease tend to be neglected, as the main focus is 
on treatment of the ICD patient. Health care professionals should also be alert to the 
uncertainties and distress of partners, with the provision of adequate information and 
support being of primary importance. This can be achieved by inviting partners to 
participate in cardiac rehabilitation, as advocated by others,30 which provides a forum 
for discussing emotional and practical aspects. Extra attention to Type D couples or 
couples with one Type D person may include encouragement to communicate with 
each other and to talk about uncertainties.
In conclusion, depressive symptoms were highest in ICD patients with a Type D 
personality if the partner also had a Type D personality, although this effect was not 
found with respect to anxiety. Future research is warranted to replicate these findings 
and investigate mechanisms and targets for intervention. Nevertheless, these results 
indicate that behavioral support should be directed not only at the ICD patient but 
also the partner.
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ABSTRACT
Objective To examine the validity and reliability of the Florida Patient Acceptance 
Scale (FPAS) and to identify correlates of patient device acceptance in a Dutch cohort 
of implantable cardioverter defibrillator (ICD) patients. 
Methods Patients with a first-time ICD (N=272, mean age=59.2±11.9, 82% men) 
recruited from the Erasmus Medical Center, Rotterdam, or the Medisch Spectrum 
Twente, Enschede, the Netherlands completed the FPAS, the Type D Scale and the 
Hospital Anxiety and Depression Scale.
Results Exploratory and confirmatory factor analyses indicated that eliminating 3 
items from the FPAS, leaving 12 items contributing to 3 factors is an equivalent to 
the original 4-factor version of the FPAS. The abbreviated FPAS had a high internal 
consistency both for the total scale and all subscales, with Cronbach’s alphas ranging 
from .76 to .82. Anxiety (OR=9.75, 95% CI:2.38-39.87, p=.002), depression 
(OR=2.96, 95% CI:0.98-8.93, p=.05), and the distressed (Type D) personality 
(OR=5.04, 95% CI:1.50-16.92, p=.01), but not demographic and clinical factors 
including shocks, were significant independent correlates of poor device acceptance. 
Conclusions A shortened 12-item, 3-factor version of the FPAS was shown to be 
a valid and internally consistent instrument to assess device acceptance in Dutch 
ICD patients. Psychological but not clinical factors were the primary correlates 
of device acceptance, which underlines the importance of taking into account the 
patient’s psychological profile when seeking to identify patients at risk for adjustment 
difficulties after ICD implantation.
Versteeg H, Starrenburg A, Denollet J, van der Palen J, Sears SF, Pedersen SS. Monitoring device 
acceptance in implantable cardioverter defibrillator patients using the Florida Patient Acceptance Survey. 
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INTRODUCTION
Implantable cardioverter defibrillator (ICD) therapy is the treatment of choice for 
preventing sudden cardiac death in patients who have survived life-threatening 
arrhythmias (secondary prevention) or are at high risk for these arrhythmias (primary 
prevention).1 Although the ICD is generally well tolerated and perceived as a potential 
lifesaver by the majority of patients,2,3 a subset of patients suffer from emotional 
distress and poor quality of life after ICD implantation.4,5
Patient device acceptance is one of the factors that might be essential in identifying 
patients at risk for these adverse patient reported outcomes, as poor acceptance has been 
associated with psychological distress and a impaired quality of life in ICD patients.2,6 
Device acceptance refers to the psychological accommodation and understanding of 
the device and the derivation of benefit in terms of biopsychosocial functioning.7 
Previous studies suggest that device acceptance is not determined by ICD indication, 
ICD shocks, time since implantation, or device or lead advisory notices,8-10 but rather 
by the presence of symptomatic heart failure and psychological factors, such as anxiety, 
depressive symptoms, and a distressed (Type D) personality.2,6,11 The latter studies used 
the Florida Patient Acceptance Survey (FPAS), which is one of the few standardized 
and validated instruments available to measure ICD acceptance.7 
The psychometric properties of the FPAS have previously been investigated in a 
North American and a Danish ICD patient sample.7,11 Results showed that the FPAS 
has good validity and internal consistency. The objectives of the current study were 
to (1) examine the psychometric properties (i.e. factor structure, internal consistency, 
and divergent validity) of the FPAS, and 2) identify correlates of device acceptance, in 
2 independent cohorts of Dutch ICD patients assessed at 10 days and 12 months post 
implantation, respectively. 
METHODS
Study design and participants 
The sample consisted of patients who had their first ICD implanted between August 
2006 and January 2009 at the Erasmus Medical Center, Rotterdam, or the Medisch 
Spectrum Twente, Enschede, the Netherlands. Patients included in Rotterdam 
participated in the ongoing Mood and personality as precipitants of arrhythmia in 
patients with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS). 
Patients included in Enschede participated in the Twente ICD Cohort Study (TICS). 
For both hospitals, exclusion criteria were age <18 years, significant cognitive 
impairments, a history of psychiatric illness other than affective/anxiety disorders, a 
life expectancy less than 1 year, and insufficient knowledge of the Dutch language. At 
10 days (Rotterdam) or 12 months (Enschede) after implantation, patients were asked 
to complete a set of standardized and validated questionnaires. The study protocol was 
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approved by the Medical Ethics Committees of the participating hospitals. The study 
was conducted in accordance with the Helsinki Declaration, and all patients provided 
written informed consent. 
Measures
Demographic and clinical variables
Information on sex, age, etiology, ICD indication, New York Heart Association 
(NYHA) functional class, left ventricular ejection fraction (LVEF), diabetes mellitus, 
and cardiac medication use were retrieved from patients’ medical records at time of 
implantation. Information on ICD shocks was obtained via device interrogation, 
while information on smoking was obtained by means of a purpose-designed question 
in the questionnaire. 
Device acceptance 
The FPAS is a measure of device acceptance consisting of 18 items.7 Items are rated on 
a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree), with a high score 
indicating more acceptance. Of all items, 15 contribute to 4 subscales: (1) Return 
to Function (4 items); (2) Device-Related Distress (5 items); (3) Positive Appraisal 
(4items); (4) Body Image Concerns (2 items). The remaining 3 items are filler items. A 
total score based on the 15 items may also be calculated. Total and subscale scores are 
linearly converted into a score between 0 and 100. A high score on Return to Function 
and Positive Appraisal means better acceptance, while a high score on Device-Related 
Distress and Body Image Concerns represents less acceptance. The convergent and 
divergent validity of the FPAS are good, and the scale has been shown to be internally 
consistent, as indicated by Cronbach’s alphas ranging from .74 to .83.6,11 For the 
current study, the FPAS was translated from English into Dutch and back-translated 
according to standard procedures. 
Type D personality 
The distressed (Type D) personality was assessed with the 14-item Type D Scale 
(DS14).12 Type D personality is defined by a general propensity to experience 
increased negative emotions paired with the non expression of these emotions in social 
interaction, due to fear of rejection or disapproval by others. The DS14 consists of 2 
subscales, negative affectivity and social inhibition, each comprising 7 items. Items of 
the DS14 are answered on a 5-point Likert scale ranging from 0 (false) to 4 (true), 
with total scores for each subscale ranging from 0 to 28. Only patients scoring high on 
both subscales according to a standardized cut-off score ≥10 are classified as having a 
Type D personality.12,13 The DS14 is a valid and reliable scale with Cronbach’s alphas 
of .88 and .86 and a high test-retest reliability over a 3-month period of r=.72 and 
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personality has previously been associated with increased distress, poor quality of life, 
and morbidity and mortality in ICD patients.14-17 The DS14 was included to examine 
the divergent validity of FPAS and the role of personality as a correlate of patient 
device acceptance.  
Anxiety and depressive symptoms
Anxiety and depressive symptoms were measured with the Hospital Anxiety and 
Depression Scale (HADS), a 14-item self-report questionnaire.18 The anxiety and 
depression subscales both consist of 7 items answered on a 4-point Likert scale ranging 
from 0 to 3, with a score range of 0-21. On both subscales, a cut-off ≥8 was used to 
indicate probable levels of clinical anxiety and depression, respectively. A review of 15 
international studies using the HADS supports the use of this cut-off, as it yields an 
optimal balance between sensitivity and specificity.19 The Dutch version of the HADS 
has been shown to be a valid and reliable instrument, with Cronbach’s alphas ranging 
from .81 to .84 and from .71 to .86, and test-retest reliability over a mean 3-week 
period being r=.89 and .86 for the anxiety and depression subscales, respectively.20 
The HADS was used to evaluate the divergent validity of the FPAS and the association 
between anxiety and depressive symptoms and device acceptance. 
Statistical analyses
Patient demographic and clinical baseline characteristics, stratified by center, were 
compared with the Chi-square test for discrete variables and the Student’s t test for 
continuous variables. Principal component analysis (PCA) with varimax rotation was 
used to determine the factor structure of the FPAS. Prior to the PCA, Bartlett’s test of 
sphericity and the Kaiser-Meyer-Olkin measure of sampling adequacy (KMO-index) 
were examined to evaluate whether the data fulfilled the assumptions for carrying out 
a PCA. Eigenvalues and scree plots were used to determine the number of factors to 
extract. To validate the factor structure of the FPAS, we also performed confirmatory 
factor analysis using maximum likelihood estimation. Three overall goodness of 
fit indices (i.e., X2, Root Mean Square Error of Approximation (RMSEA), and 
comparative fit index (CFI)) were calculated. A non-significant X2 indicates a perfect 
fit, while a reasonably good fit between the model and the observed data is obtained 
when RMSEA is ≤.06 and CFI is ≥.95.21 Cronbach’s alpha and the mean inter-item 
correlation (MIIC) were calculated to examine the internal consistency of the FPAS 
subscales. MIIC was used in addition to Cronbach’s alpha, since Cronbach’s alpha is 
highly dependent on the number of items in each scale and hence prone to be inflated 
when the number of items is high. MIIC should fall in an optimal range between .20 
and .50,22 but should be no less than .15.23 
Prior to multivariable logistic regression analysis to determine correlates of poor 
device acceptance, the FPAS total score was dichotomized, using the lowest tertile to 
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indicate poor device acceptance compared with the other two tertiles representing good 
device acceptance. Dichotomization has been advocated earlier to enhance clinical 
interpretability.24 Results of the logistic regression analysis are presented as odds ratios 
(OR) with 95% confi dence intervals (CI). All tests were two-tailed. A p-value of ≤.05 
was used to indicate statistical signifi cance. Th e analyses were performed using SPSS 









Table 1. Baseline characteristics for the total sample and stratifi ed by center
Results are presented as n (%), unless otherwise stated.
*p≤.05; **p≤.01; ***p≤.001
ACE= angiotensin converting enzyme; NYHA=New York Heart Association functional class; 
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Baseline characteristics, stratified by center, are displayed in Table 1. Patients included 
in Enschede were on average older (61.9 versus 56.5 years, p<.001), more likely to 
use diuretics (66.2% versus 48.5%, p=.003), and less likely to have a LVEF of <35% 
(68.3% versus 74.3, p=.01) at time of implantation compared with patients included 
in Rotterdam.  There were no other significant differences in baseline characteristics 
between the two cohorts. Of note, there were no significant differences in baseline 
characteristics of patients with poor versus good device acceptance (results not shown). 
In total, 25 patients (9.2%) had received (in)appropriate ICD shock(s) during 
follow-up, 23 of them belonged to the Enschede cohort (assessed at 12 months post 
implantation). Only 2 patients in the Rotterdam cohort (assessed at 10 days) had 
experienced an ICD shock. 
Factor structure of the FPAS
Factor analysis was performed to examine the structural validity of the FPAS. The 
KMO-index (.81) and Bartlett’s test of sphericity (p<.001) indicated that the data 
fulfilled the assumptions for carrying out a factor analysis. The eigenvalues >1 criterion 
confirmed the 4-factor structure of the FPAS (Table 2a). The 4 factors accounted for 
64.4% of the variance (factor 1 (Device-Related Distress)=30.5%, factor 2 (Positive 
Appraisal)=13.8%, factor 3 (Return to Function)=12.7%, factor 4 (Body Image 
Concerns)=7.4%). However, the scree plot indicated a marked “elbow” that inflected 
after the 3rd factor. Also, the factor loading for item 12 on its supposed factor (i.e., 
Device-Related Distress) was low (.03), with this item loading higher on factor 4 (i.e., 
Body Image Concerns; factor loading=.68). Factor 4 had an eigenvalue of 1.12 and 
explained only 7.4% of the variance in device acceptance.
Hence, we reran the factor analysis with 12 items, excluding the 3 items loading 
on factor 4 (i.e., items 12, 14, and 15). This yielded a 3-factor structure (Table 2b), with 
the 3 factors accounting for 63.6% of the variance (factor 1=34.9%, factor 2=16.9%, 
factor 3=11.8%) and all items loading on their expected factors. To verify our results, 
we performed confirmatory factor analyses with 15 items (4 factors) and 12 items 
(3 factors), respectively. The X2-test was statistically significant for both models (X284 
=199.0, p<.001, and X251 =99.5, p<.001, respectively), indicating that both models 
do not fit the data perfectly. However, the X2 difference test was significant (X2diff,33= 
99.44, p<.05), which suggests that the 3-factor model provides a significantly better 
fit to the data than the 4-factor model. Also, the two other goodness of fit indices 
slightly favored the 3-factor model over the 4-factor model (RMSEA=.06, p=.18 versus 
RMSEA=.07, p=.004, and CFI=.96 versus CFI=.92, respectively). 
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Internal consistency
The internal consistency of the 4 subscales (Device-Related Distress=.75; Positive 
Appraisal=.76; Return to Function=.80; Body Image Concerns=.82) and the total 
scale (.82), as measured by Cronbach’s alpha, was acceptable (Table 2a). MIICs for 
3 of the 4 subscales (Device-Related Distress=.40; Positive Appraisal=.44; Return to 
Function=.50) and the total scale (.25) were also within the optimal range of .20-.50, 
except for the MIIC for Body Image Concerns (.69). After excluding items 12, 14 
and 15 (Table 2b), the internal consistency of the Device-Related Distress subscale 
increased (.82), but the MIIC for this subscale fell just outside the optimal range 
(.54). For the total scale, the internal consistency remained stable (.82) and the MIIC 
stayed within the optimal range (.28).
Of note, analyses for the two cohorts separately did not yield significantly 
different results concerning the factor structure and internal consistency of the FPAS. 
However, as the results concerning the divergent validity and correlates of the FPAS 
did differ between the two cohorts, these results will be presented separately in the 
subsequent sections. 
In both cohorts, the FPAS, DS14 and HADS were completed at the same point 
in time (i.e., for the Rotterdam cohort all at 10 days and for the Enschede cohort all 
at 12 months post implantation), so the results are cross-sectional. Also, since the 12-
item version of the FPAS seemed to be a better measure psychometrically, this version 
will be used from here on for all analyses. Mean scores and corresponding standard 
deviations at item level and for the subscales, and the scoring algorithm for the 12-
item version are displayed in Appendix I. 
Divergent validity 
The correlation matrix on scale scores between FPAS, DS14, and HADS are shown in 
Table 3, stratified by center. 
In the Rotterdam cohort (10 days post implantation), the FPAS Positive 
Appraisal subscale did not significantly correlate with the Negative Affectivity subscale 
of the DS14. For the other subscales and total score, the overlap between the FPAS 
and Negative Affectivity in terms of shared variance ranged from 14% to 19%. The 
FPAS Return to Function subscale did not significantly overlap with the DS14 Social 
Inhibition subscale, for the other (sub)scales the shared variance ranged from 3% to 
7%. The overlap between the FPAS and HADS Anxiety ranged from 19% to 28%, 
but Anxiety was not significantly correlated with FPAS Positive Appraisal. The shared 
variance between the FPAS and HADS Depression ranged from 4% to 34%. 
In the Enschede cohort (12 months post implantation), the FPAS Positive 
Appraisal subscale also did not significantly overlap with the DS14 Negative Affectivity 
subscale. For the other FPAS (sub)scales, the overlap with Negative Affectivity ranged 
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subscale of the DS14, except for Device-Related distress (4%). The overlap between 
the FPAS (sub)scales and HADS Anxiety and Depression ranged from 5% to 31% 
and from 4% to 26%, respectively.
Despite some overlap between the FPAS and the other psychological measures, in 
particular with anxiety and depression, these findings suggest that the FPAS measures 
a construct that is conceptually different from that of personality factors and mood 
states.
Correlates of poor device acceptance 
Overall, both patient cohorts reported a positive appraisal of the device, with the mean 
FPAS total score (12 items) being high at 10 days and 12 months post implantation 
(71.8±14.9 and 73.8±16.0, respectively). Correlates of poor device acceptance, i.e. 
the lowest tertile on the FPAS total scale (score≤64.5), are shown in Table 4. For 
the Rotterdam cohort assessed at 10 days post implantation, Type D personality and 
high depression were independently associated with poorer acceptance of the ICD 
(OR=5.04, 95% CI:1.50-16.92, p=.01 and OR=4.40, 95% CI:1.04-18.65, p=.05, 
respectively). Of note, as only 2 patients (1.5%) had received an ICD shock during 
the 10 days follow-up, ICD shocks were not included as a covariate in the analysis for 
this cohort. 
In the Enschede cohort assessed at 12 months post implantation, high anxiety 
(OR=9.75, 95% CI:2.38-39.87, p=.002) and depression (OR=2.96, 95% CI:0.98-
8.93, p=.05), but not Type D personality (OR=0.71, 95% CI:0.22-2.33, p=.58), were 
significant associates of poor device acceptance. None of the demographic or clinical 
factors were associated with device acceptance. 
DISCUSSION
The current study examined the psychometric properties and correlates of the FPAS, 
a disease-specific questionnaire to assess patient device acceptance, in two cohorts of 
Dutch ICD patients assessed at 10 days and 12 months post implantation, respectively. 
Results indicated that eliminating 3 items from the FPAS, leaving 12 items contributing 
to 3 factors (i.e., Return to Function, Device-Related Distress, and Positive Appraisal) 
is a psychometrically sound alternative to the original 15-item, 4-factor version of the 
FPAS, with validity and internal consistency preserved. Also, our results confirmed 
that the FPAS measures a construct that is conceptually different from that of mood 
states and personality, despite some overlap in particular with measures of anxiety and 
depression. Correlates of device acceptance included anxiety, depression, and Type D 
personality. Demographic and clinical factors, including ICD shocks, indication, and 
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Th e current study confi rms that the FPAS is a valid and internally consistent 
measure of device acceptance, as previously shown in North American and Danish 
cohorts,7,11 indicating that the FPAS may be used to assess device acceptance beyond 
the North American context. Also, the factor structure and internal consistency of 
the FPAS were confi rmed in both of our patient cohorts, assessed at 10 days and 12 
months post implantation, indicating that it is robust over time. However, the results 
are on par with those of Pedersen and colleagues,11 who also found that FPAS item 
12 (i.e., ‘I am careful when hugging and kissing my loved ones’) was problematic 
in the Danish context, as it loaded poorly on the expected factor and had a much 
higher loading on the Body Image Concerns factor. Th is suggests that this item is 
culturally sensitive and if kept in the FPAS it needs to be rephrased. Also, in both 
the previous Danish study and the current Dutch study, the Body Image Concerns 
Table 4. Correlates of poor device acceptance, stratifi ed by centera
Multivariable logistic regression analyses
a All factors, except age, were entered as dichotomous variables. 
b All psychological factors are assessed at the same time as the FPAS.
*p≤.05; **p≤.01; ***p≤.001
NYHA=New York Heart Association functional class; LVEF=left ventricular ejection fraction.
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factor explained just a small part of the variance in device acceptance (i.e., 6% and 
7%, respectively), which might be due to this subscale only containing 2 items that 
may be not well formulated. Alternatively, these findings may be explained by the fact 
that in the current and in the Danish study the percentage of women was lower than 
in the North American study (17% versus 37%) and women may have more concerns 
about their body image than men.25 However, a recent study has shown no gender 
differences in ICD acceptance, including body image concerns.26 
Anxiety, depression, and Type D personality, and not demographic and clinical 
factors, were associated with poor device acceptance in adjusted analyses. These 
findings are in line with previous studies suggesting that the psychological profile of the 
patient is an equally and sometimes more important determinant of device acceptance 
and other patient reported outcomes than disease severity and shocks.2,6,9,11,14,27 Hence, 
an expansion of the focus beyond shocks to also include psychological determinants 
is essential to identify patients at high risk for adjustment difficulties after device 
implantation.28 Most studies, including our study, however, indicate that ICD patients 
generally view their device positively and experience low levels of device-related 
distress, even after being subjected to shock(s) or a device advisory notice.3,8-10 The 
FPAS may be especially useful for examining the normative processes of adjustment 
to ICD therapy as it does not focus on maladjustment or psychopathology.14 Hence, 
the FPAS is applicable to all patients. In addition, the FPAS has been shown to detect 
changes in psychological well being following psychosocial intervention,29 suggesting 
that it is a sufficiently sensitive measure to tap changes in outcome, if present, following 
an intervention .  
Previously, poor device acceptance has been associated with more emotional 
distress and impaired quality of life.2,6 Hence, the FPAS could be used to identify 
patients at risk for poor patient reported outcomes who need adjunctive treatment. 
Psychosocial intervention, in particular cognitive-behavioral therapy and patient 
education, has been shown to have beneficial effects on device acceptance, quality of 
life and psychological distress levels in ICD patients.29,30 
The limitations of the present study must be acknowledged. First, the study 
design was cross-sectional, and therefore, it is not possible to infer cause and effect. 
A future prospective study is warranted to determine whether psychological distress 
is a precursor of poor ICD acceptance or vice versa. Second, psychological variables 
were only assessed by means of self-report rather than interviews. However, all 
questionnaires were standardized and validated. Strengths of the current study were its 
relatively large sample size, the comparison of two independent ICD patient cohorts 
assessed at a different times post implantation, and the inclusion of information on 
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In conclusion, the present study shows that the FPAS is a valid and internally 
consistent measure of patient device acceptance. Based on previous Danish findings 
and findings of the current study, we would suggest that the FPAS be shortened to 
a 12-item version assessing 3 factors. Abbreviation of the FPAS from the original 18 
items to 12 items also makes it more suitable to use in research and clinical practice 
due to its brevity. However, until the findings of these two studies are confirmed in 
ICD cohorts in other countries, both the 12-item and the 18-item version of the 
FPAS could be used. The present and previous findings indicate that a small subgroup 
of patients experience difficulties with adjustment following ICD implantation, and 
that this likely is attributable not only to the severity of their disease and shocks but 
also to their psychological profile. The FPAS is a useful tool in research and clinical 
practice to examine the process of device adjustment and to identify patients at high 
risk for psychological difficulties after ICD implantation. Future intervention studies 
with a prospective design are warranted to examine how device acceptance can be 
augmented and the implications for well being and health outcomes of ICD patients. 
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Chapter 11
General discussion
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Cardiovascular implantable electronic device therapy represents state-of-the 
art medical technology that has become the treatment of choice to improve 
prognosis in subgroups of patients with heart disease. Particularly, the implantable 
cardioverter defibrillator (ICD) and the biventricular pacemaker providing cardiac 
resynchronization therapy (CRT) used either alone or in combination (i.e., CRT-D) 
are now implemented on a large scale with their indications also likely to expand in the 
future.1 The implicit assumption in the field is that any new and innovative technology 
that decreases morbidity and enhances survival must also be good for patients, with 
equal gains in well being and quality of life for all patients. Hence, inclusion of the 
patient perspective by means of assessing patient reported outcomes is currently not 
part of standard clinical research and practice when evaluating treatment effects of 
new innovations in the field. This dissertation focused on patient reported outcomes 
following ICD/CRT(-D) implantation and examined the role of disease- and device-
related factors versus psychological factors in explaining individual patient differences 
in these outcomes. Findings from studies on a variety of ICD and CRT(-D) patient 
samples recruited from multiple national and international centers were presented. 
In the current chapter, these findings are discussed and their implications for clinical 
practice and future research are outlined.
DISCREPANCY BETWEEN THE PHYSICIAN AND THE PATIENT 
PERSPECTIVE 
From the patient perspective, an important target of treatment is the relief of symptoms, 
reduction in functional limitations and improvement in quality of life.2,3 In clinical 
practice, the physician’s interpretation of the presence and severity of symptoms 
and limitations in patients with congestive heart failure (CHF) is often classified 
according to the New York Heart Association (NYHA) functional classification 
system. Besides improvement in echocardiographic and hemodynamic parameters, 
an improvement in ≥1 NYHA functional class is one of the most frequently used 
criteria to define response to CHF treatment (e.g., CRT) in clinical research and 
practice.4,5 However, the existing CHF literature and clinical case reports indicate that 
there is a poor relationship between the traditional physician rated indicators of CHF 
severity, including NYHA functional class and echocardiographic parameters, and 
patients’ own perceptions of health (Chapter 2).6-9 This discrepancy was emphasized 
by results presented in the current dissertation showing that most of the variation 
in patient reported health status changes following CRT implantation could not be 
explained by NYHA functional class at the time of implantation (Chapter 3), and that 
clinically relevant improvements in patient rated health status occurred in the absence 
of improvement in NYHA functional class (Chapter 4). These findings underline 
that NYHA functional class should not be used as the sole outcome measure to 
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CRT implantation, as it may not be sufficiently sensitive to tap changes perceived by 
patients. In addition, the NYHA functional classification system has been criticized 
for having poor intra- and inter-rater reliability and for primarily being a measure of 
general functional status.10,11 However, CHF patients not only experience functional 
losses but also a variety of psychosocial, socio-economic, and emotional concerns that 
may affect their daily lives.12,13 
Hence, health status measures completed by patients themselves offer important 
supplements to traditional physician rated measures, with the incorporation of the 
patient perspective likely enhancing our understanding of the burden of disease and 
treatment on patients. Such patient reported outcomes may also be used in clinical 
decision making.14,15 Recently, the Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation (COURAGE) trial showed that patients reporting more 
frequent angina complaints, assessed with the Seattle Angina Questionnaire,16 derived 
the most benefit from percutaneous coronary intervention if also treated with optimal 
medical therapy.17 These results testify to the utility of incorporating a measure of 
health status in research and clinical practice, as the patients with more severe angina 
complaints would likely not be identified based on the physician’s judgment alone, in 
particular since physicians seem to underestimate the disability of patients.18 
Besides impaired health status, ICD/CRT(-D) patients might experience 
heightened psychological distress and adjustment difficulties after implantation.19 
These psychological comorbidities are often underdiagnosed and undertreated in 
cardiology practice,20 despite evidence showing that poor patient reported health 
status and distress have unique prognostic value as they are associated with premature 
death in cardiac patients, independent of demographic factors and indicators of disease 
severity despite treatment with state-of-the-art technology.21-24 Hence, knowing which 
factors are associated with patient well being and psychological adaptation following 
ICD/CRT(-D) implantation is essential in the early identification and treatment of 
high-risk patients and may provide targets for secondary prevention.25 
BROADEN THE SCOPE: THE IMPORTANCE OF PSYCHOLOGICAL 
FACTORS
As physician rated disease severity only explains some of the variance in patient 
reported outcomes, a logical next step is to look at the influence of factors specifically 
related to device therapy. So far, the evidence regarding the impact of these factors, 
e.g., ICD shocks,26 indication,27 and device advisory notices28 is mixed. In general, 
findings from the current dissertation and previous research indicate that ICD/CRT 
patients are well able to cope with their device and experience low levels of device-
related distress, even after being subjected to shock(s) or a device advisory notification 
(Chapter 5). However, a subset (20-30%) of patients might experience symptoms 
of depression, anxiety, and even posttraumatic stress (Chapter 6) following ICD/
      General discussion
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CRT(-D) implantation.19 In this dissertation, psychological factors were shown to be 
equal or more important associates of these psychological adjustment difficulties than 
disease severity and shocks. Pre-implantation anxiety and device concerns (Chapter 
6), somatosensory amplification (Chapter 7), and poor device acceptance (Chapter 10) 
were associated with heightened psychological distress following ICD implantation, 
independent of demographic and clinical factors. Also, Type D personality, a general 
propensity for distress, was shown to be associated with impaired physical and 
mental health status in cardiovascular patients (Chapter 8), and increased depression 
and anxiety levels (Chapter 9), posttraumatic stress (Chapter 6), and poor device 
acceptance (Chapter 10) in ICD patients. These findings are in line with previous 
studies emphasizing the importance of taking into account the psychological profile of 
the patient when seeking to identify patients at risk for poor patient reported outcomes 
post ICD/CRT-D implantation.29-33 In particular, patients with a psychological 
vulnerability to experience distress (e.g., Type D personality, anxiety sensitivity, pre-
implantation ICD concerns) seem to be at high risk for psychological adjustment 
difficulties, impaired health status and poor prognosis following implantation.22,30-34 
Hence, it may be timely for us to broaden our scope beyond factors related to disease 
severity and device therapy, and to also take into account psychological factors when 
studying patient reported outcomes in ICD/CRT(-D) patients. This is paramount 
to optimize patient centered care and to bridge the gap between research and clinical 
practice.25 In the following sections, recommendations as to inclusion of the patient 
perspective in clinical practice and future research will be outlined (Table 1).
OVERCOMING THE BARRIERS OF IMPLEMENTING PATIENT 
REPORTED OUTCOMES IN CLINICAL PRACTICE
Patient reported outcomes are increasingly used as important outcome measures 
in clinical research trials on device therapy, such as the Canadian Implantable 
Defibrillator Study (CIDS), the Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT) and the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-
II).35-37 However, their incorporation in clinical practice is far from standard due to 
practical, methodological, and attitudinal barriers.38,39 Practical concerns include the 
general lack of time, money, and human resources to collect and analyze the data.38 
The use of new information infrastructures and computerized assessments might 
be one solution to mitigate these obstacles. For example, patients can complete the 
questionnaire at home or while waiting to see their physician using a touch screen 
computer. This information can then be added to the information from the medical 
history and physical examination at the initial and subsequent visits to the clinic.40,41 
However, sufficient technical support is required to make this feasible in the future.42 
A methodological issue pertains to the choice of instrument to assess patient 
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been developed that are inexpensive, easy to administer, and psychometrically sound; 
it is important to choose the most appropriate and sensitive measure for the purpose at 
hand. Generic measures, such as the Short-Form Health Survey (SF-12 and -36),43,44 
are suitable for all populations and can be used to show differences in health status 
between cardiovascular patients and the general population or patients with another 
somatic disease. However, these measures may not be sufficiently sensitive to tap 
treatment-related changes.45 The Minnesota Living with Heart Failure Questionnaire 
(MLHFQ)46 and the Kansas City Cardiomyopathy Questionnaire (KCCQ)47 are 
disease-specific questionnaires specifically developed for use in CHF patients. These 
measures are often more relevant to patients and more accurate in reflecting clinical 
changes.48 In addition, they seem to have greater prognostic value compared to health 
status assessed with a generic measure.24 The Florida Patient Acceptance Survey 
(FPAS; Chapter 10),49 Florida Shock Anxiety Scale (FSAS),50 and the ICD Patient 
Concerns Questionnaire (ICDC)51 are measures specifically developed to tap concerns 
and symptoms in ICD patients. It is important to assess patient reported outcomes 
at several time points as this allows for the rapid identification of patients whose 
health status deteriorates or whose distress levels increase or remain chronic following 
implantation.14,15 Although there is a general reduction in distress in the first year after 
implantation,52,53 in a substantial number of patients (50%) high levels of distress may 
persist over time.54-57 
The next challenge is the analysis and interpretation of the scores. How much 
change in scores represents a meaningful improvement or deterioration in patient 
reported outcomes? Several studies have suggested a minimal magnitude of change 
for indicating clinical relevance (e.g., 5 points on the KCCQ48), and these cut off 
values can be used to classify patients into improved, stable, or deteriorated. If the 
proportions of patients who do or do not report improvement after an intervention is 
known, the number of patients needed to treat can be calculated. 
Finally, the most challenging part of introducing patient reported outcomes into 
daily clinical practice is convincing the health care providers of their applicability 
and clinical usefulness.14,38,42 Although most physicians seem to have positive 
attitudes towards using patient reported measures in daily practice, their attitudes 
seem to vary depending on their familiarity with these measures and the particular 
use to which they are put.38,58 Preliminary evidence from family practice and 
oncology suggests that patient reported measures improve the physician’s awareness 
of physical and psychological problems of patients and facilitate physician-patient 
communication,38,41,58 which in turn may improve patient satisfaction and adherence 
to treatment.5,14,59 Importantly, one study in cancer patients showed that the 
incorporation of patient reported outcomes in the clinical management of patients did 
not increase the time that physicians spend on patients in clinical practice.58 Future 
research in cardiac populations is warranted to evaluate the most efficient way to use 
patient reported outcomes in clinical decision making in order to improve health 
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outcomes, such as mortality, morbidity, and quality of life.14
MANAGEMENT AND TREATMENT OF DISTRESSED PATIENTS 
Once patients with poor patient reported outcomes are recognized in clinical practice 
and physicians have determined their specific concerns and health status impairments, 
appropriate interventions should be offered to improve health status – if this is possible 
– and to reduce their psychological distress levels.60 So far, a paucity of studies have 
evaluated psychological and pharmacological interventions in device patients with the 
majority of these studies using cognitive behavioral therapy (CBT) as the mainstay of 
treatment.61,62 
CBT includes training in cognitive-behavioral techniques (i.e., identifying and 
challenging negative automatic cognitions and behaviors), which is often combined 
with psycho-education about the underlying condition, the ICD/CRT(-D) device, 
and related misconceptions or concerns that are common among patients; relaxation 
and stress management techniques; and/or group sessions to promote social support. 
CBT was shown to significantly reduce psychological distress, in particular anxiety, 
and to improve health status in ICD patients.63-69 Some studies have combined CBT 
with exercise training, with these multi-factorial interventions being more effective 
in reducing depression compared to CBT alone.65,67,69 So far, no evidence is available 
to demonstrate a positive effect of psychosocial interventions on survival or recurrent 
cardiac events in ICD, probably due to the majority of these studies being based on 
relatively small sample sizes and having short follow-up periods.61,62 Only one study 
documented an impact of CBT on use of health care facilities.65 These preliminary 
findings suggest that psychological interventions are worthwhile in ICD patients, but 
also that large-scale, well-designed psychological intervention trials are warranted to 
confirm and expand on these findings.61,62 
Psychopharmacological therapy might have supplemental value in reducing 
psychological distress. Selective serotonin reuptake inhibitors (SSRIs) appear 
preferable to treat distress in ICD/CRT patients, given their antidepressant and 
anxiolytic properties and their relatively benign (cardiac) side effects.70-72 However, 
their efficacy in cardiac patients is not well known and some SSRIs might interact 
with other medications.72,73 Hence, psychotropic medication should only be prescribed 
by physicians who know their specific effects in cardiac patients. Also, the patient’s 
preference for psychological versus pharmacological treatment should be considered 
when offering a treatment, as a recent study in depressed primary care patients showed 
that receiving the preferred treatment might convey an additional and clinically 
relevant benefit.74
Finally, as addressed in Chapter 9 of this dissertation, partners of ICD patients 
may experience levels of distress similar to patients,75 which in turn may lead to 
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health care professionals to be alert of the uncertainties and the distress of partners 
and provide them with adequate information and support.76,77 This can be achieved by 
inviting partners to participate in cardiac rehabilitation where they can express their 
emotional and practical concerns but also witness that it is safe for ICD patients to 
exercise.76,77 
KEEPING PACE WITH CARDIOVASCULAR  IMPLANTABLE  ELECTRONIC 
DEVICES - RECOMMENDATIONS FOR FUTURE RESEARCH
The incorporation of patient reported outcomes and the patient perspective in the 
cardiovascular implantable electronic device field is still in its infancy. Some ground 
has been gained, with such measures having been incorporated in primary and 
secondary prevention trials,35-37 and with more and more observational studies taking 
an interest in the patient perspective and in how patients deal with the challenges 
of expanding indications, device advisory notifications, and ICD shocks (both 
appropriate and inappropriate) that go hand in hand with device therapy. However, 
most of these studies present mean group changes in patient reported outcomes, which 
could be misleading as there is a large variability in individual responses. The present 
dissertation provides more insight into the relative importance of disease- and device-
related factors versus psychological factors in explaining variance in patient reported 
outcomes, nevertheless, a considerable number of questions still remain unanswered. 
First, the complex nature of the psychological factors associated with patient 
reported outcomes needs further investigation. Most studies so far have focused on the 
individual impact of psychological factors, while these factors tend to cluster together 
within individuals.30,78 For example, Pedersen and colleagues found that ICD patients 
with clustering of device-related concerns and Type D personality experienced higher 
levels of anxiety and had a poorer prognosis compared to patients with no or only one 
risk factor.30,79 Hence, future research on psychological risk factor clustering might 
provide the most accurate risk estimation for individual patients rather than focusing 
on single factors.78 Furthermore, it is important to enhance our understanding of the 
behavioral and biological pathways underlying the relationship between psychological 
factors and health outcomes, as this might point towards targets for secondary 
intervention. To confirm findings from observational studies, large-scale randomized 
controlled intervention trials targeting the psychological risk factors are essential. 
Such trials are also needed to determine which patients respond best to specific forms 
of psychological or pharmacological interventions, and to evaluate whether these 
interventions benefit prognosis in ICD/CRT patients. It is unlikely that a ‘one size fits 
all’ approach to intervention will work, requiring that interventions are targeted to the 
individual patient and their demographic, clinical, and psychological profile. 
Second, well-designed studies are warranted examining factors specifically related 
to device therapy, e.g. shocks and advisory notices. Up until now, studies have yielded 
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mixed results and future research should adopt a more focused and standardized 
research approach in order to be able to draw firm conclusions about their impact 
on patient reported distress and health status.26 The field of device therapy is also 
constantly evolving. The latest developments include remote monitoring of the device 
from the patients’ home, new programming strategies in order to reduce the incidence 
of ICD shocks, and subcutaneous ICDs that have no leads inside or on the heart, which 
is expected to reduce the number of procedural- and device-related complications. 
The incorporation of patient reported outcomes in the clinical evaluation of these new 
technologies is paramount to identify patients who do not benefit optimally from new 
technology, as these patients may require adjunctive intervention. 
Last but not least, most studies, including the ones in the current dissertation, 
indicate that ICD/CRT patients are generally well able to cope with their device, 
even after being subjected to shocks or device advisory notifications. Hence, it may be 
timely to shift our focus from poor patient reported outcomes to examining factors 
associated with positive adjustment after implantation, such as optimism and positive 
health expectations.80 This is particularly important in light of the current debate in 
the scientific literature81 and media82 on the negative side effects of device therapy, 
with cardiologists being concerned that patients may turn down this potentially life-
saving treatment. Cases of patients dying from sudden cardiac arrest that could have 
been prevented had they not refused an ICD have been reported in the US.82 The 
incorporation of the patient perspective in research and clinical practice will enable 
physicians and other health-care professionals involved in the management and care of 
ICD/CRT(-D) patients to provide them with evidence-based information about what 
to expect from living with device, which in turn hopefully will counteract this negative 
publicity and prevent more unnecessary deaths. This was also voiced recently in the 
musings of Westby G. Fisher, internist, cardiologist and cardiac electrophysiologist: 
“So before our patients go out to buy funeral plots, let's keep the issues of the risks 
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Table 1. Recommendations for the incorporation of the patient perspective in clinical practice 


























Proefschrift.indd   161 13-9-2011   7:30:29
162
REFERENCES
1. van Veldhuisen DJ, Maass AH, Priori SG, Stolt P, van Gelder IC, Dickstein K et al. Implementation 
of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for 
patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009; 11:1143-
1151.
2. Stanek EJ, Oates MB, McGhan WF, Denofrio D, Loh E. Preferences for treatment outcomes in 
patients with heart failure: symptoms versus survival. J Card Fail 2000; 6:225-232.
3. Stovall EL. Practice guidelines: patients' perspective. Oncology 1996; 10:255-260.
4. Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD et al. Agreement is poor 
among current criteria used to define response to cardiac resynchronization therapy. Circulation 
2010; 121:1985-1991.
5. Ekman I, Cleland JGF, Andersson B, Swedberg K. Exploring symptoms in chronic heart failure. 
Eur J Heart Fail 2005; 7:699-703.
6. Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA 
functional status classification in patients with atrial fibrillation. New York Heart Association. Am 
Heart J 1998; 135:819-824.
7. Goode KM, Nabb S, Cleland JGF, Clark AL. A comparison of patient and physician-rated New 
York Heart Association class in a community-based heart failure clinic. J Card Fail 2008; 14:379-
387.
8. Grigioni F, Carigi S, Grandi S, Potena L, Coccolo F, Bacchi-Reggiani L et al. Distance between 
patients' subjective perceptions and objectively evaluated disease severity in chronic heart failure. 
Psychother Psychosom 2003; 72:166-170.
9. Moons P, van Deyk K, de Geest S, Gewillig M, Budts W. Is the severity of congenital heart disease 
associated with the quality of life and perceived health of adult patients? Heart 2005; 91:1193-
1198.
10. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of 
systems for assessing cardiovascular functional class: advantages of a new specific activity scale. 
Circulation 1981; 64:1227-1234.
11. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R et al. Limitations of the 
New York Heart Association functional classification system and self-reported walking distances in 
chronic heart failure. Heart 2007; 93:476-482.
12. Bosworth HB, Steinhauser KE, Orr M, Lindquist JH, Grambow SC, Oddone EZ. Congestive 
heart failure patients' perceptions of quality of life: the integration of physical and psychosocial 
factors. Aging Ment Health 2004; 8:83-91.
13. Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and 
left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common 
chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002; 
23:1867-1876.
14. Rumsfeld JS. Health status and clinical practice: when will they meet? Circulation 2002; 106:5-7.
15. Spertus JA. Evolving applications for patient-centered health status measures. Circulation 2008; 
118:2103-2110.
16. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M et al. Development 
and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary 
artery disease. J Am Coll Cardiol 1995; 25:333-341.
17. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C et al. Effect of PCI on quality 
of life in patients with stable coronary disease. N Engl J Med 2008; 359:677-687.







Proefschrift.indd   162 13-9-2011   7:30:29
163       General discussion
to recognize functional disability in ambulatory patients. Ann Intern Med 1991; 114:451-454.
19. Sears SF, Conti JB. Quality of life and psychological functioning of icd patients. Heart 2002; 
87:488-493.
20. Pacifico A, Henry PD, Bardy GH, Borggrefe M, Marchlinski FE, Natale A et al. Implantable 
Defibrillator Therapy: A Clinical Guide. Dordrecht, the Netherlands: Kluwer Academic Publishers 
Group 2002.
21. Ladwig K-H, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress 
symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results 
from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry 
2008; 65:1324-1330.
22. Pelle AJM, Gidron YY, Szabó BM, Denollet J. Psychological predictors of prognosis in chronic 
heart failure. J Card Fail 2008; 14:341-350.
23. Steinberg JS, Joshi S, Schron EB, Powell J, Hallstrom A, McBurnie M. Psychosocial status predicts 
mortality in patients with life-threatening ventricular arrhythmias. Heart Rhythm 2008; 5:361-
365.
24. Mommersteeg PMC, Denollet J, Spertus JA, Pedersen SS. Health status as a risk factor in 
cardiovascular disease: a systematic review of current evidence. Am Heart J 2009; 157:208-218.
25. Krumholz HM, Peterson ED, Ayanian JZ, Chin MH, DeBusk RF, Goldman L et al. Report of the 
National Heart, Lung, and Blood Institute working group on outcomes research in cardiovascular 
disease. Circulation 2005; 111:3158-3166.
26. Pedersen SS, van den Broek KC, van den Berg M, Theuns DAMJ. Shock as a determinant of poor 
patient-centered outcomes in implantable cardioverter defibrillator patients: Is there more to it than 
meets the eye? Pacing Clin Electrophysiol 2010; 33:1430-1436.
27. Pedersen SS, Sears SF, Burg MM, van den Broek KC. Does ICD indication affect quality of life and 
levels of distress? Pacing Clin Electrophysiol 2009; 32:153-156.
28. Pedersen SS, van den Berg M, Theuns DAMJ. A viewpoint on the impact of device advisories on 
patient-centered outcomes. Pacing Clin Electrophysiol 2009; 32:1006-1011.
29. Godemann F, Butter C, Lampe F, Linden M, Werner S, Behrens S. Determinants of the quality of 
life (QoL) in patients with an implantable cardioverter/defibrillator (ICD). Qual Life Res 2004; 
13:411-416.
30. Pedersen SS, Theuns DAMJ, Erdman RAM, Jordaens L. Clustering of device-related concerns and 
Type D personality predicts increased distress in ICD patients independent of shocks. Pacing Clin 
Electrophysiol 2008; 31:20-27.
31. Pedersen SS, Theuns DAMJ, Muskens-Heemskerk A, Erdman RAM, Jordaens L. Type D personality 
but not implantable cardioverter-defibrillator indication is associated with impaired health-related 
quality of life 3 months post-implantation. Europace 2007; 9:675-680.
32. Schiffer AA, Denollet J, Pedersen SS, Broers H, Widdershoven JW. Health status in patients 
treated with cardiac resynchronization therapy: modulating effects of personality. Pacing Clin 
Electrophysiol 2008; 31:28-37.
33. van den Broek KC, Nyklicek I, Denollet J. Anxiety predicts poor perceived health in patients with 
an implantable defibrillator. Psychosomatics 2009; 50:483-492.
34. van den Broek KC, Nyklicek I, van der Voort PH, Alings M, Meijer A, Denollet J. Risk of 
ventricular arrhythmia after implantable defibrillator treatment in anxious Type D patients. J Am 
Coll Cardiol 2009; 54:531-537.
35. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L et al. Quality of 
life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008; 359:999-1008.
36. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M et al. Quality of life in the Canadian 
Proefschrift.indd   163 13-9-2011   7:30:29
164
Implantable Defibrillator Study (CIDS). Am Heart J 2002; 144:282-289.
37. Noyes K, Corona E, Veazie P, Dick AW, Zhao H, Moss AJ. Examination of the effect of implantable 
cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter 
Automatic Defibrillator Trial-II. Am J Cardiovasc Drugs 2009; 9:393-400.
38. Greenhalgh J, Meadows K. The effectiveness of the use of patient-based measures of health in 
routine practice in improving the process and outcomes of patient care: a literature review. Journal 
of Evaluation in Clinical Practice 1999; 5:401-416.
39. Lohr KN, Zebrack BJ. Using patient-reported outcomes in clinical practice: challenges and 
opportunities. Qual Life Res 2009; 18:99-107.
40. Buxton J, White M, Osoba D. Patients' experiences using a computerized program with a touch-
sensitive video monitor for the assessment of health-related quality of life. Qual Life Res 1998; 
7:513-519.
41. Velikova G, Brown JM, Smith AB, Selby PJ. Computer-based quality of life questionnaires may 
contribute to doctor-patient interactions in oncology. Br J Cancer 2002; 86:51-59.
42. Rose M, Bezjak A. Logistics of collecting patient-reported outcomes (PROs) in clinical practice: an 
overview and practical examples. Qual Life Res 2009; 18:125-136.
43. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual 
framework and item selection. Med Care 1992; 30:473-483.
44. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and 
preliminary tests of reliability and validity. Med Care 1996; 34:220-233.
45. Hevey D, McGee HM, Horgan J. Responsiveness of health-related quality of life outcome measures 
in cardiac rehabilitation: comparison of cardiac rehabilitation outcome measures. J Consult Clin 
Psychol 2004; 72:1175-1180.
46. Rector T, Kubo SH, Cohn J. Patient’s self assessment of their congestive heart failure: Content, 
reliability, and validity of a new measure: The Minnesota Living with Heart Failure Questionnaire. 
Heart failure 1987; 3:198-219.
47. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City 
Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 
2000; 35:1245-1255.
48. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P et al. Monitoring 
clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005; 
150:707-715.
49. Burns JL, Serber ER, Keim S, Sears SF. Measuring patient acceptance of implantable cardiac device 
therapy: initial psychometric investigation of the Florida Patient Acceptance Survey. J Cardiovasc 
Electrophysiol 2005; 16:384-390.
50. Kuhl EA, Dixit NK, Walker RL, Conti JB, Sears SF. Measurement of patient fears about implantable 
cardioverter defibrillator shock: an initial evaluation of the Florida Shock Anxiety Scale. Pacing 
Clin Electrophysiol 2006; 29:614-618.
51. Frizelle DJ, Lewin B, Kaye G, Moniz-Cook ED. Development of a measure of the concerns held 
by people with implanted cardioverter defibrillators: the ICDC. Br J Health Psychol 2006; 11:293-
301.
52. Carroll DL, Hamilton GA. Long-term effects of implanted cardioverter-defibrillators on health 
status, quality of life, and psychological state. Am J Crit Care 2008; 17:222-230.
53. Kapa S, Rotondi-Trevisan D, Mariano Z, Aves T, Irvine J, Dorian P et al. Psychopathology in 
patients with ICDs over time: results of a prospective study. Pacing Clin Electrophysiol 2009; 
33:198-208.







Proefschrift.indd   164 13-9-2011   7:30:29
165       General discussion
receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med 
1997; 27:57-69.
55. Pedersen SS, van den Broek KCv, Theuns DAMJ, Erdman RAM, Alings M, Meijer A et al. Risk 
of chronic anxiety in implantable defibrillator patients: A multi-center study. Int J Cardiol 2011; 
147:420-423.
56. Pedersen SS, Theuns DAMJ, Jordaens L, Kupper N. Course of anxiety and device-related concerns 
in implantable cardioverter defibrillator patients the first year post implantation. Europace 2010; 
12:1119-1126.
57. Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K et al. Prevalence and Persistence 
of Depression in Patients with Implantable Cardioverter Defibrillator: A 2-year Longitudinal Study. 
Pacing Clin Electrophysiol 2010; 33:1455-1461.
58. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life 
assessments and patient-physician communication: a randomized controlled trial. JAMA 2002; 
288:3027-3034.
59. Bartlett EE, Grayson M, Barker R, Levine DM, Golden A, Libber S. The effects of physician 
communications skills on patient satisfaction; recall, and adherence. J Chronic Dis 1984; 37:755-
764.
60. Sears SF, Stutts LA, Aranda JM, Handberg EM, Conti JB. Managing congestive heart failure 
patient factors in the device era. Congest Heart Fail 2007; 12:335-340.
61. Pedersen SS, van den Broek KC, Sears SF. Psychological intervention following implantation of an 
implantable defibrillator: a review and future recommendations. Pacing Clin Electrophysiol 2007; 
30:1546-1554.
62. Salmoirago-Blotcher E, Ockene IS. Methodological limitations of psychosocial interventions in 
patients with an implantable cardioverter-defibrillator (ICD) A systematic review. BMC Cardiovasc 
Disord 2009; 9:56.
63. Chevalier P, Cottraux J, Mollard E, Sai N, Brun S, Burri H et al. Prevention of implantable 
defibrillator shocks by cognitive behavioral therapy: a pilot trial. Am Heart J 2006; 151:191.
64. Sears SF, Sowell LDV, Kuhl EA, Kovacs AH, Serber ER, Handberg E et al. The ICD shock and 
stress management program: a randomized trial of psychosocial treatment to optimize quality of life 
in ICD patients. Pacing Clin Electrophysiol 2007; 30:858-864.
65. Lewin RJ, Coulton S, Frizelle DJ, Kaye G, Cox H. A brief cognitive behavioural preimplantation 
and rehabilitation programme for patients receiving an implantable cardioverter-defibrillator 
improves physical health and reduces psychological morbidity and unplanned readmissions. Heart 
2009; 95:63-69.
66. Irvine J, Firestone J, Ong L, Cribbie R, Dorian P, Harris L et al. A randomized controlled trial 
of cognitive behavior therapy tailored to psychological adaptation to an implantable cardioverter 
defibrillator. Psychosom Med 2011; 73:226-233.
67. Frizelle DJ, Lewin RJP, Kaye G, Hargreaves C, Hasney K, Beaumont N et al. Cognitive-behavioural 
rehabilitation programme for patients with an implanted cardioverter defibrillator: a pilot study. Br 
J Health Psychol 2004; 9:381-392.
68. Kohn CS, Petrucci RJ, Baessler C, Soto DM, Movsowitz C. The effect of psychological intervention 
on patients' long-term adjustment to the ICD: a prospective study. Pacing Clin Electrophysiol 
2000; 23:450-456.
69. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ. Comprehensive cardiac 
rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised 
controlled trial. Heart 2003; 89:155-160.
70. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT et al. Sertraline 
Proefschrift.indd   165 13-9-2011   7:30:29
166
treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288:701-
709.
71. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment 
of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 
160:749-756.
72. Januzzi JL, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on 
outcomes of patients with coronary artery disease. Arch Intern Med 2000; 160:1913-1921.
73. Askinazi C. SSRI treatment of depression with comorbid cardiac disease. Am J Psychiatry 1996; 
153:135-136.
74. Mergl R, Henkel V, Allgaier A-K, Kramer D, Hautzinger M, Kohnen R et al. Are treatment 
preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy 
in depressed primary care patients? Results from a randomized controlled trial including a patients' 
choice arm. Psychother Psychosom 2011; 80:39-47.
75. Pedersen SS, van den Berg M, Erdman RAM, van Son J, Jordaens L, Theuns DAMJ. Increased 
anxiety in partners of patients with a cardioverter-defibrillator: the role of indication for ICD 
therapy, shocks, and personality. Pacing Clin Electrophysiol 2009; 32:184-192.
76. Hazelton AG, Sears SF, Kirian K, Matchett M, Shea J. Cardiology Patient Page. Coping with my 
partner's ICD and cardiac disease. Circulation 2009; 120:e73-76.
77. Lewin RJ, Frizelle DJ, Kaye GC. A rehabilitative approach to patients with internal cardioverter-
defibrillators. Heart 2001; 85:371-372.
78. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, 
pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging 
field of behavioral cardiology. J Am Coll Cardiol 2005; 45:637-651.
79. Pedersen SS, van den Broek KC, Erdman RAM, Jordaens L, Theuns DAMJ. Pre-implantation 
implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality 
in patients with an implantable cardioverter defibrillator. Europace 2010; 12:1446-1452.
80. Sears SF, Serber ER, Lewis TS, Walker RL, Conners N, Lee JT et al. Do positive health expectations 
and optimism relate to quality-of-life outcomes for the patient with an implantable cardioverter 
defibrillator? J Cardiopulm Rehabil 2004; 24:324-331.
81. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator 
therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52:1111-1121.









Proefschrift.indd   166 13-9-2011   7:30:29
Chapter 12
Nederlandse samenvatting, dankwoord, curriculum vitae
Proefschrift.indd   167 13-9-2011   7:30:39
168
NEDERLANDSE SAMENVATTING
Op dit moment leven er meer dan 800.000 hartpatiënten in Europa met een 
cardiovasculair implanteerbaar elektronisch systeem, zoals een implanteerbare 
cardioverter defibrillator (ICD) of een biventriculaire pacemaker die cardiale 
resynchronisatie therapie (CRT) afgeeft.
Een ICD wordt geïmplanteerd bij patiënten die ventriculaire ritmestoornissen 
hebben ervaren (secundaire preventie) of die, als gevolg van een structurele hartziekte, 
een verhoogd risico hebben op deze levensbedreigende ritmestoornissen (primaire 
preventie). De ICD registreert continu informatie over het hartritme via een 
geleidingsdraad (lead) in een of beide hartkamers (ventrikels). Als er een ritmestoornis 
wordt gedetecteerd, kan een ICD deze beëindigen door middel van snelle elektrische 
pulsen, zogenaamde antitachycardie pacing, of een elektrische schok en zo een 
eventuele plotse hartdood voorkomen. 
Een biventriculaire pacemaker, of CRT-pacemaker, is bedoeld voor patiënten 
met mild tot ernstig hartfalen. Hartfalen kenmerkt zich door symptomen van 
vermoeidheid, kortademigheid en het vasthouden van vocht, veroorzaakt door een 
verminderde pompfunctie van het hart. Bij ongeveer 30% van de hartfalenpatiënten 
trekken de ventrikels vanwege een geleidingsstoornis niet gelijk samen waardoor 
de ventriculaire ejectiefractie (het percentage bloed dat bij één hartslag het lichaam 
ingepompt wordt) nog verder afneemt. Deze groep patiënten kan baat hebben bij CRT. 
Door kleine elektrische pulsen via een lead in de rechterventrikel en een op de wand 
van de linkerventrikel zorgt CRT ervoor dat beide ventrikels weer meer synchroon 
samentrekken. Bij het merendeel van de patiënten wordt er een derde lead in de 
rechterhartboezem (atrium) geplaatst zodat ook de synchronie tussen de ventrikels 
en atria verbetert. Omdat patiënten met hartfalen een verhoogd risico hebben op 
ritmestoornissen wordt een biventriculaire pacemaker, of een CRT-pacemaker, 
vaak gecombineerd met een ICD (CRT-defibrillator of CRT-D). Grootschalige 
internationale studies hebben aangetoond dat CRT bij de meeste patiënten leidt 
tot een verbeterde pompfunctie, een afname van hartfalensymptomen en een betere 
prognose. Naar aanleiding van studies als deze breiden de indicatiestellingen voor 
ICD en CRT therapie zich steeds verder uit en neemt het aantal hartpatiënten met 
een ICD of CRT systeem snel toe.
DOEL VAN DIT PROEFSCHRIFT
In onderzoek en de klinische praktijk wordt vaak aangenomen dat elke behandeling die 
de overlevingskansen verbetert ook goed moet zijn voor de patiënt en dat alle patiënten 
dezelfde verbeteringen in hun fysieke en mentale welbevinden ervaren. Het leven met 
een ICD of CRT(-D) wordt echter door iedere patiënt anders beleefd. Om een beter 
beeld te krijgen van de gevoelens en ervaringen van patiënten lag de focus van dit 
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uitkomsten zijn uitkomsten van vragenlijsten die door patiënten zelf worden ingevuld. 
Deze lijsten gaan bijvoorbeeld over de symptomen die patiënten ervaren, hun 
lichamelijk en mentaal functioneren en hun kwaliteit van leven. Ze geven inzicht in 
hoe patiënten zelf hun gezondheid waarderen (hun subjectieve gezondheidstoestand) 
en hoe zij psychologisch gezien omgaan met hun ziekte en/of de behandeling. 
Uit eerdere onderzoeken is gebleken dat ongeveer 1 op de 4 ICD dragers na de 
implantatie angstige en depressieve gevoelens en/of een verminderde kwaliteit van 
leven rapporteert. Er bestaat echter nog veel onduidelijkheid over de oorzaken van 
deze gevoelens. Het is belangrijk om dit verder te onderzoeken, zodat we kunnen 
voorspellen welke patiënten een hoog risico lopen op negatieve patiëntgerapporteerde 
uitkomsten na de implantatie. Aan deze patiënten kan dan tijdig extra (psychologische) 
hulp worden geboden om te voorkomen dat hun subjectieve welzijn verder achteruit 
gaat. Dit kan ook belangrijk zijn voor secundaire preventie, omdat is aangetoond 
dat patiëntgerapporteerde psychologische stress en een slechte subjectieve 
gezondheidstoestand samenhangen met een verhoogd risico op ziekenhuisopnames 
of overlijden.  
Het doel van dit proefschrift was om een beter beeld te krijgen van de factoren die 
samenhangen met individuele verschillen in patiëntgerapporteerde uitkomsten. Figuur 
1 geeft een overzicht van klinische, demografi sche en psychologische factoren die van 
belang zouden kunnen zijn. In de negen studies in dit proefschrift is het verband 
tussen enkele van deze factoren en patiëntgerapporteerde uitkomsten onderzocht 
in steekproeven van ICD of CRT(-D) patiënten uit verschillende (inter)nationale 
ziekenhuizen.
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VOORNAAMSTE BEVINDINGEN VAN DIT PROEFSCHRIFT
Hartfalen is een chronische en slopende ziekte die een grote invloed kan hebben op het 
dagelijks leven van patiënten. In de medische wereld wordt vaak aangenomen dat het 
subjectieve welzijn van een patiënt vooral wordt bepaald door de ernst van de ziekte. 
In de eerste drie studies in dit proefschrift bekeken we daarom het verband tussen de 
subjectieve, patiëntgerapporteerde gezondheidstoestand en de traditionele ‘objectieve’ 
maatstaven die cardiologen gebruiken om de ernst van het hartfalen te beoordelen, 
zoals echoparameters en de New York Heart Association (NYHA) functionele 
klasse. De NYHA klasse is een classificatie voor de ernst van hartfalensymptomen en 
functionele beperkingen zoals die wordt ingeschat door de arts: hoe hoger de klasse 
(I t/m IV), hoe ernstiger het hartfalen. De NYHA klasse is een van de meest gebruikte 
maten waarop de keuze van een behandeling voor hartfalen wordt gebaseerd en het 
succes daarvan wordt beoordeeld. Uit de bestaande literatuur en ervaringen uit de 
dagelijkse praktijk blijkt echter dat er nauwelijks verband bestaat tussen deze klinische 
maatstaven voor de ernst van het hartfalen en de gezondheidstoestand die de patiënt 
zelf rapporteert (Hoofdstuk 2). Zo zijn er patiënten bij wie het hartfalen volgens de 
resultaten van de hartecho, de inspanningstest en/of het laboratoriumonderzoek is 
verbeterd, maar die zelf geen verbetering ervaren, of andersom. Deze discrepantie 
wordt bevestigd in de studies beschreven in Hoofdstuk 3 en 4 van dit proefschrift. 
Zo bleek dat de verandering in de subjectieve gezondheidstoestand na de CRT-D 
implantatie niet verklaard kan worden door de NYHA klasse bij implantatie 
(Hoofdstuk 3). Patiënten met mild (NYHA klasse II) en matig ernstig (NYHA klasse 
III) hartfalen bij implantatie rapporteerden 12 maanden later gelijke verbeteringen 
op subjectieve gezondheidsdomeinen zoals fysiek en sociaal functioneren en mentale 
gezondheid. In de andere studie hebben we bij 101 CRT(-D) patiënten gekeken 
naar hun gezondheidstoestand voorafgaand aan de implantatie en 2 maanden daarna 
(Hoofdstuk 4). Bij 59 patiënten was er geen verbetering van het hartfalen volgens de 
NYHA klasse, maar toch rapporteerden 36 van deze 59 patiënten (61%) een klinisch 
relevante verbetering in hun gezondheidstoestand op een hartfalen-vragenlijst. Deze 
resultaten benadrukken dat patiëntgerapporteerde vragenlijsten een meerwaarde 
hebben voor de inschatting van de ernst van het hartfalen vanuit het perspectief van 
de patiënt in vergelijking met de traditionele functie-indeling in NYHA klassen.
Uit bovenstaande resultaten blijkt dat  het subjectieve welzijn van patiënten 
slechts voor een deel verband houdt met de ernst van het hartfalen volgens klinische 
maatstaven. ICD en CRT patiënten worden echter niet alleen geconfronteerd met de 
gevolgen van hun ziekte, maar ook met de uitdagingen die horen bij het leven met 
een ICD/CRT systeem. De complexiteit van de ICD en CRT technologie maakt dat 
deze gevoelig is voor complicaties, zoals hardwareproblemen. Een recent voorbeeld 
hiervan zijn de problemen met de Sprint Fidelis lead van Medtronic. In 2007 kwam 
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specifieke lead groter is dan bij andere Medtronic leads. Een dergelijk bericht zou 
angstgevoelens en zorgen kunnen veroorzaken bij patiënten met een Sprint Fidelis 
lead. In een studie van Deense ICD patiënten (Hoofdstuk 5) vonden wij echter dat 
patiënten met een Sprint Fidelis lead gemiddeld genomen niet méér psychologische 
problemen of een slechtere kwaliteit van leven rapporteerden dan controlepatiënten 
zonder deze Sprint Fidelis lead. Ook de manier waarop de patiënten van de Sprint 
Fidelis advisory hoorden, via een brief met een oproep om direct voor controle naar 
het ziekenhuis te komen of tijdens een routinecontrole op de polikliniek, had geen 
invloed op patiëntgerapporteerde uitkomsten. Deze bevindingen sluiten aan bij 
eerdere studies die eveneens aantonen dat patiënten over het algemeen goed omgaan 
met hun ICD en weinig psychologische stress ervaren, zelfs na het krijgen van ICD 
schokken of een advisory.
Patiënten met negatieve patiëntgerapporteerde uitkomsten zijn dus niet per 
definitie die patiënten die ernstiger ziek zijn en/of meer behandelingscomplicaties 
hebben doorgemaakt. Uit de studies in deel twee van dit proefschrift bleek dat 
het psychologische profiel van patiënten ook een belangrijke rol speelt. Zo waren 
angst en bezorgdheid over de ICD voorafgaand aan de implantatie (Hoofdstuk 6), 
somatosensorische amplificatie (Hoofdstuk 7)  en een slechte acceptatie van de ICD 
(Hoofdstuk 10) geassocieerd met verhoogde psychologische stress na implantatie, 
onafhankelijk van demografische en klinische factoren als NYHA klasse en ICD 
schokken. Somatosensorische amplificatie wordt gekenmerkt door een overdreven 
aandacht voor bepaalde normale lichamelijke sensaties en de neiging om op deze 
sensaties te reageren met gedachten die ze versterken en verontrustender maken. 
Ook persoonlijkheidsfactoren kunnen een rol spelen in individuele verschillen in 
patiëntgerapporteerde uitkomsten. Zo liet een meta-analyse van 10 studies (Hoofdstuk 
8) zien dat de ‘distressed’ (Type D) persoonlijkheid samenhangt met een slechtere 
subjectieve mentale en fysieke gezondheidstoestand bij verschillende cardiovasculaire 
patiëntengroepen. Individuen met een Type D persoonlijkheid ervaren veel negatieve 
emoties en maken zich veel zorgen, maar uiten hun gevoelens en emoties niet naar 
anderen. De studies in dit proefschrift toonden aan dat ICD patiënten met een Type D 
persoonlijkheid meer symptomen van angst, depressie (Hoofdstuk 9), posttraumatische 
stress (Hoofdstuk 6) en een slechtere acceptatie van de ICD (Hoofdstuk 10) rapporteerden 
dan patiënten zonder het Type D persoonlijkheidstype. 
CONCLUSIES EN AANBEVELINGEN
De bevindingen in dit proefschrift bevestigen eerdere studieresultaten dat 
patiëntgerapporteerde uitkomsten in dezelfde of zelfs sterkere mate samenhangen 
met het psychologisch profiel van de patiënten dan met de ernst van hun ziekte of 
behandelingscomplicaties. Het subjectieve welzijn van een patiënt is dus niet direct af 
te leiden uit de gegevens in zijn/haar medische dossier. Daarom hebben vragenlijsten 
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Proefschrift.indd   171 13-9-2011   7:30:40
172
die het perspectief van de patiënt meten een meerwaarde voor onderzoek en in de 
klinische praktijk. 
Patiëntgerapporteerde uitkomsten worden in toenemende mate meegenomen 
in onderzoeken naar de effecten van ICD/CRT(-D) therapie, maar hun toepassing 
in de dagelijkse klinische praktijk is verre van standaard, vooral vanwege praktische 
bezwaren. Er is immers geld, tijd en personeel nodig om de gegevens te verzamelen 
en te analyseren. Toch is het de moeite waard om meer onderzoek te doen naar een 
efficiënt en goedkoop gebruik van vragenlijsten in de cardiologische praktijk. Studies bij 
kankerpatiënten hebben namelijk aangetoond dat artsen door patiëntgerapporteerde 
uitkomsten een beter inzicht krijgen in de specifieke lichamelijke en psychologische 
behoeften van patiënten. Dit kan vervolgens bijdragen tot een betere communicatie 
tussen arts en patiënt, een hogere patiënttevredenheid en betere patiëntgerichte 
zorg. Door vragenlijsten op meerdere momenten af te nemen kunnen patiënten die 
psychologische stress ervaren rond de implantatie of bij wie het subjectieve welzijn 
achteruit gaat eenvoudig(er) worden geïdentificeerd. Vervolgens is het belangrijk 
dat deze patiënten de juiste hulp krijgen aangeboden, afgestemd op hun individuele 
behoeften. Zo zouden angstige patiënten bijvoorbeeld baat kunnen hebben bij 
cognitieve gedragstherapie. 
Om de interventies zo goed mogelijk af te stemmen op de behoeften van 
de individuele patiënt is meer onderzoek nodig naar de complexe invloed van 
psychologische factoren en de gedragsmatige en biologische mechanismen die 
hieraan ten grondslag liggen. Daarnaast zijn er grootschalige en gestandaardiseerde 
studies nodig naar de impact van nieuwe ontwikkelingen binnen de ICD/CRT 
technologie op patiëntgerapporteerde uitkomsten. De meest recente ontwikkelingen 
zijn het op afstand monitoren (remote monitoring) van de ICD/CRT(-D) waardoor 
patiënten minder vaak voor controle naar het ziekenhuis hoeven te komen, nieuwe 
programmeerstrategieën om het aantal ICD schokken te verlagen en de subcutane 
ICD die geen leads in of op het hart heeft. Bij het evalueren van deze ontwikkelingen 
is het essentieel om patiëntgerapporteerde uitkomsten mee te nemen zodat beter kan 
worden voorspeld welke patiënten er wel of geen baat bij zullen hebben. 
Tenslotte, over het algemeen blijkt dat de meeste patiënten goed omgaan met 
hun ICD/CRT-D) en weinig psychologische stress of aanpassingsproblemen ervaren. 
Daarom is het wellicht tijd om de focus te verleggen naar positieve patiëntgerapporteerde 
uitkomsten en de factoren die hiermee samenhangen, zoals optimisme. Dit is vooral 
belangrijk in het licht van de huidige discussie in de wetenschap en de media over 
de eventuele negatieve bijwerkingen van ICD therapie waardoor sommige patiënten 
deze levensreddende behandeling afwijzen. Door het perspectief van de patiënt mee 
te nemen in onderzoek en de klinische praktijk kunnen zorgverleners hun patiënten 
goed onderbouwde en reële informatie geven over wat ze kunnen verwachten van het 
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